Immune cell compositions comprising gp4 modifications and uses thereof

WO2024192163A3PCT designated stage expired Publication Date: 2024-11-07MEMORIAL SLOAN KETTERING CANCER CENT +3
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
PCT/US2024/019787
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-07-07
Filing Date
2024-03-13
Publication Date
2024-11-07

AI Technical Summary

Technical Problem

Current treatments for Charcot-Marie-Tooth Disease (CMTD) and systemic microbial infections are inadequate, and existing cancer therapies are ineffective, particularly for relapsed or refractory cancers, due to limitations in immune cell function and specificity.

Method used

Engineered immune cells, such as neutrophils and macrophages, are developed to overexpress or lack Gp4, using non-endogenous expression vectors and inhibitory nucleic acids, and equipped with chimeric antigen receptors (CARs) to target specific antigens, enhancing phagocytic capacity and tumor recognition.

Benefits of technology

The engineered immune cells demonstrate increased phagocytic activity, improved plasma membrane abundance, and enhanced targeting of tumor cells, leading to effective treatment of CMTD, microbial infections, and cancer, including resistant cancer types.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2024019787_07112024_PF_FP_ABST
    Figure US2024019787_07112024_PF_FP_ABST
Patent Text Reader

Abstract

Provided herein are compositions, kits, and methods for manufacturing cells for adoptive cell therapy comprising engineered immune cells that overexpress GβP4 for the treatment of Charcot-Marie-Tooth Disease (CMTD). Also disclosed herein are engineered immune cells that lack detectable expression or activity of Gβ4 for treating systemic microbial infections and for enhancing the anti-tumor response of chimeric antigen receptor (CAR) immune cells.
Need to check novelty before this filing date? Find Prior Art

Description

IMMUNE CELL COMPOSITIONS COMPRISING Gp4 MODIFICATIONS ANDUSES THEREOFCROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit of and priority to U.S. Provisional Application Nos. 63 / 452,151, filed March 14, 2023, and 63 / 512,470, filed July 7, 2023, the contents of which are incorporated herein by reference in their entireties.TECHNICAL FIELD

[0002] The present technology relates to compositions, kits, and methods for manufacturing cells for adoptive cell therapy comprising engineered immune cells that overexpress Gp4 for the treatment of Charcot-Marie-Tooth Disease (CMTD). Also disclosed herein are engineered immune cells that lack detectable expression or activity of GP4 for treating systemic microbial infections and for enhancing the anti-tumor response of chimeric antigen receptor (CAR) immune cells.GOVERNMENT SUPPORT

[0003] This invention was made with government support under CA008748 awarded by the National Institutes of Health. The government has certain rights in the invention.BACKGROUND

[0004] The following description of the background of the present technology is provided simply as an aid in understanding the present technology and is not admitted to describe or constitute prior art to the present technology.

[0005] Professional phagocytes, such as neutrophils and macrophages, mediate the clearance of pathogens, cellular debris, and apoptotic corpses1,2. For proper function, phagocytes must decide what to eat, how much to eat, and when to move following eating.SUMMARY OF THE PRESENT TECHNOLOGY

[0006] In one aspect, the present disclosure provides an engineered immune cell comprising a non-endogenous expression vector that includes a mammalian GNB4 nucleic acid sequence. In some embodiments, the mammalian GNB4 nucleic acid sequence comprises SEQ ID NO: 1 or the mammalian GNB4 nucleic acid encodes a Gp4 polypeptide comprising the amino acid sequence of SEQ ID NO: 2. The engineered immune cell may be a neutrophil or a macrophage. In some embodiments, the non-endogenous expressionvector including the mammalian GNB4 nucleic acid sequence is a plasmid, a cosmid, a bacmid, a bacterial artificial chromosome (BAC), a yeast artificial chromosome (YAC), or a viral vector (e.g., a retroviral vector).

[0007] Additionally or alternatively, in some embodiments of the engineered immune cell disclosed herein, the mammalian GNB4 nucleic acid sequence is operably linked to an expression control sequence. The expression control sequence may be an inducible promoter, a constitutive promoter, a native GNB4 promoter, or a heterologous promoter. The non-endogenous vector including the GNB4 nucleic acid sequence may further comprise at least one of a bioluminescent protein, a fluorescent protein, a chemiluminescent protein, an epitope tag, or a selectable marker.

[0008] In one aspect, the present disclosure provides an engineered immune cell, wherein the cell lacks detectable expression or activity of a mammalian Gp4 polypeptide. In another aspect, the present disclosure provides an engineered immune cell, wherein the cell expresses an inhibitory nucleic acid that specifically targets and inhibits the expression of a mammalian GP4 polypeptide. The mammalian GP4 polypeptide may comprise an amino acid sequence of SEQ ID NO: 2. The inhibitory nucleic acid may be an antisense oligonucleotide, a siRNA, a sgRNA or a shRNA. The engineered immune cell may be a neutrophil or a macrophage.

[0009] Additionally or alternatively, in some embodiments of the engineered immune cell of the present technology, the cells comprise a transgene that encodes a dominant negative GP4 construct or the Gp4-specific inhibitory nucleic acid. The transgene may be operably linked to an ubiquitous promoter, a constitutive promoter, a macrophage-specific promoter, a neutrophil-specific promoter, or an inducible promoter. In one aspect, the present disclosure provides an engineered immune cell comprising a deletion, insertion, inversion, or frameshift mutation in a nucleic acid sequence encoding GP4 (e.g., SEQ ID NO: 1). Additionally or alternatively, in some embodiments, the engineered immune cell further comprises a receptor that binds to a target antigen and / or a nucleic acid encoding the receptor. The receptor may be a chimeric antigen receptor (CAR). Additionally or alternatively, in some embodiments, the CAR comprises (i) an extracellular antigen binding domain; (ii) a transmembrane domain; and (iii) an intracellular domain, wherein the extracellular antigen binding domain binds to the target antigen. In certain embodiments, the extracellular antigen binding fragment is a single-chain variable fragment (scFv). The transmembrane domain may comprise a CD8 transmembrane domain or a CD28transmembrane domain. In certain embodiments, the intracellular domain comprises a CD3(^ signaling domain and optionally one or more costimulatory domains selected from a CD28 costimulatory domain, a 4-1BB costimulatory domain, an 0X40 costimulatory domain, an ICOS costimulatory domain, a DAP-10 costimulatory domain, a PD-1 costimulatory domain, a CTLA-4 costimulatory domain, a LAG-3 costimulatory domain, a 2B4 costimulatory domain, a BTLA costimulatory domain, or any combination thereof. Additionally or alternatively, in some embodiments of the engineered immune cell disclosed herein, the target antigen comprises a tumor antigen. Examples of tumor antigens include, but are not limited to, 5T4, alpha 5pi-integrin, 707- AP, A33, AFP, ART -4, B7H4, BAGE, Bcl-2, P-catenin, BCMA, Bcr-abl, CA125, CA19-9, CAMEL, CAP-1, CASP-8, CD4, CD5, CD19, CD20, CD21 , CD22, CD25, CDC27 / m, CD33, CD37, CD45, CD52, CD56, CD80, CD123, CDK4 / m, CEA, c-Met, CS-1, CT, Cyp-B, cyclin Bl, DAGE, DAM, EBNA, EGFR, ErbB3, ELF2M, EMMPRIN, EpCam, ephrinB2, estrogen receptor, ETV6- AML1, FAP, ferritin, folate-binding protein, GAGE, G250, GD-2, GM2, GnT-V, gp75, gplOO (Pmel 17), HAGE, HER-2 / neu, HLA-A*0201-R170I, HPV E6, HPV E7, Ki-67, HSP70-2M, HST-2, hTERT (or hTRT), iCE, IGF-1R, IL-2R, IL-5, KIAA0205, LAGE, LDLR / FUT, LRP, MAGE, MART, MART-l / melan-A, MART-2 / Ski, MC1R, mesothelin, MUC16, MUM-1 -B, myc, MUM-2, MUM-3, NA88-A, NYESO-1, NY-Eso-B, p53, proteinase-3, pl90 minor bcr-abl, Pml / RARa, PRAME, progesterone receptor, PSA, PSCA, PSM, PSMA, ras, RAGE, RU1 or RU2, RORI, SART-1 or SART-3, survivin, TEL / AML1, TGFP, TPI / m, TRP-1, TRP-2, TRP-2 / INT2, tenascin, TSTA tyrosinase, VEGF, or WT1.

[0010] In any of the preceding embodiments, the engineered immune cell is derived from an autologous donor or an allogenic donor.

[0011] In one aspect, the present disclosure provides a composition comprising an effective amount of any and all embodiments of the engineered immune cells disclosed herein and a pharmaceutically acceptable carrier.

[0012] In one aspect, the present disclosure provides a method for treating Charcot- Marie-Tooth Disease (CMTD) in a subject in need thereof comprising administering to the subject an effective amount of any and all embodiments of the Gp4-overexpressing engineered immune cells of the present technology. The subject may harbor a mutation in GNB4 or suffers from or is at risk for dominant intermediate CMT type F (CMTDIF). The Gp4-overexpressing engineered immune cells may be macrophages or neutrophils.

[0013] In one aspect, the present disclosure provides a method for treating a microbial infection in a subject in need thereof comprising administering to the subject an effective amount of any and all embodiments of the Gp4-deficient engineered immune cells disclosed herein. The microbial infection may be a fungal infection, a bacterial infection, or a viral infection. The Gp4-deficient engineered immune cells may be macrophages or neutrophils.

[0014] In another aspect, the present disclosure provides a method for treating cancer in a subject in need thereof comprising administering to the subject an effective amount of any and all embodiments of the Gp4-deficient engineered immune cells disclosed therein, wherein the Gp4-defi cient engineered immune cells further comprise a chimeric antigen receptor (CAR) that specifically binds to a tumor antigen. In some embodiments, the GP4- deficient engineered immune cells comprise macrophages or neutrophils. In some embodiments, the cancer is selected from the group consisting of adrenal cancers, bladder cancers, blood cancers, bone cancers, brain cancers, breast cancers, carcinoma, cervical cancers, colon cancers, colorectal cancers, corpus uterine cancers, ear, nose and throat (ENT) cancers, endometrial cancers, esophageal cancers, gastrointestinal cancers, head and neck cancers, Hodgkin's disease, intestinal cancers, kidney cancers, larynx cancers, acute and chronic leukemias, liver cancers, lymph node cancers, lymphomas, lung cancers, melanomas, mesothelioma, myelomas, nasopharynx cancers, neuroblastomas, nonHodgkin's lymphoma, oral cancers, ovarian cancers, pancreatic cancers, penile cancers, pharynx cancers, prostate cancers, rectal cancers, sarcoma, seminomas, skin cancers, stomach cancers, teratomas, testicular cancers, thyroid cancers, uterine cancers, vaginal cancers, vascular tumors, and metastases thereof. In some embodiments, the cancer is a relapsed or refractory cancer. In some embodiments, the cancer is resistant to one or more cancer therapies, e.g., one or more chemotherapeutic drugs.

[0015] In any and all embodiments of the methods disclosed herein, the engineered immune cells are administered pleurally, intravenously, subcutaneously, intranodally, intrathecally, intrapleurally or intraperitoneally. Additionally or alternatively, in some embodiments, the methods of the present technology further comprise administering an additional therapeutic agent.

[0016] In one aspect, the present disclosure provides a method of preparing immune cells for adoptive cell therapy comprising: (a) isolating immune cells from a donor subject; and (b) transducing the immune cells with a non-endogenous expression vector that includes a GNB4 nucleic acid sequence comprising SEQ ID NO: 1 or a nucleic acidencoding the Gp4 polypeptide comprising the amino acid sequence of SEQ ID NO: 2. The donor subject and the recipient subject may be the same or different. In certain embodiments, the immune cells isolated from the donor subject comprise macrophages or neutrophils.

[0017] In another aspect, the present disclosure provides a method of preparing immune cells for adoptive cell therapy comprising: (a) isolating immune cells from a donor subject; and (b) transducing the immune cells with (i) an inhibitory nucleic acid that specifically targets and inhibits the expression of the Gp4 nucleic acid sequence of SEQ ID NO: 1, and / or (ii) an expression vector that encodes a dominant negative Gp4 polypeptide. The inhibitory nucleic acid may be an antisense oligonucleotide, a siRNA, a sgRNA or a shRNA. In certain embodiments, the method further comprises administering the transduced cells to a recipient subject. The donor subject and the recipient subject may be the same or different. In certain embodiments, the immune cells isolated from the donor subject comprise macrophages or neutrophils.

[0018] In yet another aspect, the present disclosure provides a method of preparing immune cells for adoptive cell therapy comprising: (a) isolating immune cells from a donor subject; and (b) contacting the immune cells with at least one single guide RNA (sgRNA) and at least one endonuclease under conditions to produce engineered immune cells including a deletion, an insertion, an inversion, or a frameshift mutation in a GP4 gene, wherein the immune cells comprise an endogenous genome and wherein the sgRNA comprises at least one sequence that is complementary to a Gp4 nucleic acid sequence in the endogenous genome of the immune cells. In certain embodiments, the method further comprises administering the engineered immune cells to a recipient subject. The donor subject and the recipient subject may be the same or different. In certain embodiments, the immune cells isolated from the donor subject comprise macrophages or neutrophils.

[0019] In some embodiments, the donor subject and the recipient subject are the same. In other embodiments, the donor subject and the recipient subject are different.

[0020] Also disclosed herein are kits for treating CMTD including a vector comprising a heterologous GP4 nucleic acid and instructions for using the same to transduce immune cells. The present disclosure provides kits for treating systemic microbial infections and for enhancing the anti-tumor response of chimeric antigen receptor (CAR) immune cells comprising a Gp4-specific inhibitory nucleic acid or GP4 dominant-negative construct or avector comprising the same, and instructions for using the same to manufacture an engineered immune cell that lacks detectable expression or activity of Gp4. In any of the preceding embodiments of the kits disclosed herein, the engineered immune cell is a neutrophil or a macrophage.BRIEF DESCRIPTION OF THE DRAWINGS

[0021] Figs, la-lg: G|J4 neutrophils have increased phagocytic capacity for a wide range of targets. Fig. la. Schematic of workflow of CRISPR KO of AGP and microparticle flow cytometry phagocytosis assay. Fig. lb. WT and AGP mutants were challenged with human IgG coated microparticles (DPs) for 3 hours and phagocytosis was determined by a drop in FITC signal by flow cytometry. Data are mean ± s.d. of three experiments. One-way ANOVA, * p< 0.05, ** p< 0.01,0.0001. Fig. 1c. WT,AGP4, WT GP4 overexpressing, and AGP4 rescue cells were challenged with human IgG coated DPs. Data are mean ± s.d. of three experiments. One-way ANOVA, * p< 0.05 and0.0001. Fig. Id. AGP4 and WT cells were challenged with IgA coated DPs and were monitored for 3 hours by microscopy and accessed for individual cell phagocytic capacity. Scale bar is 20 um. Fig. le. WT and AGP4 neutrophils expressing F-tractin (red) were fed IgG coated DPs (green) and phagocytic cup closer was monitored over the course of 10-30 minutes with images taken every 15 sec. Fig. If. AGP4 and WT cells were challenged with either GFP expressing / Cypher or Alexa633 stained pseudomonas aeruginosa, FLARE aspergillus fumigatus, or UV irradiated Cypher or pHrodoRed stained apoptotic Jurkat corpses and accessed for uptake of the target by flow cytometry. Data are the mean ± s.d. from 3 separate experiments. Unpaired t test *** p< 0.001, **** p< 0.0001. Fig. 1g. Schematic of how anti-CD47 and anti-CD20 treatment inhibit RAMOS B lymphoma cell “don’t eat me” signal to promote phagocytic uptake and cancer cell clearance. AGP4 and WT cells were challenged with RAMOS B lymphoma cells with no treatment, anti-CD20, anti-CD47, or both anti-CD20 and anti-CD47. Data are mean ± s.d. of three experiments. One-way ANOVA, * p< 0.05, ** p< 0.01, **** p< 0.0001.

[0022] Figs. 2a-2d: G|J4 neutrophils unlike WT cells are not migration inhibited after phagocytosis. Fig. 2a. Schematic of micropipette assay. Figs. 2b-2d. AGP4 and WT cells were seeded onto a fibronectin coated slide and were exposed to 200 nM fMLP through a micropipette over the course of an hour. Alternatively AGP4 and WT that had consumed 1 DP were sorted and seeded at an equal 1 : 1 ratio on a fibronectin coated 35 mmcoverslip dish and were exposed to 200 nM fMLP through a micropipette over the course of an hour. Fig. 2b. Cells were tracked and the mean velocity of WT, WT + 1DP, AGP4, and AGP4 + 1DP was calculated from 3 separate 1 hour videos. Statistics were analyzed by One-way ANOVA *** p< 0.001, and0.0001. Representative images of cell morphology during migration either at baseline or after phagocytosis of 1 DP. Red angled line shows orientation and concentration of fMLP gradient. Scale bar 20 um. Fig. 2c. WT + 1DP and AGP4 + 1DP after 1 hour of exposure to 200 nM of fMLP were accessed for the distance traveled towards the point source. Statistical analysis was done by unpaired t test **** p<0.0001. Fig. 2d. Representative migration tracks for WT + 1DP and AGP4 + 1DP over the course of 1 hour exposure to 200 nM fMLP.

[0023] Figs. 3a-3h: G|J4 human neutrophil like cells have more plasma membrane and lower membrane tension. Fig. 3a. SEM images of WT and AGP mutants at baseline. Fig. 3b. AGP4 and WT cells were stained with potassium ferrocyanide + osmium tetroxide and processed for focused ion beam scanning electron microscopy (FIB- SEM). Using a helios FIB-SEM 40 nm sections were made and a 3D reconstruction and quantification of cellular compartments was made using labkit and Imaris. We performed FIB-SEM on two cells of each condition. Fig. 3c. The surface area to volume ratio for AGP4 and WT cells was calculated using labkit / Imaris. Fig. 3d. The total number of lipid droplets was calculated with AGP4 cells averaging ~50 vesicles while WT cells had ~20. Fig. 3e. The total volume of the lipid droplets was greater for the AGP4 than WT cells. Fig. 3f. Schematic of osmotic shock coulter counter experiment. Volume change in osmotically shocked WT and AGP mutants. Data are mean ± s.d. of three experiments. One-way ANOVA 0.0001. Fig. 3g. Optical trap measurements were made for AGP4 (n=39) and WT (36) before and after consuming DPs AGP4+IDP (n=30), WT+1DP (n=30), AGP4+2DPS (n=10). Data are mean ± s.d. of five experiments. One-way ANOVA, ***p< 0.001, 0.0001. Fig. 3h. WT or AGP4 were transduced with a lentivirus expressingGP4. WT (n=29), AGP4 (n=39), AGP4 rescue (n=31), and WT overexpressing GP4 (n=31) had their membrane tension measured. Data are mean ± s.d. of 5 experiments. One-way ANOVA **** p< 0.0001.

[0024] Figs. 4a-4e: G|J4 cells have larger amounts of sphingolipid species. Fig. 4a. Schematic overview of lipidomics and RNAseq workflow. WT and AGP4 cells at baseline had lipidomics performed. For RNAseq AGP4 and WT cells transcriptomes were comparedbetween baseline and after consumption of an IgG DP microparticle. Fig. 4b. Lipidomics LC-MS was performed on WT and AGP4 cells. Data represents ± s.d. of three biological replicates. Unpaired t test *** p< 0.001 and **** p< 0.0001. Fig. 4c. Schematic of myriocin treatment and expectation of decreased sphingolipid synthesis and thus less plasma membrane reservoirs in AGP4 cells. Figs. 4d-4e. WT, AGP4, or WT and AGP4 cells treated with myriocin (5 days during differentiation). Fig. 4d. membrane tension measurements for the cells was measured by a Lumikics C-trap. Data represent mean ± s.d. of 5 experiments. One-way ANOVA analysis was performed *** p< 0.001 and **** p< 0.0001. Fig. 4e. WT, AGP4 and WT, AGP4 treated with myriocin were challenged with IgG coated DPs and accessed for phagocytic uptake by flow cytometry. Data represent mean ± s.d. of 3 experiments. One-way ANOVA analysis was performed *** p< 0.001 and **** p< 0.0001.

[0025] Figs. 5a-5i: G|J4 primary human MO consume more myelin than WT MO. Fig. 5a. Model of our working hypothesis of how AGP4 primary human M contribute to CMTD. AGP4 M aberrantly consume the myelin sheath of peripheral neurons leading to demyelination, neuronal dysfunction, and death. Fig. 5b. Schematic of embryoid body formation from hiPSCs and differentiation of human primary macrophages from myeloid progenitor cells. AGP4 knockout hiPSCs were generated using CRISPR- Cas9. Three different AGP4 hiPSC lines were created along with two isogenic healthy WT controls. Primary human macrophage were generated from the three AGP4 lines along with two isogenic WT healthy controls. Fig. 5c. AGP4 (n=64) and WT isogenic control (n=46) primary human macrophage had their membrane tension measured using a C-trap. Data represent mean ± s.d. of 5 experiments. Unpaired t test **** p< 0.0001. Fig. 5d. Membrane tether length was measured by pulling membrane tethers until they snapped. The full max extension was calculated. Data represent mean ± s.d. of 5 experiments. Unpaired t test **** p< 0.0001. Fig. 5e. AGP4 and WT isogenic control M were osmotically shocked and allowed to expand to their full volume to access excess plasma membrane reservoirs. Cells were measured with a CellVue Blue coulter counter. Data is from 3 separate experiments with one-way ANOVA analysis performed0.0001. Fig. 5f To corroborate the phagocytic phenotype in human primary AGP4 M we challenged the cells with IgG coated DP microparticles for 2 hour and assessed phagocytic uptake by florescence microscopy. Data represent mean ± s.d. of 5 experiments. Unpaired t test **** p< 0.0001. Fig. 5g. Schematic of phagocytosis assay with CFSE / pHrodostained myelin. Fig. 5h. AGP4 and WT isogenic control cells were plated on fibronectin coated cover slips and myelin stained with CFSE / pHrodoRed was added. The cells were incubated with the stained myelin for 7 to 8 hours and images were taken ever 4 minutes. Representative images at 0, 3.5, and 7 hours after addition for both WT and AGP4 M$. Non-phagocytosed myelin CFSE (green), Phagocytosed myelin (red), cellular nuclei (blue). Fig- 5i. The number of pHrodoRed positive AGP4 and WT isogenic control was tabulated to access what percentage of cells had phagocytosed the myelin. Data are the mean ± s.d of 18 separate videos for each condition over three separate experiments. Unpaired t test **** p< 0.0001.

[0026] Figs. 6a-6c: Deletion of G(14 doesn’t effect differentiation of HL60 progenitors into neutrophils. Fig. 6a. Flow cytometry confirmation of GP knockouts. WT cells (red) and respective knocked out GP in blue. Fig. 6b. Western blot confirmation of AGP4 P-actin (green) and GP4 (red). Fig. 6c. WT and AGP4HL6O neutrophil progenitors were differentiated and stained with either human anti -CD 15 or anti-CD16 antibodies. Differentiated cells (green) and undifferentiated cells (gray).

[0027] Fig. 7: Deformable microparticles phagocytosis system. Schematic of DP microparticle fabrication, conjugating, coating of DP microparticles. Additionally, a schematic of how the labeled DPs once phagocytosed are quickly acidified in the phagolysosome leading to a drop in FITC signal and thus indicating uptake.

[0028] Figs. 8a-8f: G|J4 are capable of phagocytosing more of a wide range of diverse targets. Fig. 8a. Schematic of cell intrinsic phagocytosis experiment. AGP4 and WT cells were first stained with different fluorophores and were mixed in the same well. Fig. 8b. The cells were challenged with IgG coated DPs to access if the AGP4 phagocytic phenotype was cell intrinsic. Data are mean ± s.d. of three experiments. Unpaired t test **** p<0.0001. Fig. 8c. Flow cytometry confirmation of GP4 overexpression in AGP4 rescued cells. Fig. 8d. DP microparticles were coated with either phosphatidylserine (PS), complement (iC3B), human IgG, or human IgA to mimic efferocytosis, complement, FcyR, or FccrR mediated phagocytosis respectively. Data are mean ± s.e.m. of 3 experiments. Unpaired t-test **** p< 0.0001. Fig. 8e. AGP4 and WT cells were challenged with S. aureus bioparticles and the phagocytic activity was monitored by flow cytometry. Data are mean ± s.d. of three experiments. Unpaired t test **** p< 0.0001. Fig. 8f. The total number of AGP4 and WT cells that had killed the phagocytosed FLARE fungi was accessedby flow cytometry. Data are mean ± s.d. of three experiments. Unpaired t test **** p< 0.0001.

[0029] Figs. 9a-9d: AG|J4 cells have more plasma membrane and lipid droplets than WT cells. Fig. 9a. AGP4 than WT cells were stained with BioDIPY dye to stain and confirm the presence of lipid droplets (green), Hoerscht for nuclei (blue), and expressed F- tractin for F-actin expression (red). Scale bar 7 um. Fig. 9b. Lipid droplets were quantified from 20 frames to get total lipid droplets per cell in a frame. Unpaired t test **** p< 0.001. Fig. 9c. Glass coverslip chamber slides were coated with human IgG and AGP4 or WT cells expressing F-tractin-GFP and stained with cell mask orange were dropped onto slides to access cell spread and frustrated phagocytic cup size. Data are mean ± s.d. of three experiments, WT (n=45 cells), AGP4 (n= 36 cells). Unpaired t test * p< 0.05. Fig. 9d. Plasma membrane tethers were pulled until breaking using a C-trap. The length at tether breaking was measured for WT (n= 24), AGP4 (n=39), AGP4+IDP (n=27), WT+1DP (n=9), AGP4+2DPS (n=6). Data are mean ± s.e.m. of 5 experiments. One-way ANOVA, * p< 0.05, ** p< 0.01, **** p< 0.0001.

[0030] Figs. lOa-lOf: G|J4 cells have more sphingolipids and that sphingomyelin and ceramides are key components of plasma membrane reservoirs. Fig. 10a. Schematic of lipidomic pipeline performed on AGP4 and WT cells at steady state. Fig. 10b. PCA analysis was performed. AGP4 and WT cells clustered together nicely on a PCA plot. Fig. 10c. We identified a total of 98 different species in the two cell types. Overall there was more lipid content in the AGP4 cells with Ceramides and sphingomyelin contributing the most. PC species were removed from the graph for clarity as both cells had high levels of PC obscuring differences. Fig. lOd. Not all lipid species were upregulated in AGP4 cells some were rather enriched in WT cells or no change was observed between the two cell types. Fig. lOe. Schematic of myriocin inhibition of sphingolipid synthesis. Fig. lOf. AGP4 and WT cells were treated with myriocin acutely for 6 hours and then were fed IgG coated DP microparticles. There was no effect or reversion of the phagocytosis phenotype in myriocin treated AGP4 cells.

[0031] Figs, lla-llg: AG(14 primary murine neutrophils derived from ER-HoxB8 GMPs corroborate HL60 neutrophil phagocytosis phenotype. Fig. Ila. Schematic of generation of AGP4 and WT primary murine neutrophils from ER-HoxB8 progenitors. Fig. 11b. Flow confirmation of knockout of GP4. Fig. 11c. AGP4 and WT ER-HoxB8progenitors were differentiated and stained for CD1 lb and Ly6G expression. Differentiated cells (purple) and undifferentiated (gray). No difference in the ability to differentiate was observed. Fig. lid. Optical trap measurements were made on AGP4 and WT primary murine neutrophils. Data are mean s.d. from 3 experiments. Unpaired t test **** p< 0.0001. Fig. lie. Plasma membrane tethers were pulled until breaking to ascertain excess plasma membrane reservoirs. Data are mean s.d. from 3 experiments. Unpaired t test **** p< 0.05. Fig. Ilf. Osmotic shock was performed on AGP4 and WT primary murine neutrophils derived from ER-HoxB8 cells. Data are mean s.d. from 3 experiments.Unpaired t test **** p< 0.0001. Fig. 11g. AGP4 and WT primary murine neutrophils were fed pHrodo Red stained Staph aureus bioparticles and after 1 hour phagocytosis was accessed by flow cytometry. Data are from 3 separate experiments. Unpaired t test * p< 0.05 and **** p< 0.0001.

[0032] Fig 12: Schematic of generating primary human M<P from hiPSC’s and embryoid bodies. AGP4 and WT isogenic control hiPSCs were first plated onto irradiated mouse embryonic fibroblast (MEF). Once stabilized to grow on feeder cells embryoid body formation was induced. This process took one to two months. After Embryoid bodies (EB’s) were created granulocyte monocyte progenitor (GMPs) were continually produced. The GMPs were isolated and differentiated into primary human M over the course of 3 to 5 days.

[0033] Fig 13: CRISPR confirmation of AGP4 in primary human M. CRISPR KO was performed on hiPSC’s and several AGP4 and WT isogenic controls (cells that were not edited but went through the same process) had genomic DNA isolated from them, PCR was performed, and sanger sequencing was done to confirm gene editing.

[0034] Figs. 14a-14b: Confirmation of AG|J4 and WT primary human M<P are successfully generated from hiPSCs and that they have larger plasma membrane reservoirs. Fig. 14a. To access if AGP4 and WT isogenic control hiPSCs could successfully differentiate into primary human M we stained progenitors and mature M with anti-CD14, anti-CD68, and anti-CDl IB antibodies and performed flow cytometry. Fig. 14b. Working model of distinct progenitors giving rise to different professional phagocytic subtypes. WT progenitors express GP4 that acts as a break on plasma membrane abundance thus upon differentiation the professional phagocyte is limited in its consumption and motility. When GP4 is absent in the progenitor the cells the resulting differentiatedprofessional phagocytic cells has excess plasma membrane thus allowing it to engulf multiple targets while continuing to migrate in search of additional targets.

[0035] Figs. 15a-15h: G|J4 deficiency boosts phagocytic responses during in vivo fungal infection. WT and Gnb4- / - mice infected with FLARE A. fumigatus were assessed for in vivo phagocytosis and fungal infection after 18 h or 24 h. Fig. 15a. Schematic of the FLARE system. Conidia express dsRed and are labeled with AF633. Phagocytes become dsRed+AF633+ upon coni dial uptake, and then transition to dsRed-AF633+ as internalized conidia are destroyed. Fig. 15b. Neutrophil infiltration into the lung, 18 h post-infection. Fig. 15c. Quantification of A. fumigatus phagocytosis by lung neutrophils at the 18 h time point. Fig. 15d. Fungal CFU in lung extracts at the 18 h time point. Data in b-d represent mean s.d. of 3 experiments. Unpaired t test **** p< 0.0001. Fig. 15e. Representative flow cytometry plots showing neutrophil phagocytosis of FLARE A. fumigatus in the lungs, dLN, and spleen 24 h post-infection (magenta gates). Gates for neutrophils containing live (orange) and dead (blue) conidia are shown. Fig. 15f. Quantification of neutrophils bearing engulfed FLARE A. fumigatus in the dLN, 24 h post-infection. Fig. 15g. Quantification of neutrophils bearing engulfed FLARE A. fumigatus in the spleen, 24 h post-infection. Fig. 15h. Quantification of the neutrophils in the dLN containing live A. fumigatus, 24 h postinfection. Data in Figs. 15f-15h represent mean s.d. of 3 experiments. Unpaired t test **** p< 0.0001.

[0036] Figs. 16a-16d: Generation of Gnb4- / - mice. Figs. 16a-16b. Gnb4- / - mice were created by targeting exon 4 using CRISPR-Cas9. Fig. 16a. Above, a schematic diagram indicating the two double stranded breaks induced by CRISPR-Cas9, which afforded deletion of exon 4 along with some associated intronic sequences. Below, predicted mRNA and protein generated by the WT and knock-out Gnb4 loci. Only relevant sequences from exons 3, 4, and 5 are shown. Deletion of exon 4 leads to translational frameshift and premature termination of the Gnb4 protein at the magenta stop codon. Fig. 16b. Representative genotyping showing Gnb4 knock-out (KO) and WT bands. Fig. 16c. WT and Gnb4- / - mice infected with FLARE A. fumigatus were assessed for in vivo phagocytosis and fungal infection after 18 h. Graph shows quantification of fungal killing frequency, determined by dividing the number of Ly6G+CDl Ib+Siglec F- neutrophils containing dead conidia (dsRed-AF633+) by the total number of AF633+ neutrophils. Data are mean s.d. from 3 experiments. Fig. 16d. Quantification of AF633+ neutrophils in the blood 24 hours post i.t. infection with FLARE conidia.

[0037] Figs. 17a-17d: Survival of Gnb4- / - mice in fungal infection model.DETAILED DESCRIPTION

[0038] It is to be appreciated that certain aspects, modes, embodiments, variations and features of the present methods are described below in various levels of detail in order to provide a substantial understanding of the present technology.

[0039] In practicing the present methods, many conventional techniques in molecular biology, protein biochemistry, cell biology, immunology, microbiology and recombinant DNA are used. See, e.g., Sambrook and Russell eds. (2001) Molecular Cloning: A Laboratory Manual, 3rd edition; the series Ausubel et al. eds. (2007) Current Protocols in Molecular Biology, the series Methods in Enzymology (Academic Press, Inc., N.Y.); MacPherson et al. (1991) CT? 1: A Practical Approach (IRL Press at Oxford University Press); MacPherson et al. (1995) PCR 2: A Practical Approach,' Harlow and Lane eds. ( \ 999 Antibodies, A Laboratory Manual,' Freshney (2005) Culture of Animal Cells: A Manual of Basic Technique, 5th edition; Gait ed. (1984) Oligonucleotide Synthesis,' U.S. Patent No. 4,683,195; Hames and Higgins eds. (1984) Nucleic Acid Hybridization,' Anderson (1999) Nucleic Acid Hybridization,' Hames and Higgins eds. (1984) Transcription and Translation; Immobilized Cells and Enzymes (IRL Press (1986)); Perbal (1984) A Practical Guide to Molecular Cloning; Miller and Calos eds. (1987) Gene Transfer Vectors for Mammalian Cells (Cold Spring Harbor Laboratory); Makrides ed. (2003) Gene Transfer and Expression in Mammalian Cells; Mayer and Walker eds. (1987) Immunochemical Methods in Cell and Molecular Biology (Academic Press, London); and Herzenberg et al. eds (1996) Weir ’s Handbook of Experimental Immunology. Methods to detect and measure levels of polypeptide gene expression products (i.e., gene translation level) are well-known in the art and include the use of polypeptide detection methods such as antibody detection and quantification techniques. (See also, Strachan & Read, Human Molecular Genetics, Second Edition. (John Wiley and Sons, Inc., NY, 1999)).

[0040] Here we show that plasma membrane abundance is a key integrator of these physiological decisions. Neutrophils and macrophages lacking the heterotrimeric G-protein subunit GP4 exhibited dramatic expansion of their plasma membranes, accompanied by profound increase in both the rate and amplitude of their phagocytic responses. GP4 deficient neutrophils also lost the ability to arrest following cargo uptake. Lipidomic analysis linked these phenotypes to increased sphingolipid levels, and inhibitors ofsphingolipid synthesis reversed both plasma membrane expansion and hyperphagy in GP4 deficient cells. GP4 mutations are associated with Charcot-Marie-Tooth Disease (CMTD)3'7, a neurodegenerative disorder characterized by demyelination of peripheral nerves and infiltration of macrophages into the endoneurium. We investigated a potential role for phagocytosis in CMTD and found that induced pluripotent stem cell-derived macrophages lacking GP4 hyperconsumed purified myelin and also demyelinated cocultures of neurons and Schwann cells. Collectively, these results identify plasma membrane abundance as a master regulator of myeloid effector function and suggest that dysregulated phagocytosis underlies at least some forms of CMTD.Definitions

[0041] Unless defined otherwise, all technical and scientific terms used herein have the meaning commonly understood by a person skilled in the art to which this disclosure belongs. The following references provide one of skill with a general definition of many of the terms used in the present disclosure. Singleton et al., Dictionary of Microbiology and Molecular Biology (2nd ed. 1994); The Cambridge Dictionary of Science and Technology (Walker ed., 1988); The Glossary of Genetics, 5th Ed., R. Rieger etal. (eds.), Springer Verlag (1991); and Hale & Marham, The Harper Collins Dictionary of Biology (1991). As used herein, the following terms have the meanings ascribed to them below, unless specified otherwise. The terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the disclosure.

[0042] As used herein, the singular forms “a”, “an” and “the” are intended to include the plural forms as well, unless the context clearly indicates otherwise.

[0043] As used herein, the term “about” or “approximately” means within an acceptable error range for the particular value as determined by one of ordinary skill in the art, which will depend in part on how the value is measured or determined, i.e., the limitations of the measurement system. For example, “about” can mean within 3 or more than 3 standard deviations, per the practice in the art. Alternatively, “about” can mean a range of up to 20%, up to 10%, up to 5%, or up to 1% of a given value. Alternatively, particularly with respect to biological systems or processes, the term can mean within an order of magnitude, within 5- fold, or within 2-fold, of a value.

[0044] As used herein, the term “administration” of an agent to a subject includes any route of introducing or delivering the agent to a subject to perform its intended function.Administration can be carried out by any suitable route, including, but not limited to, intravenously, intramuscularly, intraperitoneally, subcutaneously, and other suitable routes as described herein. Administration includes self-administration and the administration by another. “Administration” of a cell or vector or other agent and compositions containing same can be performed in one dose, continuously or intermittently throughout the course of treatment. Methods of determining the most effective means and dosage of administration are known to those of skill in the art and will vary with the composition used for therapy, the purpose of the therapy, the target cell being treated, and the subject being treated. Single or multiple administrations can be carried out with the dose level and pattern being selected by the treating physician or in the case of animals, by the treating veterinarian. In some embodiments, administering or a grammatical variation thereof also refers to more than one doses with certain interval. In some embodiments, the interval is 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 1 week, 10 days, 2 weeks, 3 weeks, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 1 year or longer. In some embodiments, one dose is repeated for once, twice, three times, four times, five times, six times, seven times, eight times, nine times, ten times or more. Suitable dosage formulations and methods of administering the agents are known in the art. Route of administration can also be determined and method of determining the most effective route of administration are known to those of skill in the art and will vary with the composition used for treatment, the purpose of the treatment, the health condition or disease stage of the subject being treated, and target cell or tissue. Non-limiting examples of route of administration include oral administration, intraperitoneal, infusion, nasal administration, inhalation, injection, and topical application. In some embodiments, the administration is an infusion (for example to peripheral blood of a subject) over a certain period of time, such as about 30 minutes, about 1 hour, about 2 hours, about 3 hours, about 4 hours, about 5 hours, about 6 hours, about 7 hours, about 8 hours, about 9 hours, about 10 hours, about 11 hours, about 12 hours, about 24 hours or longer.

[0045] As used herein “adoptive cell therapeutic composition” refers to any composition comprising cells suitable for adoptive cell transfer. In exemplary embodiments, the adoptive cell therapeutic composition comprises peripheral blood mononuclear cells. In one embodiment, the adoptive cell therapeutic composition comprises neutrophils or macrophages.

[0046] The term “amino acid” refers to naturally occurring and non-naturally occurring amino acids, as well as amino acid analogs and amino acid mimetics that function in a mannersimilar to the naturally occurring amino acids. Naturally encoded amino acids are the 20 common amino acids (alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, and valine) and pyrolysine and selenocysteine. Amino acid analogs refer to agents that have the same basic chemical structure as a naturally occurring amino acid, i.e., an a carbon that is bound to a hydrogen, a carboxyl group, an amino group, and an R group, such as, homoserine, norleucine, methionine sulfoxide, methionine methyl sulfonium. Such analogs have modified R groups (such as, norleucine) or modified peptide backbones, but retain the same basic chemical structure as a naturally occurring amino acid. In some embodiments, amino acids forming a polypeptide are in the D form. In some embodiments, the amino acids forming a polypeptide are in the L form. In some embodiments, a first plurality of amino acids forming a polypeptide is in the D form and a second plurality is in the L form.

[0047] Amino acids are referred to herein by either their commonly known three letter symbols or by the one-letter symbols recommended by the IUPAC-IUB Biochemical Nomenclature Commission. Nucleotides, likewise, are referred to by their commonly accepted single-letter code.

[0048] As used herein, the term “analog” refers to a structurally related polypeptide or nucleic acid molecule having the function of a reference polypeptide or nucleic acid molecule.

[0049] As used herein, the term “antibody” means not only intact antibody molecules, but also fragments of antibody molecules that retain immunogen-binding ability. Such fragments are also well known in the art and are regularly employed both in vitro and in vivo. Accordingly, as used herein, the term “antibody” means not only intact immunoglobulin molecules but also the well-known active fragments F(ab')2, and Fab. F(ab')2, and Fab fragments that lack the Fc fragment of intact antibody, clear more rapidly from the circulation, and may have less non-specific tissue binding of an intact antibody (Wahl et al., J. Nucl. Med. 24:316-325 (1983)). Antibodies may comprise whole native antibodies, monoclonal antibodies, human antibodies, humanized antibodies, camelised antibodies, multispecific antibodies, bispecific antibodies, chimeric antibodies, Fab, Fab', single chain V region fragments (scFv), single domain antibodies (e.g., nanobodies and single domain cam elid antibodies), VNAR fragments, Bi-specific T-cell engager (BiTE) antibodies, minibodies, disulfide-linked Fvs (sdFv), and anti-idiotypic (anti-Id) antibodies, intrabodies, fusion polypeptides, unconventional antibodies and antigen binding fragmentsof any of the above. In particular, antibodies include immunoglobulin molecules and immunologically active fragments of immunoglobulin molecules, z.e., molecules that contain an antigen binding site. Immunoglobulin molecules can be of any type (e.g., IgG, IgE, IgM, IgD, IgA, and IgY), class (e.g., IgGl, IgG2, IgG3, IgG4, IgAl, and IgA2), or subclass.

[0050] In certain embodiments, an antibody is a glycoprotein comprising at least two heavy (H) chains and two light (L) chains inter-connected by disulfide bonds. Each heavy chain is comprised of a heavy chain variable region (abbreviated herein as VH) and a heavy chain constant (CH) region. The heavy chain constant region is comprised of three domains, CHI, CH2, and CH3. Each light chain is comprised of a light chain variable region (abbreviated herein as VL) and a light chain constant CL region. The light chain constant region is comprised of one domain, CL. The VH and VL regions can be further subdivided into regions of hypervariability, termed complementarity determining regions (CDR), interspersed with regions that are more conserved, termed framework regions (FR). Each VH and VL is composed of three CDRs and four FRs arranged from amino-terminus to carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4. The variable regions of the heavy and light chains contain a binding domain that interacts with an antigen. The constant regions of the antibodies may mediate the binding of the immunoglobulin to host tissues or factors, including various cells of the immune system (e.g., effector cells) and the first component (Cl q) of the classical complement system. As used herein interchangeably, the terms “antigen binding portion”, “antigen binding fragment”, or “antigen binding region” of an antibody, refer to the region or portion of an antibody that binds to the antigen and which confers antigen specificity to the antibody; fragments of antigen binding proteins, for example antibodies, include one or more fragments of an antibody that retain the ability to specifically bind to an antigen. It has been shown that the antigen binding function of an antibody can be performed by fragments of a full-length antibody. Examples of antigen binding portions encompassed within the term “antibody fragments” of an antibody include a Fab fragment, a monovalent fragment consisting of the VL, VH, CL and CHI domains; a F(ab)2 fragment, a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region; a Fd fragment consisting of the VH and CHI domains; a Fv fragment consisting of the VL and VH domains of a single arm of an antibody; a dAb fragment (Ward et al.. Nature 341 : 544-546 (1989)), which consists of a VH domain; and an isolated complementarity determiningregion (CDR). An “isolated antibody” or “isolated antigen binding protein” is one which has been identified and separated and / or recovered from a component of its natural environment. “Synthetic antibodies” or “recombinant antibodies” are generally generated using recombinant technology or using peptide synthetic techniques known to those of skill in the art.

[0051] Antibodies and antibody fragments can be wholly or partially derived from mammals (e.g., humans, non-human primates, goats, guinea pigs, hamsters, horses, mice, rats, rabbits and sheep) or non-mammalian antibody producing animals (e.g., chickens, ducks, geese, snakes, and urodele amphibians). The antibodies and antibody fragments can be produced in animals or produced outside of animals, such as from yeast or phage (e.g., as a single antibody or antibody fragment or as part of an antibody library).

[0052] Furthermore, although the two domains of the Fv fragment, VL and VH, are coded for by separate genes, they can be joined, using recombinant methods, by a synthetic linker that enables them to be made as a single protein chain in which the VL and VH regions pair to form monovalent molecules. These are known as single chain Fv (scFv); see e.g., Bird et al., Science 242:423-426 (1988); and Huston et al., Proc. Natl. Acad. Sci. 85 : 5879-5883 (1988). These antibody fragments are obtained using conventional techniques known to those of ordinary skill in the art, and the fragments are screened for utility in the same manner as are intact antibodies.

[0053] As used herein, the term “single-chain variable fragment” or “scFv” is a fusion protein of the variable regions of the heavy (VH) and light chains (VL) of an immunoglobulin (e.g., mouse or human) covalently linked to form a VH: :VL heterodimer. The heavy (VH) and light chains (VL) are either joined directly or joined by a peptide- encoding linker (e.g., about 10, 15, 20, 25 amino acids), which connects the N-terminus of the VH with the C-terminus of the VL, or the C-terminus of the VH with the N-terminus of the VL. The linker is usually rich in glycine for flexibility, as well as serine or threonine for solubility. The linker can link the heavy chain variable region and the light chain variable region of the extracellular antigen binding domain. In certain embodiments, the linker comprises amino acids having GGGGSGGGGSGGGGS (SEQ ID NO: 16). In certain embodiments, the nucleic acid sequence encoding the amino acid sequence of SEQ ID NO: 16 is ggcggcggcggatctggaggtggtggctcaggtggcggaggctcc (SEQ ID NO: 17).

[0054] Despite removal of the constant regions and the introduction of a linker, scFv proteins retain the specificity of the original immunoglobulin. Single chain Fv polypeptide antibodies can be expressed from a nucleic acid comprising VH- and VL-encoding sequences as described by Huston, et al. (Proc. Nat. Acad. Set. USA, 85:5879-5883 (1988)). See, also, U.S. Patent Nos. 5,091,513, 5,132,405 and 4,956,778; and U.S. Patent Publication Nos. 20050196754 and 20050196754. Antagonistic scFvs having inhibitory activity have been described (see, e.g., Zhao et al., Hybridoma (Larchmt) 27(6):455-51 (2008); Peter et al., J Cachexia Sarcopenia Muscle (2012); Shieh et al., J Imunol 183(4):2277-85 (2009); Giomarelli et al., Thromb Haemost 97(6):955-63 (2007); Fife eta., J Clin Invs 116(8):2252- 61 (2006); Brocks et al., Immunotechnology 3(3): 173-84 (1997); Moosmayer et al., Ther Immunol 2(10):31- 40 (1995). Agonistic scFvs having stimulatory activity have been described (see, e.g., Peter et al., J Biol Chem 25278(38):36740-7 (2003); Xie et al., Nat Biotech 15(8):768-71 (1997); Ledbetter et al., Crit Rev Immunol 17(5-6):427-55 (1997); Ho et al., Bio Chim Biophys Acta 1638(3):257-66 (2003)).

[0055] As used herein, an “antigen” refers to a molecule to which an antibody can selectively bind. The target antigen may be a protein e.g., an antigenic peptide), carbohydrate, nucleic acid, lipid, hapten, or other naturally occurring or synthetic compound. An antigen may also be administered to an animal subject to generate an immune response in the subject.

[0056] By “binding affinity” is meant the strength of the total noncovalent interactions between a single binding site of a molecule e.g., an antibody) and its binding partner e.g., an antigen). Without wishing to be bound by theory, affinity depends on the closeness of stereochemical fit between antibody combining sites and antigen determinants, on the size of the area of contact between them, and on the distribution of charged and hydrophobic groups. Affinity also includes the term “avidity,” which refers to the strength of the antigen-antibody bond after formation of reversible complexes e.g., either monovalent or multivalent). Methods for calculating the affinity of an antibody for an antigen are known in the art, comprising use of binding experiments to calculate affinity. The affinity of a molecule X for its partner Y can generally be represented by the dissociation constant (Ka). A low-affinity complex contains an antibody that generally tends to dissociate readily from the antigen, whereas a high-affinity complex contains an antibody that generally tends to remain bound to the antigen for a longer duration. Antibody activity in functional assays e.g., flow cytometry assay) is also reflective of antibody affinity. Antibodies and affinitiescan be phenotypically characterized and compared using functional assays e.g., flow cytometry assay).

[0057] As used herein, “CDRs” are defined as the complementarity determining region amino acid sequences of an antibody which are the hypervariable regions of immunoglobulin heavy and light chains. See, e.g., Kabat et al. , Sequences of Proteins of Immunological Interest, 4th U. S. Department of Health and Human Services, National Institutes of Health (1987). Generally, antibodies comprise three heavy chain and three light chain CDRs or CDR regions in the variable region. CDRs provide the majority of contact residues for the binding of the antibody to the antigen or epitope. In certain embodiments, the CDRs regions are delineated using the Kabat system (Kabat, E. A., et al. Sequences of Proteins of Immunological Interest, Fifth Edition, U.S. Department of Health and Human Services, NIH Publication No. 91-3242(1991)).

[0058] As used herein, the term “cell population” refers to a group of at least two cells expressing similar or different phenotypes. In non-limiting examples, a cell population can include at least about 10, at least about 100, at least about 200, at least about 300, at least about 400, at least about 500, at least about 600, at least about 700, at least about 800, at least about 900, at least about 1000 cells, at least about 10,000 cells, at least about 100,000 cells, at least about 1 x 106cells, at least about 1 x 107cells, at least about 1 x 108cells, at least about 1 x 109cells, at least about 1 x 1010cells, at least about 1 x 1011cells, at least about U 1012cells, or more cells expressing similar or different phenotypes.

[0059] As used herein, “complementary” sequences refer to two nucleotide sequences which, when aligned anti-parallel to each other, contain multiple individual nucleotide bases which pair with each other. Paring of nucleotide bases forms hydrogen bonds and thus stabilizes the double strand structure formed by the complementary sequences. It is not necessary for every nucleotide base in two sequences to pair with each other for sequences to be considered “complementary”. Sequences may be considered complementary, for example, if at least 30%, 40%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% of the nucleotide bases in two sequences pair with each other. In some embodiments, the term complementary refers to 100% of the nucleotide bases in two sequences pair with each other. In addition, sequences may still be considered “complementary” when the total lengths of the two sequences are significantly different from each other. For example, a primer of 15 nucleotides may be considered “complementary” to a longer polynucleotide containing hundreds of nucleotides if multipleindividual nucleotide bases of the primer pair with nucleotide bases in the longer polynucleotide when the primer is aligned anti-parallel to a particular region of the longer polynucleotide. Nucleotide bases paring is known in the field, such as in DNA, the purine adenine (A) pairs with the pyrimidine thymine (T) and the pyrimidine cytosine (C) always pairs with the purine guanine (G); while in RNA, adenine (A) pairs with uracil (U) and guanine (G) pairs with cytosine (C). Further, the nucleotide bases aligned anti-parallel to each other in two complementary sequences, but not a pair, are referred to herein as a mismatch.

[0060] As used herein, a “control” is an alternative sample used in an experiment for comparison purpose. A control can be “positive” or “negative.” For example, where the purpose of the experiment is to determine a correlation of the efficacy of a therapeutic agent for the treatment for a particular type of disease, a positive control (a composition known to exhibit the desired therapeutic effect) and a negative control (a subject or a sample that does not receive the therapy or receives a placebo) are typically employed.

[0061] As used herein, the term, “co-stimulatory signaling domain,” or “co-stimulatory domain”, refers to the portion of the CAR comprising the intracellular domain of a co- stimulatory molecule. Co-stimulatory molecules are cell surface molecules other than antigen receptors or Fc receptors that provide a second signal required for efficient activation and function of lymphocytes upon binding to antigen. Examples of such co- stimulatory molecules include CD27, CD28, 4-1BB (CD137), 0X40 (CD134), CD30, CD40, PD-1, ICOS (CD278), LFA-1, CD2, CD7, LIGHT, NKD2C, B7-H2 and a ligand that specifically binds CD83. Accordingly, while the present disclosure provides exemplary costimulatory domains derived from CD28 and 4- IBB, other costimulatory domains are contemplated for use with the CARs described herein. The inclusion of one or more co- stimulatory signaling domains can enhance the efficacy and expansion of immune cells expressing CAR receptors. The intracellular signaling and co-stimulatory signaling domains can be linked in any order in tandem to the carboxyl terminus of the transmembrane domain.

[0062] As used herein, the term “effective amount” or “therapeutically effective amount” refers to a quantity of an agent sufficient to achieve a beneficial or desired clinical result upon treatment. In the context of therapeutic applications, the amount of a therapeutic agent administered to the subject can depend on the type and severity of the disease or condition and on the characteristics of the individual, such as general health, age, sex, body weight,effective concentration of the engineered immune cells administered, and tolerance to drugs. It can also depend on the degree, severity, and type of disease. The skilled artisan will be able to determine appropriate dosages depending on these and other factors. An effective amount can be administered to a subject in one or more doses. In terms of treatment, an effective amount is an amount that is sufficient to palliate, ameliorate, stabilize, reverse or slow the progression of the disease, or otherwise reduce the pathological consequences of the disease. The effective amount is generally determined by the physician on a case-by-case basis and is within the skill of one in the art.

[0063] As used herein, the term “engineered immune cell” refers to an immune cell that is genetically modified.

[0064] As used herein, the term “expression” refers to the process by which polynucleotides are transcribed into mRNA and / or the process by which the transcribed mRNA is subsequently being translated into peptides, polypeptides, or proteins. If the polynucleotide is derived from genomic DNA, expression can include splicing of the mRNA in a eukaryotic cell. The expression level of a gene can be determined by measuring the amount of mRNA or protein in a cell or tissue sample. In one aspect, the expression level of a gene from one sample can be directly compared to the expression level of that gene from a control or reference sample. In another aspect, the expression level of a gene from one sample can be directly compared to the expression level of that gene from the same sample following administration of the compositions disclosed herein. The term “expression” also refers to one or more of the following events: (1) production of an RNA template from a DNA sequence (e.g., by transcription) within a cell; (2) processing of an RNA transcript (e.g., by splicing, editing, 5’ cap formation, and / or 3’ end formation) within a cell; (3) translation of an RNA sequence into a polypeptide or protein within a cell; (4) post-translational modification of a polypeptide or protein within a cell; (5) presentation of a polypeptide or protein on the cell surface; and (6) secretion or presentation or release of a polypeptide or protein from a cell.

[0065] As used herein, an "expression vector" includes vectors capable of expressing DNA that is operatively linked with regulatory sequences, such as promoter regions, that are capable of effecting expression of such DNA fragments. Such additional segments can include promoter and terminator sequences, and optionally can include one or more origins of replication, one or more selectable markers, an enhancer, a polyadenylation signal, and the like. Expression vectors are generally derived from plasmid or viral DNA, or can contain elements of both. Thus, an expression vector refers to a recombinant DNA or RNA construct,such as a plasmid, a phage, recombinant virus or other vector that, upon introduction into an appropriate host cell, results in expression of the cloned DNA. Appropriate expression vectors are well known to those of skill in the art and include those that are replicable in eukaryotic cells and / or prokaryotic cells and those that remain episomal or those which integrate into the host cell genome.

[0066] As used herein, the term “heterologous nucleic acid molecule or polypeptide” refers to a nucleic acid molecule (e.g., a cDNA, DNA or RNA molecule) or polypeptide that is either not normally expressed or is expressed at an aberrant level in a cell or sample obtained from a cell. This nucleic acid can be from another organism, or it can be, for example, an mRNA molecule that is not normally expressed in a cell or sample.

[0067] As used herein, the term “immune cell” refers to any cell that plays a role in the immune response of a subject. Immune cells are of hematopoietic origin, and include lymphocytes, such as B cells and T cells ; natural killer cells; myeloid cells, such as monocytes, macrophages, dendritic cells, eosinophils, neutrophils, mast cells, basophils, and granulocytes. As used herein, the term “engineered immune cell” refers to an immune cell that is genetically modified. As used herein, the term “native immune cell” refers to an immune cell that naturally occurs in the immune system.

[0068] As used herein, "operably linked" with reference to nucleic acid sequences, regions, elements or domains means that the nucleic acid regions are functionally related to each other. For example, nucleic acid encoding a leader peptide can be operably linked to nucleic acid encoding a polypeptide, whereby the nucleic acids can be transcribed and translated to express a functional fusion protein, wherein the leader peptide effects secretion of the fusion polypeptide. In some instances, the nucleic acid encoding a first polypeptide (e.g., a leader peptide) is operably linked to nucleic acid encoding a second polypeptide and the nucleic acids are transcribed as a single mRNA transcript, but translation of the mRNA transcript can result in one of two polypeptides being expressed. For example, an amber stop codon can be located between the nucleic acid encoding the first polypeptide and the nucleic acid encoding the second polypeptide, such that, when introduced into a partial amber suppressor cell, the resulting single mRNA transcript can be translated to produce either a fusion protein containing the first and second polypeptides, or can be translated to produce only the first polypeptide. In another example, a promoter can be operably linked to nucleic acid encoding a polypeptide, whereby the promoter regulates or mediates the transcription of the nucleic acid.

[0069] The term “myeloid cell” refers to all immature, mature, undifferentiated, and differentiated white blood cell populations that are derived from myeloid progenitors including tissue specific and specialized varieties, and encompasses, by way of non-limiting example, granulocytes (z.e., mast cells, neutrophils, eosinophils and basophils), monocytes, macrophages, and dendritic cells.

[0070] As used herein, the “percent homology” between two amino acid sequences is equivalent to the percent identity between the two sequences. The percent identity between the two sequences is a function of the number of identical positions shared by the sequences (z.e., % homology = # of identical positions / total # of positions x 100), taking into account the number of gaps, and the length of each gap, which need to be introduced for optimal alignment of the two sequences. The comparison of sequences and determination of percent identity between two sequences can be accomplished using a mathematical algorithm.

[0001] The percent homology between two amino acid sequences can be determined using the algorithm of E. Meyers and W. Miller (Comput. AppL Biosci., 4: 1 1-17 (1988)) which has been incorporated into the ALIGN program (version 2.0), using a PAM120 weight residue table, a gap length penalty of 12 and a gap penalty of 4. In addition, the percent homology between two amino acid sequences can be determined using the Needleman and Wunsch (J Mol. Biol. 48:444-453 (1970)) algorithm which has been incorporated into the GAP program in the GCG software package (available at www.gcg.com), using either a Blossum 62 matrix or a PAM250 matrix, and a gap weight of 16, 14, 12, 10, 8, 6, or 4 and a length weight of 1, 2, 3, 4, 5, or 6.

[0071] Additionally or alternatively, the amino acids sequences of the presently disclosed subject matter can further be used as a “query sequence” to perform a search against public databases to, for example, identify related sequences. Such searches can be performed using the XBLAST program (version 2.0) of Altschul, et al. (1990) J. Mol. Biol. 215 :403-10. BLAST protein searches can be performed with the XBLAST program, score = 50, wordlength = 3 to obtain amino acid sequences homologous to the specified sequences disclosed herein. To obtain gapped alignments for comparison purposes, Gapped BLAST can be utilized as described in Altschul et al.. (1997) Nucleic Acids Res.25(17):3389-3402. When utilizing BLAST and Gapped BLAST programs, the default parameters of the respective programs (e.g., XBLAST and NBLAST) can be used.

[0072] The terms “polynucleotide”, “nucleic acid” and “oligonucleotide” are used interchangeably and refer to a polymeric form of nucleotides of any length, either deoxyribonucleotides or ribonucleotides or analogs thereof. Polynucleotides can have any three-dimensional structure and may perform any function, known or unknown. The following are non-limiting examples of polynucleotides: a gene or gene fragment (for example, a probe, primer, EST or SAGE tag), exons, introns, messenger RNA (mRNA), transfer RNA, ribosomal RNA, ribozymes, cDNA, recombinant polynucleotides, branched polynucleotides, plasmids, vectors, isolated DNA of any sequence, isolated RNA of any sequence, nucleic acid probes and primers. A polynucleotide can comprise modified nucleotides, such as methylated nucleotides and nucleotide analogs. If present, modifications to the nucleotide structure can be imparted before or after assembly of the polynucleotide. The sequence of nucleotides can be interrupted by non-nucleotide components. A polynucleotide can be further modified after polymerization, such as by conjugation with a labeling component. The term also refers to both double- and single-stranded molecules. Unless otherwise specified or required, any embodiment of this disclosure that is a polynucleotide encompasses both the double-stranded form and each of two complementary single-stranded forms known or predicted to make up the double-stranded form. A polynucleotide is composed of a specific sequence of four nucleotide bases: adenine (A); cytosine (C); guanine (G); thymine (T); and uracil (U) for thymine when the polynucleotide is RNA. Thus, the term “polynucleotide sequence” is the alphabetical representation of a polynucleotide molecule. This alphabetical representation can be input into databases in a computer having a central processing unit and used for bioinformatics applications such as functional genomics and homology searching.

[0073] The terms “polypeptide,” “peptide,” and “protein” are used interchangeably herein to refer to a polymer of amino acid residues. The terms apply to naturally occurring amino acid polymers as well as amino acid polymers in which one or more amino acid residues is a non-naturally occurring amino acid, e.g., an amino acid analog. The terms encompass amino acid chains of any length, including full length proteins, wherein the amino acid residues are linked by covalent peptide bonds.

[0074] As used herein, “expression control sequence” or “regulatory region” of a nucleic acid molecule means a cis- acting nucleotide sequence that influences expression, positively or negatively, of an operatively linked gene. Regulatory regions include sequences of nucleotides that confer inducible (z.e., require a substance or stimulus for increasedtranscription) expression of a gene. When an inducer is present or at increased concentration, gene expression can be increased. Regulatory regions also include sequences that confer repression of gene expression (z.e., a substance or stimulus decreases transcription). When a repressor is present or at increased concentration gene expression can be decreased. Regulatory regions are known to influence, modulate or control many in vivo biological activities including cell proliferation, cell growth and death, cell differentiation and immune modulation. Regulatory regions typically bind to one or more trans-acting proteins, which results in either increased or decreased transcription of the gene.

[0075] Particular examples of gene regulatory regions are promoters and enhancers. Promoters are sequences located around the transcription or translation start site, typically positioned 5' of the translation start site. Promoters usually are located within 1 Kb of the translation start site, but can be located further away, for example, 2 Kb, 3 Kb, 4 Kb, 5 Kb or more, up to and including 10 Kb. Enhancers are known to influence gene expression when positioned 5' or 3' of the gene, or when positioned in or a part of an exon or an intron. Enhancers also can function at a significant distance from the gene, for example, at a distance from about 3 Kb, 5 Kb, 7 Kb, 10 Kb, 15 Kb or more.

[0076] Regulatory regions also include, but are not limited to, in addition to promoter regions, sequences that facilitate translation, splicing signals for introns, maintenance of the correct reading frame of the gene to permit in-frame translation of mRNA and, stop codons, leader sequences and fusion partner sequences, internal ribosome binding site (IRES) elements for the creation of multigene, or polycistronic, messages, polyadenylation signals to provide proper polyadenylation of the transcript of a gene of interest and stop codons, and can be optionally included in an expression vector.

[0077] As used herein, the term “separate” therapeutic use refers to an administration of at least two active ingredients at the same time or at substantially the same time by different routes.

[0078] As used herein, the term “sequential” therapeutic use refers to administration of at least two active ingredients at different times, the administration route being identical or different. More particularly, sequential use refers to the whole administration of one of the active ingredients before administration of the other or others commences. It is thus possible to administer one of the active ingredients over several minutes, hours, or daysbefore administering the other active ingredient or ingredients. There is no simultaneous treatment in this case.

[0079] As used herein, the term “simultaneous” therapeutic use refers to the administration of at least two active ingredients by the same route and at the same time or at substantially the same time.

[0080] As used herein, the terms “subject,” “individual,” or “patient” are used interchangeably and refer to an individual organism, a vertebrate, or a mammal and may include humans, non-human primates, rodents, and the like (e.g., which is to be the recipient of a particular treatment, or from whom cells are harvested). In certain embodiments, the individual, patient or subject is a human.

[0081] “Treating” or “treatment” as used herein covers the treatment of a disease or disorder described herein, in a subject, such as a human, and includes: (i) inhibiting a disease or disorder, i.e., arresting its development; (ii) relieving a disease or disorder, i.e., causing regression of the disorder; (iii) slowing progression of the disorder; and / or (iv) inhibiting, relieving, or slowing progression of one or more symptoms of the disease or disorder. Therapeutic effects of treatment include, without limitation, inhibiting recurrence of disease, alleviation of symptoms, diminishment of any direct or indirect pathological consequences of the disease, preventing metastases, decreasing the rate of disease progression, amelioration or palliation of the disease state, and remission or improved prognosis. It is also to be appreciated that the various modes of treatment of diseases as described herein are intended to mean “substantial,” which includes total but also less than total treatment, and wherein some biologically or medically relevant result is achieved. The treatment may be a continuous prolonged treatment for a chronic disease or a single, or few time administrations for the treatment of an acute condition.

[0082] The compositions used in accordance with the disclosure can be packaged in dosage unit form for ease of administration and uniformity of dosage. The term "unit dose" or "dosage" refers to physically discrete units suitable for use in a subject, each unit containing a predetermined quantity of the composition calculated to produce the desired responses in association with its administration, i.e., the appropriate route and regimen. The quantity to be administered, both according to number of treatments and unit dose, depends on the result and / or protection desired. Precise amounts of the composition also depend on the judgment of the practitioner and are peculiar to each individual. Factors affecting doseinclude physical and clinical state of the subject, route of administration, intended goal of treatment (alleviation of symptoms versus cure), and potency, stability, and toxicity of the particular composition. Upon formulation, solutions are administered in a manner compatible with the dosage formulation and in such amount as is therapeutically or prophylactically effective. The formulations are easily administered in a variety of dosage forms, such as the type of injectable solutions described herein.GB4

[0083] The G-Protein-Coupled Receptor (GPCR) superfamily includes over 800 members in humans and is the largest group of cell-surface seven-transmembrane receptors. GPCRs translate the signal from extracellular ligands into intracellular responses and have a ligand-binding pocket, with seven motif a-helices, in the extracellular region, and a cytoplasmic domain engaged in G-proteins binding, guanosine triphosphate (GTP)-binding heterotrimers, consisting of a, P, and y subunits. The human genome contains five genes (GNB1 to GNB5) encoding the different Gp subunits.

[0084] Heterozygous pathogenic variants in GNB4 gene have been reported as causative of intermediate Charcot-Marie-Tooth disease F (CMTDIF, MIM#615185), an autosomal dominant form of CMT. CMT is a neurologic disorder characterized by progressive distal muscle atrophy and weakness and variable nerve conduction velocities ranging from the demyelinating to the axonal range. The pathogenicity of the variants and the importance of GPCR signaling in peripheral-nerve function in humans were supported by the reduced GP4 immunostaining in the axon and Schwann cells of peripheral nerves of affected individuals.

[0085] An exemplary Gp4 nucleic acid sequence is provided below:>NM_021629.4 Homo sapiens G protein subunit beta 4 (GNB4), mRNA (SEQ ID NO: 1) GTGGCCGGCGGCTCTGGTCTCGGCTGTGAGCTGCGCTCTCCACGCCGGCTCCGCGCTCCAGGGGCTGCTG AGCGCCCAGCGGACACCGGCAGCGCGCGGTCGACGCGGGCCTGAGCTCCCTCCAGCTGTTTTCACTCATT AGCTCCTGAGGTAAACAAATTGAAAAAATGAGCGAACTGGAACAGTTGAGGCAAGAAGCAGAACAACTGC GGAATCAGATTCAGGATGCTCGGAAAGCATGTAATGATGCAACGCTTGTTCAGATTACATCAAATATGGA CTCTGTGGGTCGAATACAAATGCGAACAAGACGTACACTGAGGGGCCACCTAGCTAAAATCTATGCTATG CATTGGGGATACGATTCCAGGCTGCTAGTCAGTGCTTCTCAAGATGGAAAATTAATTATTTGGGATAGCT ATACAACAAATAAGATGCATGCTATTCCTTTGAGGTCCTCCTGGGTGATGACCTGTGCTTATGCTCCCTC TGGTAATTATGTTGCCTGTGGAGGCTTGGACAACATCTGCTCTATATATAACTTAAAGACCAGAGAGGGA AATGTGAGAGTAAGCCGAGAGTTGCCAGGTCACACAGGGTACTTGTCCTGCTGTCGTTTTTTAGATGACAGCCAAATTGTTACAAGTTCAGGAGATACAACTTGTGCTTTATGGGACATCGAAACTGCCCAGCAGACCACCACATTCACTGGGCATTCTGGAGATGTGATGAGTCTTTCTTTGAGTCCTGACATGAGGACTTTTGTTTCTGGTGCTTGTGATGCCTCTTCCAAATTATGGGATATTCGAGATGGAATGTGTAGACAGTCTTTCACGGGACATGTCTCAGATATCAATGCTGTCAGTTTTTTCCCAAATGGATATGCCTTCGCCACTGGCTCTGATGATGCCACTTGCCGGCTCTTTGACCTTCGTGCAGATCAAGAGTTATTATTGTATTCTCATGACAATATCATCTGTGGAATCACTTCTGTAGCCTTCTCAAAAAGTGGGCGTCTCTTGTTGGCTGGTTACGATGACTTTAATTGTAATGTATGGGACACGCTAAAAGGAGATCGTGCAGGTGTCCTTGCTGGTCATGACAACCGTGTGAGCTGCTTAGGTGTAACTGATGATGGCATGGCTGTGGCAACAGGCTCTTGGGACAGTTTTCTTAGAATCTGGAATTAACAGTGTCATACATATTTGTTCTCCATTGATATATCTGGAGAAATCAATGCTACAGCCTATAGCTGTGAAAAAATTCTACCTTATATTTGCAGGTGAAGATTTTTCTATTAGATTATCTACAAAAACAAGCTTTCAGTAAACTACCAAAAAAAAAGTGGGGGTGGAGGAAAAAAGGCAAAGGCGCCTTCTGAGATCAAAAGGACCAGTGTATTAATTTGAGGGGTTGGGTTATTTTAACCTTGGTGAATTGTTGTGTGTACTCAGAGTGTATTTTCTTTGTGTAGAACAGAATGTACACATTATAGCAGCTCGCCATTGTGTTTGCATTTTTTAAGAAGTACATTTTTAACTTTGTATACACAAGAAATGTCATATTTTTGAGTTTTGTAATGGAAGAACCAGGCACAGAAACAGACAGAAATGATACTGTATGTGTGTGTATTTATGTCTGAAGAAAGTCCCCTTGAATTCTGATATCTCTTTGAATCTAAGAGATCCTGATAGCTTCATGTTTAAGAGCATTGACAGGTGGGGCACCTCTGAGGGGAGTTCATTGTTTCTCATGCATCATTTGCCATATACTATTAATCAAAGTGCTTGCTTTCAGTCCTTTGAGGGGACAGATAATCTGAAGGCCAGAGATTAGAGATTTCACTGATATTTTGGACATACATAAGAAACATCATTATAATTAATAAAAAGTAGGTAATAGCATATAAATGGTTCTTGACATTTTAAAAGCCTGGTTATGATCAGTTGACACTTTGAGTACCCCCCTAAATAGCTGGACTTTCCTTTTCATTTCATATTTGGAACTAAGTTTGTAGCGTATACTCATCTTTCAGAAGTTTGGTAAACATTGGGATTGTCCCTGCATCTGAACATCTTTCCCAGTGCTATCAGTATACATCTAGAGAGGAAATGCAATGTGACAGTGTTACATTTGGAGAGAAGTGTGAAATCTAACCAATCGCTAGCACATATTTGTTGTAATACGGTGGTTTATTTCATGTTTGCATACTATAAAATCTGAATTGATGTGAAATATCTGTGCCTTTAAATTTCTTAAACCTTTAAGCTTTTTGTTCTGTTTTGCAACATTTTGTAGTATTTCTTCCCTTCCTTAGCACAAAATACTGGTTTCTAAGTGGTTTTGCTTCAAAGGATGTCTAGATGTAAGTGATTCCACTTAAAGCCAAAATAAAAATTCCTAAAGCAGTTCTTAAAGGAGTTAGAGAGCTATATTAAACAGTTTTTCTGTGGTATAATAATGTGTCTCTTACTAGAAGTCCCCCACGACCAAGTTAAAGATACTTTTCCTGTTGGATTCTCTTTTACAAATAAGTCTAAATGACTGATAATAGAAGATTGTTAGTCTTGCTTGATGGTAAAGTCTTGGATTATTCTGATATATAGACGTGCATTGTTTTGTAACTTAGTTACTTTTCAGATAGGTCTGTGTTAACTTTTGAACATGTGTAACTTAACCTAAATACTCCCAAACTTTACCTCTAAATTTTTGTTTTTATGTTGTGAATGTGCTAATATGTGCATCAACTGTAAAGATGTATCAGTTTTATTAAAATCAGTTGACAATTAGAATAATAAAGTGGATAAAGGCAAATTAAGATATAGGACCAAAACAGAATATTGTAGATGGCAGTTATGAATGTATATTTATATTTTGATTAAGATTTCTATTAACTTTTTGGCTGGGCAGAGTGGCTTACACCTATAATCCCAGCAATTTGGGAGGCCAAGGTGGGCAGATCACTTGAGGTCAGGAGTTCGCGACCAGCCTACCCAACATGGTGAAACCCCATCTCTTCTAAAAATACAAACATTAGCCGGGCGTGGTGGCACATTCCTGTAATCCCAGCTACTCGGGAGGCTGAGGCAGGAGATTCGCCTGAACCCGGGAGGCAGAGGTTGCAGTGAGCCGAGATTGTGCCACTGCACTCCAGCCTAGGCGACAGAGTGAGACTCCATCTCAAATTGGAAAAAAAAAAAATTATATGAACTTTTGCTATTAATGTTTATTTGTAGGCTATTTATATCACTTCATAAAGAACAGTTCTTTGAGAAAAGAATAAAGGAATGTATTCATTTCCAGAAAAAGAGGGTTGGGGAAAGTTTGCCATGTAGGTTAGTCAGAAGAAAGCAATTCTATTATGCATAAAAATAACCTTAAATATGTAAGAGAGTATCTCCTCTACTTAAAAGTTATTATAGTAGTCACAGGCATACAGACCACAGGAATTCTATGGTCTTAACATATTTTAAAATTACATTTATTTTAATGTTCTTAAAGTTTATGAAGAGGAGTTTAAAGCAATTCCCATAATTAAATATTTACTCGGCAACTAAAAACTATTTAACACTTGTGGTTAATTATACACATAAACAAATGGCGACAGAGTAGCCTCACTACCACAATTACTTCATGGTTACACCTTTGCTTTCTAATAATAGGGGCTCCAGTTGCTAAATATATTTGTTTACTTACAGTTTAAGTTGAGCTGATTGTTGAATTCTGTTATTGTTCCTGAATTCAATGAGTATATAATTTGTAGAGATGTTGAATAGTTTGGATCTTAGTTTTTAAGGCTGAAAAATCTGGCTGGATTTAGTTTTTAAAAATTTGCATCATCAAGAATATTGCAGTTAATGTTCCTTTTTTTTTTTTTTTAAAGACAGAGTCTCACTCTGTCACCCAGGCTGGAGTGTACAGTGGTGTGATTTTGGCTCATTGCAACCTCAACCTCTGCCTCCTGGGTTCAAGCAATTCTTGTGCCTCAGCCTCCCAAGTAGCTGGGACTATAGGCATGTGCCACCATGCCCGGCTAATTTTTGTATTTTTAGTAGAGATGGGGTTTCACCATCTTGGCCAGTCTGATCTCGTACTCCTGGCCTCAAGTGATCCACCAGCCTCAGCCTCCCAAAGTGCTGGGATTACAGACGTGAGCCACCGTGCCCAGCCAGGTTTCCTTCTTTACCTTCTAAGAAACATTTAAACATAATGTGCCTGAGAAGGTTAATTTGTTGACTCTGTAGCATGTCAAGAAGAGTAGTTTTTTGAGATCTGGCAAGAATATTTTAGAGATACATATTCTTTTCTAAGTATGTTATCACCCTGTGGTGTTGAGCATATCGTCCCAAAAACCTGCTTCAGCAAGCAGTTCTTGGCCAGGCATGGTGGCTCACACCTGTAATCCCAGCACTTTGGGAGGCCGAGGCAGGTGGATCACGAGGTCAGGAGTTCAAGACCAGCCTGGCCAAGATGGTGAAACCCCATCTCTACTAAAAATACAAAAATTAGCCGGGCGTGGAGGTGGGCGCCTGTCAGCTACTCGTGAGGCTGAGGCAGAGAATTACTTGAACTCAGGAGGTGGAGGTTTTGGTGAGCTGAGATGGCGCCACTGCACTCCAACCCGAGCGACAGAGCAAGATTCCGTCCCAAAAAGAAAAAGCAGTTTTTGCCATCAGCAAGGATATCTCCTCCACTTTAATGGACAGGCCTCATTTTTGGCAGCTATGCTGTTTGAGATGTAGACTGAATATCCAAGGTTCCTCCCTAGCTCAAGTTTTTACTTGTGATTACACACACCACATTGAATTCCGTCTTCAGAGGCAAAGATTTGGGCTTCATATCTCAACAGCAAAAGGGCCTGTTCAGCAATTCCCTTCATTTTAGACTCATATGACCTCAGCGATTGCATGATAGTAGTAAACTAGTCTCCTGGAAATAATGGATGTAGGTGCTTCTAGAATATGTTACAGAATTTCAGACTTAACCTATTAATAGATAAATGGATCTTGACTTAAGGTGACAAAATGAAACTTTTATTATTGCTTAAAAATGCTGTGCCAATATTGTATAACTAGCTCCTCTAATACTTTTGGTATTTTGGATTTAATAATAAGACCTTAAGCATTTTAAATGTGAACATGTTCAGGGAAGTATGCTTTGATGTAAATGTCTCAGATCTAAGTTGTAACACAATTGAATACTTGTGGCTTATTCTTGGTTTAACTTAGGAAAACTGGTTAAACAATCCCCCATTTGGGCCTGTCATCATTTTAATAGTGACGATGTTCTTTCTGAAATCTTCAGGGTCGGAGTCAGGCTGAATTTTTTTAAAAATTAAATATTATGTTCAAATTCTTTCCTTTTTGCCATTGTGAAAAAGCAAAATTTTAAATGATTTCTCCTGTTAGAATTTTTAAAAATACCCACAGGTTGGACCATCTTTCTTATGGGTTGCACAATGAATTTATATTTTAAATTAGATTAAGTAGAATGTGAAGTACATTTCAGATTTACTAGTTTTCTTTCCATTGTTCATTTTGGGTTGCCTCAGATTCAGTGTATATTTTAAAATATTGGTTACATAATAGGTACTCAATGAAATGGTTTATAGTAGAATATCTAAGCTAGCACTTTATTTTAAAAAGTAACTTATTAATTAATCACACATTGATGGTACACCTTGTATTTAGCAAATGTTTGCATGTTGATAAAATCTCCTATGTCTTCTTTCTTAAATCCA GTTGCTGATTTTGTAAAATACAGTTGTGATAAAGCAGCATTACGGGGGGGAAAAAGCTATATTCCAACTG GTGTTAAATGTATTCAACAAAATCTTACATCATACAGTATTTATTTCTTAATTAATAGAACTTCAGTGAT ATACTTGGTAGATATCTCAAGCCTTTTGTCTTTTACACAATGGTGCTCTATCCTATTGTTTTCTTTTCAA AGAAGCATCTGAACACTTGCATTTCTATTTTCCTATCCAAAGGCATCCACATCTAAGTGTGTTTTTAAAG TTGATTAAAATTATTTTTCTGTTAAAGCATTCTGAAAGTGTTTGTCTTTACCTAGAATGATTTGTACACA CTCGTGGTCAACTGAACATGAATGTCAGTAGTAGTCTAATTATGGGAAGGGTAAACGTGTTAGATTAAGG CTCTTAAAGCTCTAAACCATATAAACTATGGACTTGTATCATGATTTAACTGTTCTTAGATCTTTCTTAC ACAGTGATTCATTCCTCTATTTGTACAGTGGCTTTATGAAATGTTGTGAATTGATACTGTAATCAATAAA GTGCTTTTAACCAGA

[0086] In some embodiments, the engineered immune cells comprise a heterologous nucleic acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 1. Additionally or alternatively, in some embodiments, the expression levels and / or activity of Gp4 in the engineered immune cell is at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 20, at least 30, at least 40, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, at least 200, at least 300, at least 400, at least 500, at least 600, at least 700, at least 800, at least 900, or at least 1000 times higher compared to that observed in a native immune cell, wherein the engineered immune cell is of the same lineage as the native immune cell.

[0087] In some embodiments, the engineered immune cell further comprises a first regulatory sequence operatively linked to the nucleic acid encoding the GP4. In further embodiments, the first regulatory sequence directs the expression of the GP4. Additionally or alternatively, in some embodiments, the first regulatory sequence comprises, or consists essentially of, or yet further consists of a promoter, for example a constitutive promoter or a conditional promoter. In further embodiments, the conditional promoter is an immune cell specific promoter.

[0088] In one aspect, the engineered immune cells provided herein overexpress Gp4 and / or comprise a heterologous nucleic acid encoding the Gp4 gene. The engineered immune cells disclosed herein can be generated by in vitro transduction of immune cells with a nucleic acid as disclosed herein.

[0089] An exemplary GP4 amino acid sequence is provided below:>NP_067642.1 guanine nucleotide-binding protein subunit beta-4 [Homo sapiens] (SEQ ID NO: 2)MSELEQLRQEAEQLRNQIQDARKACNDATLVQITSNMDSVGRIQMRTRRTLRGHLAKIYAMHWGYDSRLL VSASQDGKLIIWDSYTTNKMHAIPLRSSWVMTCAYAPSGNYVACGGLDNICSIYNLKTREGNVRVSRELP GHTGYLSCCRFLDDSQIVTSSGDTTCALWDIETAQQTTTFTGHSGDVMSLSLSPDM RTFVSGACDASSKL WDIRDGMCRQSFTGHVSDINAVSFFPNGYAFATGSDDATCRLFDLRADQELLLYSHDNIICGITSVAFSK SGRLLLAGYDDFNCNVWDTLKGDRAGVLAGHDNRVSCLGVTDDGMAVATGSWDSFLRIWN

[0090] In some embodiments, the engineered immune cells express a heterologous amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 2, or a biological equivalent thereof. In further embodiments, the biological equivalent of SEQ ID NO: 2 comprises one or more conservative amino acid substitutions relative to SEQ ID NO: 2, respectively. Additionally or alternatively, in some embodiments, the phagocytic capacity of the biological equivalent is substantially similar to that of the protein of SEQ ID NO: 2.Polynucleotides., Polypeptides and Analogs

[0091] Also included in the presently disclosed subject matter are Gp4 polynucleotides and their corresponding polypeptides or fragments, Gp4-specific inhibitory nucleic acids or GP4 dominant-negative constructs that may be modified in ways that enhance their functional activity when expressed in an engineered immune cell. The presently disclosed subject matter provides methods for optimizing an amino acid sequence or a nucleic acid sequence by producing an alteration in the sequence. Such alterations can comprise certain mutations, deletions, insertions, or post-translational modifications. The presently disclosed subject matter further comprises analogs of any naturally-occurring polypeptide of the presently disclosed subject matter. Analogs can differ from a naturally-occurring polypeptide of the presently disclosed subject matter by amino acid sequence differences, by post-translational modifications, or by both. Analogs of the presently disclosed subject matter can generally exhibit at least about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%), about 98%, about 99% or more identity or homology with all or part of a naturally-occurring amino, acid sequence of the presently disclosed subject matter. The length of sequence comparison is at least about 5, about 10, about 15, about 20, about 25, about 50, about 75, about 100 or more amino acid residues. Again, in an exemplary approach to determining the degree of identity, a BLAST program can be used, with a probability score between e'3and e'100indicating a closely related sequence. Modifications comprise in vivo and in vitro chemical derivatization ofpolypeptides, e.g., acetylation, carboxylation, phosphorylation, or glycosylation; such modifications can occur during polypeptide synthesis or processing or following treatment with isolated modifying enzymes. Analogs can also differ from the naturally-occurring polypeptides of the presently disclosed subject matter by alterations in primary sequence. These include genetic variants, both natural and induced (for example, resulting from random mutagenesis by irradiation or exposure to ethanemethyl sulfate or by site-specific mutagenesis as described in Sambrook, Fritsch and Maniatis, Molecular Cloning: A Laboratory Manual (2nd ed.), CSH Press, 1989, or Ausubel et al., supra). Also included are cyclized peptides, molecules, and analogs which contain residues other than L-amino acids, e.g., D-amino acids or non-naturally occurring or synthetic amino acids, e.g., beta (P) or gamma (y) amino acids.

[0092] In addition to full-length polypeptides, the presently disclosed subject matter also provides fragments of any one of the polypeptides or peptide domains of the presently disclosed subject matter. A fragment can be at least about 5, about 10, about 13, or about 15 amino acids. In some embodiments, a fragment is at least about 20 contiguous amino acids, at least about 30 contiguous amino acids, or at least about 50 contiguous amino acids. In some embodiments, a fragment is at least about 60 to about 80, about 100, about 200, about 300 or more contiguous amino acids. Fragments of the presently disclosed subject matter can be generated by methods known to those of ordinary skill in the art or can result from normal protein processing (e.g., removal of amino acids from the nascent polypeptide that are not required for biological activity or removal of amino acids by alternative mRNA splicing or alternative protein processing events).

[0093] Non-protein analogs have a chemical structure designed to mimic the functional activity of a protein. Such analogs are administered according to methods of the presently disclosed subject matter. Such analogs can exceed the physiological activity of the original polypeptide. Methods of analog design are well known in the art, and synthesis of analogs can be carried out according to such methods by modifying the chemical structures such that the resultant analogs increase the therapeutic activity of the original polypeptide when expressed in an engineered immune cell. These chemical modifications include, but are not limited to, substituting alternative R groups and varying the degree of saturation at specific carbon atoms of a reference polypeptide. The protein analogs can be relatively resistant to in vivo degradation, resulting in a more prolonged therapeutic effect upon administration.Assays for measuring functional activity include, but are not limited to, those described in the Examples below.

[0094] In accordance with the presently disclosed subject matter, the polynucleotides encoding GP4 can be modified by codon optimization. Codon optimization can alter both naturally occurring and recombinant gene sequences to achieve the highest possible levels of productivity in any given expression system. Factors that are involved in different stages of protein expression include codon adaptability, mRNA structure, and various ciselements in transcription and translation. Any suitable codon optimization methods or technologies that are known to ones skilled in the art can be used to modify the polynucleotides of the presently disclosed subject matter, including, but not limited to, OptimumGene™, Encor optimization, and Blue Heron.

[0095] In some embodiments, a nucleic acid as disclosed herein further comprises a regulatory sequence directing the expression of the GP4 gene, the Gp4-specific inhibitory nucleic acid, GP4 dominant-negative constructs, or any receptor (e.g., CAR) disclosed herein. In certain embodiments, the nucleic acid comprises a single regulatory sequence directing the expression of both of the Gp4-specific inhibitory nucleic acid or GP4 dominant-negative construct and the receptor (e.g., CAR). In other embodiments, the nucleic acid comprises a first regulatory sequence directing the expression of the GP4- specific inhibitory nucleic acid or the GP4 dominant-negative construct and a second regulatory sequence directing the expression of the receptor (e.g., CAR). In other embodiments, the first regulatory sequence is the same as the second regulatory sequence. In some embodiments, the first regulatory sequence is different from the second regulatory sequence.Vectors

[0096] Many expression vectors are available and known to those of skill in the art and can be used for nonendogenous expression of the GP4 gene, Gp4-specific inhibitory nucleic acids or Gp4 dominant-negative constructs. The choice of expression vector will be influenced by the choice of host expression system. Such selection is well within the level of skill of the skilled artisan. In general, expression vectors can include transcriptional promoters and optionally enhancers, translational signals, and transcriptional and translational termination signals. Expression vectors that are used for stable transformation typically have a selectable marker which allows selection and maintenance of thetransformed cells. In some cases, an origin of replication can be used to amplify the copy number of the vector in the cells.

[0097] Vectors also can contain additional nucleotide sequences operably linked to the ligated nucleic acid molecule, such as, for example, an epitope tag such as for localization, e.g., a hexa-his tag or a myc tag, hemagglutinin tag or a tag for purification, for example, a GST fusion, and a sequence for directing protein secretion and / or membrane association.

[0098] Expression of the heterologous GP4 gene, Gp4-specific inhibitory nucleic acids, or GP4 dominant-negative constructs can be controlled by any promoter / enhancer known in the art. Suitable bacterial promoters are well known in the art and described herein below. Other suitable promoters for mammalian cells, yeast cells and insect cells are well known in the art and some are exemplified below. Selection of the promoter used to direct expression of a heterologous nucleic acid depends on the particular application and is within the level of skill of the skilled artisan. Promoters which can be used include but are not limited to eukaryotic expression vectors containing the SV40 early promoter (Bernoist and Chambon, Nature 290:304-310(1981)), the promoter contained in the 3' long terminal repeat of Rous sarcoma virus (Yamamoto et al., Cell 22:787-797(1980)), the herpes thymidine kinase promoter (Wagner et al., Proc. Natl. Acad. Set. USA 75: 1441-1445 (1981)), the regulatory sequences of the metallothionein gene (Brinster et al., Nature 296:39-42 (1982)); prokaryotic expression vectors such as the P-lactamase promoter (Jay et al., Proc. Natl. Acad. Set. USA 75:5543 (1981)) or the tac promoter (DeBoer et al., Proc. Natl. Acad. Set. USA 50:21-25(1983)); see also "Useful Proteins from Recombinant Bacteria": in Scientific American 242:79-94 (1980)); plant expression vectors containing the nopaline synthetase promoter (Herrera- Estrella et al., Nature 505:209-213(1984)) or the cauliflower mosaic virus 35S RNA promoter (Gardner et al., Nucleic Acids Res. 9:2871(1981)), and the promoter of the photosynthetic enzyme ribulose bisphosphate carboxylase (Herrera-Estrella et al., Nature 510: 1 15-120(1984)); promoter elements from yeast and other fungi such as the Gal4 promoter, the alcohol dehydrogenase promoter, the phosphoglycerol kinase promoter, the alkaline phosphatase promoter, and the following animal transcriptional control regions that exhibit tissue specificity and have been used in transgenic animals: elastase I gene control region which is active in pancreatic acinar cells (Swift et al., Cell 55:639-646 (1984); Ornitz et al., Cold Spring Harbor Symp. Quant. Biol. 50:399- 409(1986); MacDonald, Hepatology 7:425-515 (1987)); insulin gene control region which is active in pancreatic beta cells (Hanahan et al., Nature 515: 115-122 (1985)),immunoglobulin gene control region which is active in lymphoid cells (Grosschedl et al., Cell 55:647-658 (1984); Adams et al., Nature 515:533-538 (1985); Alexander etal., Mol. Cell Biol. 7: 1436-1444 (1987)), mouse mammary tumor virus control region which is active in testicular, breast, lymphoid and mast cells (Leder et al., Cell 15:485-495 (1986)), albumin gene control region which is active in liver (Pinckert et al., Genes and Devel. 1 :268-276 (1987)), alpha-fetoprotein gene control region which is active in liver (Krumlauf etal., Mol. Cell. Biol. 5: 1639-403 (1985)); Hammer et al., Science 255:53-58 (1987)), alpha- 1 antitrypsin gene control region which is active in liver (Kelsey et al., Genes and Devel. 7: 161-171 (1987)), beta globin gene control region which is active in myeloid cells (Magram et al., Nature 515:338-340 (1985)); Kollias et al., Cell 5:89-94 (1986)), myelin basic protein gene control region which is active in oligodendrocyte cells of the brain (Readhead et al., Cell 15:703-712 (1987)), myosin light chain-2 gene control region which is active in skeletal muscle (Shani, Nature 514:283-286 (1985)), and gonadotrophic releasing hormone gene control region which is active in gonadotrophs of the hypothalamus (Mason et al., Science 254: 1372- 1378 (1986)).

[0099] In addition to the promoter, the expression vector typically contains a transcription unit or expression cassette that contains all the additional elements required for the expression of the Gp4 gene in host cells. A typical expression cassette contains a promoter operably linked to the nucleic acid sequence encoding the polypeptide chains of interest and signals required for efficient polyadenylation of the transcript, ribosome binding sites and translation termination. Additional elements of the cassette can include enhancers. In addition, the cassette typically contains a transcription termination region downstream of the structural gene to provide for efficient termination. The termination region can be obtained from the same gene as the promoter sequence or can be obtained from different genes.

[0100] Some expression systems have markers that provide gene amplification such as thymidine kinase and dihydrofolate reductase. Alternatively, high yield expression systems not involving gene amplification are also suitable, such as using a baculovirus vector in insect cells, with a nucleic acid sequence of interest under the direction of the polyhedron promoter or other strong baculovirus promoter.

[0101] Any methods known to those of skill in the art for the insertion of DNA fragments into a vector can be used to construct expression vectors containing a nucleic acid encoding any of the polypeptides provided herein. These methods can include in vitrorecombinant DNA and synthetic techniques and in vivo recombinants (genetic recombination). The insertion into a cloning vector can, for example, be accomplished by ligating the DNA fragment into a cloning vector which has complementary cohesive termini. If the complementary restriction sites used to fragment the DNA are not present in the cloning vector, the ends of the DNA molecules can be enzymatically modified. Alternatively, any site desired can be produced by ligating nucleotide sequences (linkers) onto the DNA termini; these ligated linkers can contain specific chemically synthesized nucleic acids encoding restriction endonuclease recognition sequences.

[0102] Exemplary plasmid vectors useful to produce the polypeptides provided herein contain a strong promoter, such as the HCMV immediate early enhancer / promoter or the MHC class I promoter, an intron to enhance processing of the transcript, such as the HCMV immediate early gene intron A, and a polyadenylation (poly A) signal, such as the late SV40 poly A signal.

[0103] Genetic modification of engineered immune cells (e.g. macrophages, neutrophils) can be accomplished by transducing a substantially homogeneous cell composition with a recombinant DNA or RNA construct. The vector can be a retroviral vector (e.g., gamma retroviral), which is employed for the introduction of the DNA or RNA construct into the host cell genome. For example, a polynucleotide encoding Gp4 can be cloned into a retroviral vector and expression can be driven from its endogenous promoter, from the retroviral long terminal repeat, or from an alternative internal promoter.

[0104] Non-viral vectors or RNA may be used as well. Random chromosomal integration, or targeted integration (e.g., using a nuclease, transcription activator-like effector nucleases (TALENs), Zinc-finger nucleases (ZFNs), and / or clustered regularly interspaced short palindromic repeats (CRISPRs), or transgene expression (e.g., using a natural or chemically modified RNA) can be used.

[0105] For initial genetic modification of the cells to provide Gp4 overexpressing cells, a retroviral vector can be employed for transduction. However, any other suitable viral vector or non-viral delivery system can be used for genetic modification of cells. For subsequent genetic modification of the cells to provide cells comprising an antigen presenting complex comprising at least two co-stimulatory ligands, retroviral gene transfer (transduction) likewise proves effective. Combinations of retroviral vector and an appropriate packaging line are also suitable, where the capsid proteins will be functional forinfecting human cells. Various amphotropic virus-producing cell lines are known, including, but not limited to, PA12 (Miller et al. (1985) Mol. Cell. Biol. 5:431-437); PA317 (Miller et al. (1986) Mol. Cell. Biol. 6:2895-2902); and CRIP (Danos et al. (1988) roc. Natl. Acad. Sci. USA 85:6460-6464). Non -amphotropic particles are suitable too, e.g., particles pseudotyped with VSVG, RD114 or GALV envelope and any other known in the art.

[0106] Possible methods of transduction also include direct co-culture of the cells with producer cells, e.g., by the method of Bregni, et al., Blood 80: 1418-1422(1992), or culturing with viral supernatant alone or concentrated vector stocks with or without appropriate growth factors and poly cations, e.g., by the method of Xu, et al., Exp. Hemat. 22:223-230 (1994); and Hughes, et al., J. Clin. Invest. 89: 1817 (1992).

[0107] Transducing viral vectors can be used to express a co-stimulatory ligand and / or secretes a cytokine (e.g., 4-1 BBL and / or IL- 12) in an engineered immune cell. In some embodiments, the chosen vector exhibits high efficiency of infection and stable integration and expression (see, e.g., Cayouette et al., Human Gene Therapy 8:423-430 (1997); Kido et al., Current Eye Research 15:833-844 (1996); Bloomer et al., Journal of Virology 71 :6641- 6649, 1997; Naldini et al., Science 272:263 267 (1996); and Miyoshi et al., Proc. Natl. Acad. Sci. U.S.A. 94: 10319, (1997)). Other viral vectors that can be used include, for example, adenoviral, lentiviral, and adeno-associated viral vectors, vaccinia virus, a bovine papilloma virus, or a herpes virus, such as Epstein-Barr Virus (also see, for example, the vectors of Miller, Human Gene Therapy 15-14, (1990); Friedman, Science 244: 1275-1281 (1989); Eglitis et al., BioTechniques 6:608-614, (1988); Tolstoshev et al., Current Opinion in Biotechnology 1 :55-61(1990); Sharp, The Lancet 337 : 1277-1278 (1991); Cornetta et al., Nucleic Acid Research and Molecular Biology 36:311-322 (1987); Anderson, Science 226:401-409 (1984); Moen, Blood Cells 17:407-416 (1991); Miller et al., Biotechnology 7:980-990 (1989); Le Gal La Salle et al., Science 259:988-990 (1993); and Johnson, Chest 107:77S-83S (1995)). Retroviral vectors are particularly well developed and have been used in clinical settings (Rosenberg et al., N. Engl. J. Med 323:370 (1990); Anderson et al., U.S. Pat. No. 5,399,346).

[0108] In certain non-limiting embodiments, the vector expressing GP4 is a retroviral vector, e.g., an oncoretroviral vector. In some instances, the retroviral vector is a SFG retroviral vector or murine stem cell virus (MSCV) retroviral vector. In certain non-limiting embodiments, the vector expressing a Gp4 nucleic acid sequence is a lentiviral vector. Incertain non-limiting embodiments, the vector expressing a GP4 nucleic acid sequence is a transposon vector.

[0109] Non-viral approaches can also be employed for the expression of a protein in a cell. For example, a nucleic acid molecule can be introduced into a cell by administering the nucleic acid in the presence of lipofection (Feigner et al., Proc. Nat'L Acad. Sci. U.S.A. 84:7413, (1987); Ono et al., Neuroscience Letters 17:259 (1990); Brigham et al., Am. J. Med. Sci. 298:278, (1989); Staubinger et al., Methods in Enzymology 101 :512 (1983)), asialoorosomucoid-polylysine conjugation (Wu et al., Journal of Biological Chemistry 263 : 14621 (1988); Wu et al., Journal of Biological Chemistry 264: 16985 (1989)), or by microinjection under surgical conditions (Wolff et al., Science 247: 1465 (1990)). Other non- viral means for gene transfer include transfection in vitro using calcium phosphate, DEAE dextran, electroporation, and protoplast fusion. Liposomes can also be potentially beneficial for delivery of DNA into a cell. Transplantation of normal genes into the affected tissues of a subject can also be accomplished by transferring a normal nucleic acid into a cultivatable cell type ex vivo (e.g., an autologous or heterologous primary cell or progeny thereof), after which the cell (or its descendants) are injected into a targeted tissue or are injected systemically. Recombinant receptors can also be derived or obtained using transposases or targeted nucleases e.g., Zinc finger nucleases, meganucleases, or TALE nucleases). Transient expression may be obtained by RNA electroporation.

[0110] cDNA expression for use in polynucleotide therapy methods can be directed from any suitable promoter e.g., the human cytomegalovirus (CMV), simian virus 40 (SV40), or metallothionein promoters), and regulated by any appropriate mammalian regulatory element or intron (e.g., the elongation factor la enhancer / promoter / intron structure). For example, if desired, enhancers known to preferentially direct gene expression in specific cell types can be used to direct the expression of a nucleic acid. The enhancers used can include, without limitation, those that are characterized as tissue- or cell-specific enhancers. Alternatively, if a genomic clone is used as a therapeutic construct, regulation can be mediated by the cognate regulatory sequences or, if desired, by regulatory sequences derived from a heterologous source, including any of the promoters or regulatory elements described above.

[0111] The resulting cells can be grown under conditions similar to those for unmodified cells, whereby the modified cells can be expanded and used for a variety of purposes.

[0112] In some embodiments, a vector as disclosed herein comprises a regulatory sequence directing the expression of a Gp4-specific inhibitory nucleic acid or a GP4 dominant-negative construct and any receptor disclosed herein (e.g., CAR). In further embodiments, the vector comprises a single regulatory sequence directing the expression of both of the Gp4-specific inhibitory nucleic acid or GP4 dominant-negative construct and the receptor (e.g., CAR). In other embodiments, the vector comprises a first regulatory sequence directing the expression of the Gp4-specific inhibitory nucleic acid or the GP4 dominant-negative construct and a second regulatory sequence directing the expression of the receptor (e.g., CAR). In other embodiments, the first regulatory sequence is the same as the second regulatory sequence. In some embodiments, the first regulatory sequence is different from the second regulatory sequence.Chimeric Antigen Receptors (CARs)

[0113] In some embodiments, the engineered immune cells provided herein express at least one chimeric antigen receptor (CAR). CARs are engineered receptors, which graft or confer a specificity of interest onto an immune effector cell. For example, CARs can be used to graft the specificity of a monoclonal antibody onto an immune cell, such as a macrophage or neutrophil. In some embodiments, transfer of the coding sequence of the CAR is facilitated by nucleic acid vector, such as a retroviral vector.

[0114] There are currently three generations of CARs. In some embodiments, the engineered immune cells provided herein express a “first generation” CAR. “First generation” CARs are typically composed of an extracellular antigen binding domain (e.g., a single-chain variable fragment (scFv)) fused to a transmembrane domain fused to cytoplasmic / intracellular domain of the T cell receptor (TCR) chain. “First generation” CARs typically have the intracellular domain from the CD3(^ chain, which is the primary transmitter of signals from endogenous TCRs. “First generation” CARs can provide de novo antigen recognition and cause activation of both CD4+and CD8+T cells through their CD3(^ chain signaling domain in a single fusion molecule, independent of HLA-mediated antigen presentation.

[0115] In some embodiments, the engineered immune cells provided herein express a “second generation” CAR. “Second generation” CARs add intracellular domains from various co-stimulatory molecules (e.g., CD28, 4-1BB, ICOS, 0X40) to the cytoplasmic tail of the CAR to provide additional signals to the T cell. “Second generation” CARs comprisethose that provide both co-stimulation (e.g., CD28 or 4-1BB) and activation (e.g., CD3Q.

[0116] In some embodiments, the engineered immune cells provided herein express a “third generation” CAR. “Third generation” CARs comprise those that provide multiple costimulation (e.g., CD28 and 4-1BB) and activation (e.g., CD3Q.

[0117] In accordance with the presently disclosed subject matter, the CARs of the engineered immune cells provided herein comprise an extracellular antigen-binding domain, a transmembrane domain and an intracellular domain. Further, the activity of the engineered immune cells can be adjusted by selection of co-stimulatory molecules included in the chimeric antigen receptor.

[0118] Extracellular Antigen-Binding Domain of a CAR. In certain embodiments, the extracellular antigen-binding domain of a CAR specifically binds a tumor antigen. In certain embodiments, the extracellular antigen-binding domain is derived from a monoclonal antibody (mAb) that binds to a tumor antigen. In some embodiments, the extracellular antigen-binding domain comprises an scFv. In some embodiments, the extracellular antigen-binding domain comprises a Fab, which is optionally crosslinked. In some embodiments, the extracellular binding domain comprises a F(ab)2. In some embodiments, any of the foregoing molecules are included in a fusion protein with a heterologous sequence to form the extracellular antigen-binding domain. In certain embodiments, the extracellular antigen-binding domain comprises a human scFv that binds specifically to a tumor antigen. In certain embodiments, the scFv is identified by screening scFv phage library with a tumor antigen-Fc fusion protein.

[0119] Examples of tumor antigens include, but are not limited to, 5T4, alpha 5(31 - integrin, 707-AP, A33, AFP, ART-4, B7H4, BAGE, Bcl-2, P-catenin, BCMA, Bcr-abl, CA125, CA19-9, CAMEL, CAP-1, CASP-8, CD4, CD5, CD19, CD20, CD21 , CD22, CD25, CDC27 / m, CD33, CD37, CD45, CD52, CD56, CD80, CD123, CDK4 / m, CEA, c- Met, CS-1, CT, Cyp-B, cyclin Bl, DAGE, DAM, EBNA, EGFR, ErbB3, ELF2M, EMMPRIN, EpCam, ephrinB2, estrogen receptor, ETV6-AML1, FAP, ferritin, folate- binding protein, GAGE, G250, GD-2, GM2, GnT-V, gp75, gplOO (Pmel 17), HAGE, HER- 2 / neu, HLA-A*0201-R170I, HPV E6, HPV E7, Ki -67, HSP70-2M, HST-2, hTERT (or hTRT), iCE, IGF-1R, IL-2R, IL-5, KIAA0205, LAGE, LDLR / FUT, LRP, MAGE, MART, MART-l / melan-A, MART-2 / Ski, MC1R, mesothelin, MUC16, MUM-1 -B, myc, MUM-2, MUM-3, NA88-A, NYESO-1, NY-Eso-B, p53, proteinase-3, p!90 minor bcr-abl,Pml / RARa, PRAME, progesterone receptor, PSA, PSCA, PSM, PSMA, ras, RAGE, RU1 or RU2, RORI, SART-1 or SART-3, survivin, TEL / AML1, TGFp, TPI / m, TRP-1, TRP-2, TRP-2 / INT2, tenascin, TSTA tyrosinase, VEGF, or WTE Other examples of tumor antigens include a2b b3 (Glycoprotein Ilb / IIIa), a4, a4b7, a4b7 +aEb7, a5, Activin receptor type-2B, ALK1, Alpha-synuclein, amyloid beta, APP, AXL, Blood Group A, CAIX, CCL-2, CD105 (endoglin), CD115 (CSF1R), CD116a (CSF2Ra), CD123, CD152 (CTLA4),CD 184 (CXCR4), CD 19, CD 192 (CCR2), CD 194 (CCR4), CD 195 (CCR5), CD20, CD200, CD22, CD221 (IGF1R), CD248, CD25, CD257 (BAFF), CD26, CD262 (DR5), CD276 (B7H3), CD3, CD30 (TNFRSF8), CD319 (SLAMF7), CD33, CD332 (FGFR2), CD350 (FZD10), CD37, CD371 (CLEC12A), CD38, CD4, CD49b (a2), CD51 (a5), CD52, CD56, CD61 (a4b3), CD70, CD73 (NT5E), CD74, CEA, Claudin-18.2, cMET, CRLR, DLL3, DLL4, DNA / histone (Hl) complex, EGFR, EpCAM, EGFR- HER3, EGFRvIII, EphA3, ERGT(GalNAc) Tn Antigen, FLT1, FOLR1, frizzled family receptor (FZD), Lewis Y, Lewis X, GCGR, GD2, GD2 a-acetyl, GD3, GM1, GM1 fucosyl, GM2, GPA33, GPNMB, GUCY2C, HER2, HER3, HGFR (cMET), IgHe, IGLF2, Kallikreins, LINGO 1, L0XL2, Ly6 / PLAUR domain-containing protein 3, MADCAM1, MAG, Mesothelin, MT1-MMP (MMP14), MUC1, Mucin 5 AC, NaPi2b, NeuGc-GM3, notch, NOTCH2 / NOTCH3 receptors, oxLDL, P-selectin, PCSK9, PDGFRA, PDGFRa, phosphatidylserine, polysialic acid, PSMA, PVRL4, RGMA, CD240D Blood group D antigen, root plate-specific spondin3, serum amyloid P component, STEAP-1, TACSTD2, TGFb, TWEAKR, TYRP1, VEGFR2, VSIR, CD171 (L1CAM), CD19, CD47, pMHC[NY-ES01], pMHC[MARTl], pMHCfMAGEAl], pMHC[Tyrosinase], pMHC[gplOO], pMHC[MUCl], pMHC[tax], pMHC[WT-l], pMHC[EBNA-l], pMHC[LMP2], pMHC[hTERT], GPC3, CD80, CD23, and fibronectin extra domain-B.

[0120] In certain embodiments, the extracellular antigen-binding domain of a presently disclosed CAR has a high binding specificity and high binding affinity to a tumor antigen. For example, in some embodiments, the extracellular antigen-binding domain of the CAR (embodied, for example, in a human scFv or an analog thereof) binds to a particular tumor antigen with a dissociation constant (Kd) of about 1 x 10'5M or less. In certain embodiments, the Kd is about 5 x 10'6M or less, about 1 x 10'6M or less, about 5 x 10'7M or less, about 1 x 10'7M or less, about 5 x 10'8M or less, about 1 x 10'8M or less, about 5 x 10'9or less, about 4 x 10'9or less, about 3 x 10'9or less, about 2 x 10'9or less, or about 1 x 10'9M or less. In certain non-limiting embodiments, the Kd is from about 3 x 10'9M orless. In certain non-limiting embodiments, the Kd is from about 3 x 10'9to about 2 x 10'7.

[0121] Binding of the extracellular antigen-binding domain (embodiment, for example, in an scFv or an analog thereof) of a tumor antigen-specific CAR can be confirmed by, for example, enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA), FACS analysis, bioassay (e.g., growth inhibition), or Western Blot assay. Each of these assays generally detect the presence of protein-antibody complexes of particular interest by employing a labeled reagent (e.g., an antibody, or an scFv) specific for the complex of interest. For example, the scFv can be radioactively labeled and used in a radioimmunoassay (RIA) (see, for example, Weintraub, B., Principles of Radioimmunoassays, Seventh Training Course on Radioligand Assay Techniques, The Endocrine Society, March, 1986, which is incorporated by reference herein). The radioactive isotope can be detected by such means as the use of a y counter or a scintillation counter or by autoradiography. In certain embodiments, the extracellular antigen-binding domain of the tumor antigen-specific CAR is labeled with a fluorescent marker. Nonlimiting examples of fluorescent markers include green fluorescent protein (GFP), blue fluorescent protein (e.g., EBFP, EBFP2, Azurite, and mKalamal), cyan fluorescent protein (e.g., ECFP, Cerulean, and CyPet), and yellow fluorescent protein (e.g., YFP, Citrine, Venus, and YPet). In certain embodiments, the scFv of a tumor antigen-specific CAR is labeled with GFP.

[0122] In some embodiments, the extracellular antigen-binding domain of the expressed CAR binds to a tumor antigen that is expressed by a tumor cell. In some embodiments, the extracellular antigen-binding domain of the expressed CAR binds to a tumor antigen that is expressed on the surface of a tumor cell.

[0123] In certain embodiments, the extracellular antigen-binding domain (e.g., human scFv) comprises a heavy chain variable (VH) region and a light chain variable (VL) region, optionally linked with a linker sequence, for example a linker peptide (e.g., SEQ ID NO: 16), between the heavy chain variable (VH) region and the light chain variable (VL) region.

[0124] In certain non-limiting embodiments, an extracellular antigen-binding domain of the presently disclosed CAR can comprise a linker connecting the heavy chain variable (VH) region and light chain variable (VL) region of the extracellular antigen-binding domain. As used herein, the term “linker” refers to a functional group (e.g., chemical or polypeptide) that covalently attaches two or more polypeptides or nucleic acids so that they areconnected to one another. As used herein, a “peptide linker” refers to one or more amino acids used to couple two proteins together (e.g., to couple VH and VL domains). In certain embodiments, the linker comprises amino acids having the sequence set forth in SEQ ID NO: 16. In certain embodiments, the nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 16 is set forth in SEQ ID NO: 17.

[0125] Additionally or alternatively, in some embodiments, the extracellular antigenbinding domain can comprise a leader or a signal peptide sequence that directs the nascent protein into the endoplasmic reticulum. The signal peptide or leader can be essential if the CAR is to be glycosylated and anchored in the cell membrane. The signal sequence or leader sequence can be a peptide sequence (about 5, about 10, about 15, about 20, about 25, or about 30 amino acids long) present at the N-terminus of the newly synthesized proteins that direct their entry to the secretory pathway.

[0126] In certain embodiments, the signal peptide is covalently joined to the N-terminus of the extracellular antigen-binding domain. In certain embodiments, the signal peptide comprises a human CD8 signal polypeptide comprising amino acids having the sequence set forth in SEQ ID NO: 18 as provided below: MALPVTALLLPLALLLHAARP (SEQ ID NO: 18).

[0127] The nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 18 is set forth in SEQ ID NO: 19, which is provided below:ATGGCCCTGCCAGTAACGGCTCTGCTGCTGCCACTTGCTCTGCTCCTCCATGCAG CCAGGCCT (SEQ ID NO: 19).

[0128] In certain embodiments, the signal peptide comprises a human CD8 signal polypeptide comprising amino acids having the sequence set forth in SEQ ID NO: 20 as provided below: MALPVTALLLPLALLLHA (SEQ ID NO: 20).

[0129] The nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 20 is set forth in SEQ ID NO: 21, which is provided below: ATGGCTCTCCCAGTGACTGCCCTACTGCTTCCCCTAGCGCTTCTCCTGCATGCA (SEQ ID NO: 21).

[0130] In certain embodiments, the signal peptide comprises a mouse CD8 signal polypeptide comprising amino acids having the sequence set forth in SEQ ID NO: 22 as provided below: MASPLTRFLSLNLLLLGESII (SEQ ID NO: 22).

[0131] The nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 22 isset forth in SEQ ID NO: 23, which is provided below:

[0132] ATGGCCAGCCCCCTGACCAGGTTCCTGAGCCTGAACCTGCTGCTGCT GGGCGAGAGCATCATC (SEQ ID NO: 23).

[0133] In certain embodiments, the signal peptide comprises a mouse CD8 signal polypeptide comprising amino acids having the sequence set forth in SEQ ID NO: 24 as provided below: MASPLTRFLSLNLLLLGE (SEQ ID NO: 24).

[0134] The nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 24 is set forth in SEQ ID NO: 25, which is provided below: ATGGCCAGCCCCCTGACCAGGTTCCTGAGCCTGAACCTGCTGCTGCTGGGCGAG (SEQ ID NO: 25).

[0135] Transmembrane Domain of a CAR. In certain non-limiting embodiments, the transmembrane domain of the CAR comprises a hydrophobic alpha helix that spans at least a portion of the membrane. Different transmembrane domains result in different receptor stability. After antigen recognition, receptors cluster and a signal is transmitted to the cell. In accordance with the presently disclosed subject matter, the transmembrane domain of the CAR can comprise a CD8 polypeptide, a CD28 polypeptide, a CD3(^ polypeptide, a CD4 polypeptide, a 4- IBB polypeptide, an 0X40 polypeptide, an ICOS polypeptide, a CTLA-4 polypeptide, a PD-1 polypeptide, a LAG-3 polypeptide, a 2B4 polypeptide, a BTLA polypeptide, a synthetic peptide (e.g., a transmembrane peptide not based on a protein associated with the immune response), or a combination thereof.

[0136] In certain embodiments, the transmembrane domain of a presently disclosed CAR comprises a CD28 polypeptide. The CD28 polypeptide can have an amino acid sequence that is at least about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, about 99% or 100% homologous to the sequence having a UniProtKB Reference No: P10747 or NCBI Reference No: NP006130 (SEQ ID NO: 26), or fragments thereof, and / or may optionally comprise up to one or up to two or up to three conservative amino acid substitutions. In certain embodiments, the CD28 polypeptide can have an amino acid sequence that is a consecutive portion of SEQ ID NO: 26 which is at least 20, or at least 30, or at least 40, or at least 50, and up to 220 amino acids in length. Additionally or alternatively, in non- limiting various embodiments, the CD28 polypeptide has an amino acid sequence of amino acids 1 to 220, 1 to 50, 50 to 100, 100 to 150, 114 to 220, 150 to 200, or 200 to 220 of SEQ ID NO: 26. In certain embodiments, the CAR of the presentdisclosure comprises a transmembrane domain comprising a CD28 polypeptide, and optionally an intracellular domain comprising a co-stimulatory signaling region that comprises a CD28 polypeptide. In certain embodiments, the CD28 polypeptide comprised in the transmembrane domain and the intracellular domain has an amino acid sequence of amino acids 114 to 220 of SEQ ID NO: 26. In certain embodiments, the CD28 polypeptide comprised in the transmembrane domain has an amino acid sequence of amino acids 153 to 179 of SEQ ID NO: 26.

[0137] SEQ ID NO: 26 is provided below:MLRLLLALNLFPSIQVTGNKILVKQSPMLVAYDNALSCKYSYNLFSREFRASLHKG LDSAVEVCWYGNYSQQLQVYSKTGFNCDGKLGNESVTFYLQNLYQTDIYFCKIEV MYPPPYLDNEKSNGTIIHVKGKHLCPSPLFPGPSKPFWVLVWGGVLACYSLLVTVA FIIFWVRSKRSRLLHSDYMNMTPRRPGPTRKHYQPYAPPRDFAAYRS (SEQ ID NO: 26)

[0138] In accordance with the presently disclosed subject matter, a “CD28 nucleic acid molecule” refers to a polynucleotide encoding a CD28 polypeptide. In certain embodiments, the CD28 nucleic acid molecule encoding the CD28 polypeptide comprised in the transmembrane domain (and optionally the intracellular domain (e.g., the costimulatory signaling region)) of the presently disclosed CAR (e.g., amino acids 114 to 220 of SEQ ID NO: 26 or amino acids 153 to 179 of SEQ ID NO: 26) comprises at least a portion of the sequence set forth in SEQ ID NO: 27 as provided below. attgaagttatgtatcctcctccttacctagacaatgagaagagcaatggaaccattatccatgtgaaagggaaacacctttgtccaagt cccctatttcccggaccttctaagcccttttgggtgctggtggtggttggtggagtcctggcttgctatagcttgctagtaacagtggcct ttattattttctgggtgaggagtaagaggagcaggctcctgcacagtgactacatgaacatgactccccgccgccccgggcccaccc gcaagcattaccagccctatgccccaccacgcgacttcgcagcctatcgctcc (SEQ ID NO: 27)

[0139] In certain embodiments, the transmembrane domain comprises a CD8 polypeptide. The CD8 polypeptide can have an amino acid sequence that is at least about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, about 99% or about 100%) homologous to SEQ ID NO: 28 (homology herein may be determined using standard software such as BLAST or FASTA) as provided below, or fragments thereof, and / or may optionally comprise up to one or up to two or up to three conservative amino acid substitutions. In certain embodiments, the CD8 polypeptide can have an amino acid sequence that is a consecutive portion of SEQ ID NO: 28 which is at least 20, or at least 30, or at least 40, or at least 50, and up to 235 amino acids in length. Additionally oraltematively, in various embodiments, the CD8 polypeptide has an amino acid sequence of amino acids 1 to 235, 1 to 50, 50 to 100, 100 to 150, 150 to 200, or 200 to 235 of SEQ ID NO: 28.

[0140] MALPVTALLLPLALLLHAARPSQFRVSPLDRTWNLGETVELKCQVLLSN PTSGCSWLFQPRGAAASPTFLLYLSQNKPKAAEGLDTQRFSGKRLGDTFVLTLSDF RRENEGYYFCSALSNSIMYFSHFVPVFLPAKPTTTPAPRPPTPAPTIASQPLSLRPEAC RPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCNHRNRRRVCKCPRP WKSGDKPSLSARYV (SEQ ID NO: 28)

[0141] In certain embodiments, the transmembrane domain comprises a CD8 polypeptide comprising amino acids having the sequence set forth in SEQ ID NO: 29 as provided below:

[0142] PTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWA PLAGTCGVLLLSLVITLYCN (SEQ ID NO: 29)

[0143] In accordance with the presently disclosed subject matter, a “CD8 nucleic acid molecule” refers to a polynucleotide encoding a CD8 polypeptide. In certain embodiments, the CD8 nucleic acid molecule encoding the CD8 polypeptide comprised in the transmembrane domain of the presently disclosed CAR (SEQ ID NO: 29) comprises nucleic acids having the sequence set forth in SEQ ID NO: 30 as provided below.

[0144] CCCACCACGACGCCAGCGCCGCGACCACCAACCCCGGCGCCCACGAT CGCGTCGCAGCCCCTGTCCCTGCGCCCAGAGGCGTGCCGGCCAGCGGCGGGGG GCGCAGTGCACACGAGGGGGCTGGACTTCGCCTGTGATATCTACATCTGGGCGC CCCTGGCCGGGACTTGTGGGGTCCTTCTCCTGTCACTGGTTATCACCCTTTACTG CAAC (SEQ ID NO: 30)

[0145] In certain non-limiting embodiments, a CAR can also comprise a spacer region that links the extracellular antigen-binding domain to the transmembrane domain. The spacer region can be flexible enough to allow the antigen-binding domain to orient in different directions to facilitate antigen recognition while preserving the activating activity of the CAR. In certain non-limiting embodiments, the spacer region can be the hinge region from IgGl, the CH2CH3 region of immunoglobulin and portions of CD3, a portion of a CD28 polypeptide (e.g., SEQ ID NO: 26), a portion of a CD8 polypeptide (e.g., SEQ ID NO: 28), a variation of any of the foregoing which is at least about 80%, at least about 85%, at least about 90%, or at least about 95% homologous thereto, or a synthetic spacersequence. In certain non-limiting embodiments, the spacer region may have a length between about 1-50 (e.g., 5-25, 10-30, or 30-50) amino acids.

[0146] Intracellular Domain of a CAR. In certain non-limiting embodiments, an intracellular domain of the CAR can comprise a CD3(^ polypeptide, which can activate or stimulate a cell. CD3(^ comprises 3 ITAMs, and transmits an activation signal to the cell after antigen is bound. The CD3(^ polypeptide can have an amino acid sequence that is at least about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, about 99% or about 100% homologous to the sequence having a NCBI Reference No: NP_932170 (SEQ ID NO: 31), or fragments thereof, and / or may optionally comprise up to one or up to two or up to three conservative amino acid substitutions.

[0147] In certain embodiments, the CD3(^ polypeptide can have an amino acid sequence that is a consecutive portion of SEQ ID NO: 32 which is at least 20, or at least 30, or at least 40, or at least 50, and up to 164 amino acids in length. Additionally or alternatively, in various embodiments, the CD3(^ polypeptide has an amino acid sequence of amino acids 1 to 164, 1 to 50, 50 to 100, 100 to 150, or 150 to 164 of SEQ ID NO: 32. In certain embodiments, the CD3^ polypeptide has an amino acid sequence of amino acids 52 to 164 of SEQ ID NO: 32.

[0148] SEQ ID NO: 32 is provided below:MKWKALFTAAILQAQLPITEAQSFGLLDPKLCYLLDGILFIYGVILTALFLRVKFSRS ADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPQRRKNPQEGLYN ELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 32)

[0149] In certain embodiments, the CD3(^ polypeptide has the amino acid sequence set forth in SEQ ID NO: 33, which is provided below: RVKFSRSAEPPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNP QEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQ ALPPR (SEQ ID NO: 33)

[0150] In certain embodiments, the CD3(^ polypeptide has the amino acid sequence set forth in SEQ ID NO: 34, which is provided below: RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNP QEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQ ALPPR (SEQ ID NO: 34)

[0151] In accordance with the presently disclosed subject matter, a “CD3(^ nucleic acid molecule” refers to a polynucleotide encoding a CD3(^ polypeptide. In certain embodiments, the CD3^ nucleic acid molecule encoding the CD3^ polypeptide (SEQ ID NO: 33) comprised in the intracellular domain of the presently disclosed CAR comprises a nucleotide sequence as set forth in SEQ ID NO: 35 as provided below.AGAGTGAAGTTCAGCAGGAGCGCAGAGCCCCCCGCGTACCAGCAGGGCCAGAA CCAGCTCTATAACGAGCTCAATCTAGGACGAAGAGAGGAGTACGATGTTTTGG ACAAGAGACGTGGCCGGGACCCTGAGATGGGGGGAAAGCCGAGAAGGAAGAA CCCTCAGGAAGGCCTGTACAATGAACTGCAGAAAGATAAGATGGCGGAGGCCT ACAGTGAGATTGGGATGAAAGGCGAGCGCCGGAGGGGCAAGGGGCACGATGG CCTTTACCAGGGTCTCAGTACAGCCACCAAGGACACCTACGACGCCCTTCACAT GCAGGCCCTGCCCCCTCGCG (SEQ ID NO: 35)

[0152] In certain embodiments, the CD3(^ nucleic acid molecule encoding the CD3(^ polypeptide (SEQ ID NO: 34) comprised in the intracellular domain of the presently disclosed CAR comprises a nucleotide sequence as set forth in SEQ ID NO: 36 as provided below.AGAGTGAAGTTCAGCAGGAGCGCAGACGCCCCCGCGTACCAGCAGGGCCAGAA CCAGCTCTATAACGAGCTCAATCTAGGACGAAGAGAGGAGTACGATGTTTTGG ACAAGAGACGTGGCCGGGACCCTGAGATGGGGGGAAAGCCGAGAAGGAAGAA CCCTCAGGAAGGCCTGTACAATGAACTGCAGAAAGATAAGATGGCGGAGGCCT ACAGTGAGATTGGGATGAAAGGCGAGCGCCGGAGGGGCAAGGGGCACGATGG CCTTTACCAGGGTCTCAGTACAGCCACCAAGGACACCTACGACGCCCTTCACAT GCAGGCCCTGCCCCCTCGCTAA (SEQ ID NO: 36)

[0153] In certain non-limiting embodiments, an intracellular domain of the CAR further comprises at least one signaling region. The at least one signaling region can include a CD28 polypeptide, a 4-1BB polypeptide, an 0X40 polypeptide, an ICOS polypeptide, a DAP- 10 polypeptide, a PD-1 polypeptide, a CTLA-4 polypeptide, a LAG-3 polypeptide, a 2B4 polypeptide, a BTLA polypeptide, a synthetic peptide (not based on a protein associated with the immune response), or a combination thereof.

[0154] In certain embodiments, the signaling region is a co-stimulatory signaling region.

[0155] In certain embodiments, the co-stimulatory signaling region comprises at leastone co-stimulatory molecule, which can provide optimal lymphocyte activation. As used herein, “co-stimulatory molecules” refer to cell surface molecules other than antigen receptors or their ligands that are required for an efficient response of lymphocytes to antigen. The at least one co-stimulatory signaling region can include a CD28 polypeptide, a 4-1BB polypeptide, an 0X40 polypeptide, an ICOS polypeptide, a DAP-10 polypeptide, or a combination thereof. The co-stimulatory molecule can bind to a co-stimulatory ligand, which is a protein expressed on cell surface that upon binding to its receptor produces a co- stimulatory response, i.e., an intracellular response that effects the stimulation provided when an antigen binds to its CAR molecule. Co-stimulatory ligands, include, but are not limited to CD80, CD86, CD70, OX40L, 4-1BBL, CD48, TNFRSF14, and PD- LI. As one example, a 4-1BB ligand (i.e., 4-1BBL) may bind to 4-1BB (also known as “CD 137”) for providing an intracellular signal that in combination with a CAR signal induces an effector cell function of the CAR+expressing cell. CARs comprising an intracellular domain that comprises a co-stimulatory signaling region comprising 4-1BB, ICOS or DAP-10 are disclosed in U.S. 7,446,190, which is herein incorporated by reference in its entirety. In certain embodiments, the intracellular domain of the CAR comprises a co-stimulatory signaling region that comprises a CD28 polypeptide. In certain embodiments, the intracellular domain of the CAR comprises a co-stimulatory signaling region that comprises two co-stimulatory molecules: CD28 and 4-1BB or CD28 and 0X40.

[0156] 4- IBB can act as a tumor necrosis factor (TNF) ligand and have stimulatory activity. The 4- IBB polypeptide can have an amino acid sequence that is at least about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, about 99% or 100% homologous to the sequence having a UniProtKB Reference No: P41273 or NCBI Reference No: NP_001552 (SEQ ID NO: 37) or fragments thereof, and / or may optionally comprise up to one or up to two or up to three conservative amino acid substitutions.

[0157] SEQ ID NO: 37 is provided below:MGNSC YNIVATLLLVLNFERTRSLQDPC SNCP AGTFCDNNRNQICSPCPPNSF S SAG GQRTCDICRQCKGVFRTRKEC S STSNAECDCTPGFHCLGAGC SMCEQDCKQGQEL TKKGCKDCCFGTFNDQKRGICRPWTNCSLDGKSVLGTKERDWCGPSPADLSPGAS SVTPPAPAREPGHSPQIISFFLALTSTALLFLLFFLTLRFSWKRGRKKLLYIFKQPFMR PVQTTQEEDGCSCRFPEEEEGGCEL (SEQ ID NO: 37)

[0158] In certain embodiments, the 4- IBB co-stimulatory domain has the amino acid sequence set forth in SEQ ID NO: 38, which is provided below:KRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCEL (SEQ ID NO: 38)

[0159] In accordance with the presently disclosed subject matter, a “4-1BB nucleic acid molecule” refers to a polynucleotide encoding a 4- IBB polypeptide. In certain embodiments, the 4- IBB nucleic acid molecule encoding the 4- IBB polypeptide (SEQ ID NO: 38) comprised in the intracellular domain of the presently disclosed CAR comprises a nucleotide sequence as set forth in SEQ ID NO: 39 as provided below.AAACGGGGCAGAAAGAAGCTCCTGTATATATTCAAACAACCATTTATGAGACC AGTACAAACTACTCAAGAGGAAGATGGCTGTAGCTGCCGATTTCCAGAAGAAG AAGAAGGAGGATGTGAACTG (SEQ ID NO: 39)

[0160] An 0X40 polypeptide can have an amino acid sequence that is at least about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, about 99% or 100% homologous to the sequence having a UniProtKB Reference No: P43489 or NCBI Reference No: NP_003318 (SEQ ID NO: 40), or fragments thereof, and / or may optionally comprise up to one or up to two or up to three conservative amino acid substitutions.

[0161] SEQ ID NO: 40 is provided below: MCVGARRLGRGPCAALLLLGLGLSTVTGLHCVGDTYPSNDRCCHECRPGNGMVS RCSRSQNTVCRPCGPGFYNDWSSKPCKPCTWCNLRSGSERKQLCTATQDTVCRCR AGTQPLDSYKPGVDCAPCPPGHFSPGDNQACKPWTNCTLAGKHTLQPASNSSDAIC EDRDPPATQPQETQGPPARPITVQPTEAWPRTSQGPSTRPVEVPGGRAVAAILGLGL VLGLLGPLAILLALYLLRRDQRLPPDAHKPPGGGSFRTPIQEEQADAHSTLAKI (SEQ ID NO: 40)

[0162] In accordance with the presently disclosed subject matter, an “0X40 nucleic acid molecule” refers to a polynucleotide encoding an 0X40 polypeptide.

[0163] An ICOS polypeptide can have an amino acid sequence that is at least about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, about 99% or 100% homologous to the sequence having a NCBI Reference No: NP_036224 (SEQ ID NO: 41) or fragments thereof, and / or may optionally comprise up to one or up to two or up to three conservative amino acid substitutions.

[0164] SEQ ID NO: 41 is provided below:MKSGLWYFFLFCLRIKVLTGEINGSANYEMFIFHNGGVQILCKYPDIVQQFKMQLL KGGQILCDLTKTKGSGNTVSIKSLKFCHSQLSNNSVSFFLYNLDHSHANYYFCNLSI FDPPPFKVTLTGGYLHIYESQLCCQLKFWLPIGC AAF VWCILGCILICWLTKKKYS S SVHDPNGEYMFMRATAKKSRLTDVTL (SEQ ID NO: 41)

[0165] In accordance with the presently disclosed subject matter, an “ICOS nucleic acid molecule” refers to a polynucleotide encoding an ICOS polypeptide.

[0166] CTLA-4 is an inhibitory receptor expressed by activated T cells, which when engaged by its corresponding ligands (CD80 and CD86; B7-1 and B7-2, respectively), mediates activated T cell inhibition or anergy. In both preclinical and clinical studies, CTLA-4 blockade by systemic antibody infusion, enhanced the endogenous anti-tumor response albeit, in the clinical setting, with significant unforeseen toxicities.

[0167] CTLA-4 contains an extracellular V domain, a transmembrane domain, and a cytoplasmic tail. Alternate splice variants, encoding different isoforms, have been characterized. The membrane-bound isoform functions as a homodimer interconnected by a disulfide bond, while the soluble isoform functions as a monomer. The intracellular domain is similar to that of CD28, in that it has no intrinsic catalytic activity and contains one YVKM motif (SEQ ID NO: 42) able to bind PI3K, PP2A and SHP-2 and one proline-rich motif able to bind SH3 containing proteins. One role of CTLA-4 in inhibiting T cell responses seem to be directly via SHP-2 and PP2A dephosphorylation of TCR-proximal signaling proteins such as CD3 and LAT. CTLA-4 can also affect signaling indirectly via competing with CD28 for CD80 / 86 binding. CTLA-4 has also been shown to bind and / or interact with PI3K, CD80, AP2M1, and PPP2R5A.

[0168] In accordance with the presently disclosed subject matter, a CTLA-4 polypeptide can have an amino acid sequence that is at least about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, about 99% or about 100% homologous to UniProtKB / Swiss- Prot Ref. No.: P16410.3 (SEQ ID NO: 43) (homology herein may be determined using standard software such as BLAST or FASTA) or fragments thereof, and / or may optionally comprise up to one or up to two or up to three conservative amino acid substitutions.

[0169] SEQ ID NO: 43 is provided below: MACLGFQRHKAQLNLATRTWPCTLLFFLLFIPVFCKAMHVAQPAWLASSRGIASFV CEYASPGKATEVRVTVLRQADSQVTEVCAATYMMGNELTFLDDSICTGTSSGNQL TIQGLRAMDTGLYICKVELMYPPPYYLGIGNGTQIYVIDPEPCPDSDFLLWILAAVSS GLFFYSFLLTAVSLSKMLKKRSPLTTGVYVKMPPTEPECEKQFQPYFIPIN (SEQ ID NO: 43)

[0170] In accordance with the presently disclosed subject matter, a “CTLA-4 nucleicacid molecule” refers to a polynucleotide encoding a CTLA-4 polypeptide.

[0171] PD-1 is a negative immune regulator of activated T cells upon engagement with its corresponding ligands PD-L1 and PD-L2 expressed on endogenous macrophages and dendritic cells. PD-1 is a type I membrane protein of 268 amino acids. PD-1 has two ligands, PD-L1 and PD-L2, which are members of the B7 family. The protein's structure comprises an extracellular IgV domain followed by a transmembrane region and an intracellular tail. The intracellular tail contains two phosphorylation sites located in an immunoreceptor tyrosine-based inhibitory motif and an immunoreceptor tyrosine- based switch motif, that PD-1 negatively regulates TCR signals. SHP- 1 and SHP-2 phosphatases bind to the cytoplasmic tail of PD-1 upon ligand binding. Upregulation of PD-L1 is one mechanism tumor cells may evade the host immune system. In pre-clinical and clinical trials, PD-1 blockade by antagonistic antibodies induced anti -tumor responses mediated through the host endogenous immune system. In accordance with the presently disclosed subject matter, a PD-1 polypeptide can have an amino acid sequence that is at least about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, about 99% or about 100% homologous to NCBI Reference No: NP_005009.2 (SEQ ID NO: 44) or fragments thereof, and / or may optionally comprise up to one or up to two or up to three conservative amino acid substitutions.

[0172] SEQ ID NO: 44 is provided below: MQIPQAPWPVVWAVLQLGWRPGWFLDSPDRPWNPPTFSPALLWTEGDNATFTCSF SNTSESFVLNWYRMSPSNQTDKLAAFPEDRSQPGQDCRFRVTQLPNGRDFHMSVV RARRNDSGTYLCGAISLAPKAQIKESLRAELRVTERRAEVPTAHPSPSPRPAGQFQT LVVGWGGLLGSLVLLVWVLAVICSRAARGTIGARRTGQPLKEDPSAVPVFSVDYG ELDFQWREKTPEPPVPCVPEQTEYATIVFPSGMGTSSPARRGSADGPRSAQPLRPED GHCSWPL (SEQ ID NO: 44)

[0173] In accordance with the presently disclosed subject matter, a “PD-1 nucleic acid molecule” refers to a polynucleotide encoding a PD-1 polypeptide.

[0174] Lymphocyte-activation protein 3 (LAG-3) is a negative immune regulator of immune cells. LAG-3 belongs to the immunoglobulin (Ig) superfamily and contains 4 extracellular Ig-like domains. The LAG3 gene contains 8 exons. The sequence data, exon / intron organization, and chromosomal localization all indicate a close relationship of LAG3 to CD4. LAG3 has also been designated CD223 (cluster of differentiation 223).

[0175] In accordance with the presently disclosed subject matter, a LAG-3 polypeptide can have an amino acid sequence that is at least about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, about 99% or about 100% homologous to UniProtKB / Swiss- Prot Ref. No.: P18627.5 (SEQ ID NO: 45) or fragments thereof, and / or may optionally comprise up to one or up to two or up to three conservative amino acid substitutions.

[0176] SEQ ID NO: 45 is provided below:MWEAQFLGLLFLQPLWVAPVKPLQPGAEVPWWAQEGAPAQLPCSPTIPLQDLSLL RRAGVTWQHQPDSGPPAAAPGHPLAPGPHPAAPSSWGPRPRRYTVLSVGPGGLRS GRLPLQPRVQLDERGRQRGDFSLWLRPARRADAGEYRAAVHLRDRALSCRLRLRL GQASMTASPPGSLRASDWVILNCSFSRPDRPASVHWFRNRGQGRVPVRESPHHHLA ESFLFLPQVSPMDSGPWGCILTYRDGFNVSIMYNLTVLGLEPPTPLTVYAGAGSRVG LPCRLPAGVGTRSFLTAKWTPPGGGPDLLVTGDNGDFTLRLEDVSQAQAGTYTCHI HLQEQQLNATVTLAIITVTPKSFGSPGSLGKLLCEVTPVSGQERFVWSSLDTPSQRSF SGPWLEAQEAQLLSQPWQCQLYQGERLLGAAVYFTELSSPGAQRSGRAPGALPAG HLLLFLILGVLSLLLLVTGAFGFHLWRRQWRPRRFSALEQGIHPPQAQSKIEELEQEP EPEPEPEPEPEPEPEPEQL (SEQ ID NO: 45)

[0177] In accordance with the presently disclosed subject matter, a “LAG-3 nucleic acid molecule” refers to a polynucleotide encoding a LAG-3 polypeptide.

[0178] Natural Killer Cell Receptor 2B4 (2B4) mediates non-MHC restricted cell killing on NK cells and subsets of T cells. To date, the function of 2B4 is still under investigation, with the 2B4-S isoform believed to be an activating receptor, and the 2B4-L isoform believed to be a negative immune regulator of immune cells. 2B4 becomes engaged upon binding its high-affinity ligand, CD48. 2B4 contains a tyrosine-based switch motif, a molecular switch that allows the protein to associate with various phosphatases. 2B4 has also been designated CD244 (cluster of differentiation 244).

[0179] In accordance with the presently disclosed subject matter, a 2B4 polypeptide can have an amino acid sequence that is at least about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, about 99% or about 100% homologous to UniProtKB / Swiss-Prot Ref. No.: Q9BZW8.2 (SEQ ID NO: 46) or fragments thereof, and / or may optionally comprise up to one or up to two or up to three conservative amino acid substitutions.

[0180] SEQ ID NO: 46 is provided below:MLGQWTLILLLLLKVYQGKGCQGSADHWSISGVPLQLQPNSIQTKVDSIAWKKLLPSQNGFHHILKWENGSLPSNTSNDRFSFIVKNLSLLIKAAQQQDSGLYCLEVTSISGK VQTATFQVFVFESLLPDKVEKPRLQGQGKILDRGRCQVALSCLVSRDGNVSYAWY RGSKLIQTAGNLTYLDEEVDINGTHTYTCNVSNPVSWESHTLNLTQDCQNAHQEFR FWPFLVIIVILSALFLGTLACFCVWRRKRKEKQSETSPKEFLTIYEDVKDLKTRRNHE QEQTFPGGGSTIYSMIQSQSSAPTSQEPAYTLYSLIQPSRKSGSRKRNHSPSFNSTIYE VIGKSQPKAQNPARLSRKELENFDVYS (SEQ ID NO: 46)

[0181] In accordance with the presently disclosed subject matter, a “2B4 nucleic acid molecule” refers to a polynucleotide encoding a 2B4 polypeptide.

[0182] B- and T-lymphocyte attenuator (BTLA) expression is induced during activation of T cells, and BTLA remains expressed on Thl cells but not Th2 cells. Like PD1 and CTLA4, BTLA interacts with a B7 homolog, B7H4. However, unlike PD-1 and CTLA-4, BTLA displays T-Cell inhibition via interaction with tumor necrosis family receptors (TNF- R), not just the B7 family of cell surface receptors. BTLA is a ligand for tumor necrosis factor (receptor) superfamily, member 14 (TNFRSF14), also known as herpes virus entry mediator (HVEM). BTLA-HVEM complexes negatively regulate T-cell immune responses. BTLA activation has been shown to inhibit the function of human CD8+cancer-specific T cells. BTLA has also been designated as CD272 (cluster of differentiation 272).

[0183] In accordance with the presently disclosed subject matter, a BTLA polypeptide can have an amino acid sequence that is at least about 85%>, about 90%, about 95%, about 96%, about 97%, about 98%, about 99% or about 100% homologous to UniProtKB / Swiss- Prot Ref. No.: Q7Z6A9.3 (SEQ ID NO: 47) or fragments thereof, and / or may optionally comprise up to one or up to two or up to three conservative amino acid substitutions.

[0184] SEQ ID NO: 47 is provided below:MKTLPAMLGTGKLFWVFFLIPYLDIWNIHGKESCDVQLYIKRQSEHSILAGDPFELE CPVKYCANRPHVTWCKLNGTTCVKLEDRQTSWKEEKNISFFILHFEPVLPNDNGSY RCSANFQSNLIESHSTTLYVTDVKSASERPSKDEMASRPWLLYRLLPLGGLPLLITTC FCLFCCLRRHQGKQNELSDTAGREINLVDAHLKSEQTEASTRQNSQVLLSETGIYD NDPDLCFRMQEGSEVYSNPCLEENKPGIVYASLNHSVIGPNSRLARNVKEAPTEYA SICVRS (SEQ ID NO: 47)

[0185] In accordance with the presently disclosed subject matter, a “BTLA nucleic acid molecule” refers to a polynucleotide encoding a BTLA polypeptide.Engineered Immune Cells

[0186] The engineered immune cells can be generated from peripheral donor lymphocytes, e.g., those disclosed in Sadelain, M., et al., Nat Rev Cancer 3 :35-45 (2003), in Morgan, R.A. et al. (2006) Science 314: 126-129, in Panelli et al. (2000) J Immunol 164:495-504; Panelli et al. (2000) J Immunol 164:4382-4392 (2000), and in Dupont et al. (2005) Cancer Res 65:5417-5427; Papanicolaou et al. (2003) Blood 102:2498-2505. The engineered immune cells (e.g., macrophages, neutrophils) can be autologous, non- autologous (e.g., allogeneic), or derived in vitro from engineered progenitor or stem cells.

[0187] The unpurified source of immune cells can be any known in the art, such as the bone marrow, fetal, neonate or adult or other hematopoietic cell source, e.g., fetal liver, peripheral blood or umbilical cord blood. Various techniques can be employed to separate the cells. For instance, negative selection methods can remove non-immune cell initially. Monoclonal antibodies are particularly useful for identifying markers associated with particular cell lineages and / or stages of differentiation for both positive and negative selections.

[0188] A large proportion of terminally differentiated cells can be initially removed by a relatively crude separation. For example, magnetic bead separations can be used initially to remove large numbers of irrelevant cells. In some embodiments, at least about 80%, usually at least 70% of the total hematopoietic cells will be removed prior to cell isolation.

[0189] Procedures for separation include, but are not limited to, density gradient centrifugation; resetting; coupling to particles that modify cell density; magnetic separation with antibody-coated magnetic beads; affinity chromatography; cytotoxic agents joined to or used in conjunction with a mAb, including, but not limited to, complement and cytotoxins; and panning with antibody attached to a solid matrix, e.g., plate, chip, elutriation or any other convenient technique.

[0190] Techniques for separation and analysis include, but are not limited to, flow cytometry, which can have varying degrees of sophistication, e.g., a plurality of color channels, low angle and obtuse light scattering detecting channels, impedance channels.

[0191] The cells can be selected against dead cells, by employing dyes associated with dead cells such as propidium iodide (PI). In some embodiments, the cells are collected in a medium comprising 2% fetal calf serum (FCS) or 0.2% bovine serum albumin (BSA) or any other suitable, preferably sterile, isotonic medium.

[0192] Immune cells Overexpressing G >4

[0193] The presently disclosed subject matter provides engineered immune cells that overexpress a mammalian Gp4 polypeptide. In certain embodiments, immune cells can be transduced with a vector comprising nucleic acid sequences that encode a mammalian Gp4 polypeptide. In some embodiments, the mammalian GP4 polypeptide comprises the amino acid sequence of SEQ ID NO: 2.

[0194] The engineered immune cells of the presently disclosed subject matter can express non-endogenous levels of Gp4 for the treatment of CMTD. Such engineered immune cells can be administered to a subject (e.g., a human subject) in need thereof for the treatment of CMTD. In some embodiments, the immune cell is a macrophage or neutrophil.

[0195] In certain embodiments, the presently disclosed engineered immune cells (e.g., macrophages, neutrophils) expresses from about 1 to about 5, from about 1 to about 4, from about 2 to about 5, from about 2 to about 4, from about 3 to about 5, from about 3 to about 4, from about 4 to about 5, from about 1 to about 2, from about 2 to about 3, from about 3 to about 4, or from about 4 to about 5 vector copy numbers per cell of a Gp4 heterologous nucleic acid.

[0196] G / i4 Depleted Immune Cells

[0197] In one aspect, the present disclosure provides compositions for adoptive cell therapy comprising engineered immune cells (e.g., neutrophils, macrophages) that either express a dominant negative Gp4 polypeptide and / or that lack detectable expression or activity of a wild-type GP4. An engineered neutrophil or macrophage may comprise one or more disruptions in endogenous genes encoding a GP4 polypeptide (e.g., CRISPR knockouts) and / or one or more transgenes that inhibit expression or activity of GP4 (e.g., a dominant negative GP4 construct, or an inhibitory RNA (e.g., shRNA, siRNA) targeting GP4).

[0198] Gene suppression can be performed in a number of ways. For example, gene expression can be suppressed by knock out, altering a promoter of a gene, and / or by inhibiting transcriptional or translational activity. This can be done at an organism level or at a tissue, organ, and / or cellular level. Gene suppression methods may comprise overexpressing a dominant negative protein. This method can result in overall decreased function of a functional wild-type gene. Additionally, expressing a dominant negative gene can result in a phenotype that is similar to that of a knockout and / or knockdown.Sometimes a stop codon can be inserted or created (e.g., by nucleotide replacement), in one or more genes, which can result in a nonfunctional transcript or protein (sometimes referred to as knockout). For example, if a stop codon is created within the middle of one or more genes, the resulting transcription and / or protein can be truncated, and can be nonfunctional. However, in some cases, truncation can lead to an active (a partially or overly active) protein. If a protein is overly active, this can result in a dominant negative protein.

[0199] Alternatively, one or more genes can be suppressed by administering inhibitory nucleic acids, e.g., siRNA, shRNA, antisense or microRNA. For example, an inhibitory nucleic acid (e.g., siRNA, shRNA, antisense or microRNA) or a nucleic acid expressing a dominant negative protein can be stably transfected into a cell to knockdown expression. Alternatively, an inhibitory nucleic acid (e.g., siRNA, shRNA, antisense or microRNA) or a nucleic acid expressing a dominant negative protein can be integrated into the genome of a neutrophil or macrophage, thus knocking down a gene within the neutrophil or macrophage.

[0200] In some embodiments, a neutrophil or macrophage comprises a nucleic acid encoding an exogenous dominant negative GP4 construct. The GP4 dominant-negative construct may comprise a GP4 nucleic acid that includes GNB4 c,158G>A (p.Gly53Asp) or c.265A>G(p.Lys89Glu) mutation. Expression of dominant negative transgenes can suppress expression and / or function of a wild-type counterpart of the dominant negative transgene. Thus, for example, a neutrophil or macrophage comprising a dominant negative GP4 transgene can have similar phenotypes compared to a different neutrophil or macrophage in which the expression of the Gp4 is suppressed.

[0201] Transgenes can be useful for expressing, e.g., overexpressing, exogenous dominant negative genes at a level greater than background, i.e., a cell that has not been transfected with a transgene. Nucleic acids comprising transgenes that encode transgene products can be placed into an organism, cell, tissue, or organ. Accordingly, in some embodiments, the engineered neutrophil or macrophage comprises a transgene that encodes a dominant negative Gp4. A transgene of a dominant negative Gp4 can refer to a transgene comprising a nucleotide sequence encoding the dominant negative GP4.

[0202] Also provided herein are neutrophils or macrophages comprising one or more transgenes that encode one or more inhibitory nucleic acids that can suppress genetic expression, e.g., can knockdown a gene. RNAs that suppress genetic expression can comprise, but are not limited to, antisense, shRNA, siRNA, RNAi, and microRNA. Forexample, transgenes encoding siRNA, RNAi, and / or microRNA can be delivered to a macrophage or neutrophil to suppress genetic expression. For example, an engineered macrophage or neutrophil may comprise a transgene encoding an inhibitory nucleic acid (e.g., siRNA, RNAi, antisense etc.) that specifically targets and inhibits the expression of the nucleic acid sequence of SEQ ID NO: 1. An engineered macrophage or neutrophil may comprise about 1, 2, 3, 4, 5, or more transgenes encoding one or more inhibitory nucleic acids that suppress the activity and / or expression of Gp4.

[0203] Transgenes of the present technology can be incorporated into a cell. When inserted into a cell, a transgene can be either a complementary DNA (cDNA) segment, which is a copy of messenger RNA (mRNA), or a genomic DNA segment (with or without introns). A transgene may be inserted within a coding genomic region or a noncoding genomic region. A transgene may be inserted into a genome with or without homologous recombination.

[0204] One or more of the transgenes disclosed herein can be derived from different species. For example, one or more transgenes can comprise a human gene, a mouse gene, a rat gene, a pig gene, a bovine gene, a dog gene, a cat gene, a monkey gene, a chimpanzee gene, or any combination thereof. For example, a transgene can be from a human, having a human genetic sequence. One or more transgenes can comprise human genes.

[0205] A transgene of the present technology can be inserted into a genome of a macrophage or neutrophil in a random or site-specific manner. For example, a transgene can be inserted to a random locus in a genome of a macrophage or neutrophil. A transgene can include its own promoter or can be inserted into a position where it is under the control of an endogenous promoter. Alternatively, a transgene can be inserted into a gene, such as an intron of a gene or an exon of a gene, a promoter, or a non-coding region. A transgene can be inserted such that the insertion disrupts a gene, e.g., an endogenous gene. A transgene insertion can be guided by recombination arms that can flank a transgene. Sometimes, more than one copy of a transgene can be inserted into a random locus in a genome. For example, multiple copies can be inserted into a random locus in a genome. This can lead to increased overall expression than if a transgene was randomly inserted once. Alternatively, a copy of a transgene can be inserted into a gene, and another copy of a transgene can be inserted into a different gene. A transgene can be targeted so that it could be inserted to a specific locus in a genome of a macrophage or neutrophil.

[0206] Expression of any transgene disclosed herein can be controlled by one or more promoters. A promoter can be an ubiquitous promoter, a constitutive promoter, a tissuespecific promoter or an inducible promoter. Expression of a transgene that is inserted adjacent to or near a promoter can be regulated. For example, a transgene can be inserted near or next to a ubiquitous promoter. Examples of ubiquitous promoters include, but are not limited to, a CAGGS promoter, an hCMV promoter, a PGK promoter, an SV40 promoter, or a ROSA26 promoter. A promoter may be endogenous or exogenous. For example, one or more transgenes can be inserted adjacent or near to an endogenous or exogenous ROSA26 promoter. Tissue specific promoter or cell-specific promoters can be used to control the location of expression. Inducible promoters can be used as well. These inducible promoters can be turned on and off when desired, by adding or removing an inducing agent. Examples of inducible promoters include, but are not limited to, Lac, tac, trc, trp, araBAD, phoA, recA, proU, cst-1, tetA, cadA, nar, PL, cspA, T7, VHB, Mx, and / or Trex.

[0207] In another aspect, a macrophage or neutrophil can be engineered to knock out endogenous genes. For example, knocking out one or more genes may comprise deleting one or more genes from a genome of a macrophage or neutrophil (e.g., GP4). Knocking out can also comprise removing all or a part of a gene sequence (e.g., deletion) from a macrophage or neutrophil (e.g., GP4). It is also contemplated that knocking out can comprise replacing all or a part of a gene in a genome of a macrophage or neutrophil with one or more nucleotides. Knocking out one or more genes can also comprise inserting a sequence in one or more genes (e.g., insertion), thereby disrupting expression of the one or more genes. For example, inserting a sequence can generate a stop codon in the middle of one or more genes (e.g., nonsense mutation). Inserting a sequence can also shift the open reading frame of one or more genes (e.g., frameshift mutation).

[0208] By way of example only, one or more endogenous genes may be knocked out using an endonuclease selected from the group consisting of a CRISPR system (e.g., a Cas endonuclease), TALEN, Zinc Finger, transposon-based, ZEN, meganuclease, Mega-TAL, and any combination thereof.

[0209] CRISPR System. Methods described herein can take advantage of a CRISPR system. There are at least five types of CRISPR systems which all incorporate RNAs and Cas proteins. Types I, III, and IV assemble a multi-Cas protein complex that is capable of cleaving nucleic acids that are complementary to the crRNA. Types I and III both requirepre-crRNA processing prior to assembling the processed crRNA into the multi-Cas protein complex. Types II and V CRISPR systems comprise a single Cas protein complexed with at least one guiding RNA.

[0210] The general mechanism and recent advances of CRISPR system is discussed in Cong, L. etal., Science, 339 (6121): 819-823 (2013); Fu, Y. et al., Nature Biotechnology, 31, 822-826 (2013); Chu, V T et al., Nature Biotechnology 33, 543-548 (2015); Shmakov, S. et al., Molecular Cell, 60, 1-13 (2015); Makarova, K S et al., Nature Reviews Microbiology, 13, 1-15 (2015). Site-specific cleavage of a target DNA occurs at locations determined by both 1) base-pairing complementarity between the guide RNA and the target DNA (also called a protospacer) and 2) a short motif in the target DNA referred to as the protospacer adjacent motif (PAM). For example, an engineered cell can be generated using a CRISPR system, e.g., a type II CRISPR system. A Cas enzyme used in the methods disclosed herein can be Cas9, which catalyzes DNA cleavage. Enzymatic action by Cas9 derived from Streptococcus pyogenes or any closely related Cas9 can generate double stranded breaks at target site sequences which hybridize to about 20 nucleotides of a guide sequence and that have a protospacer-adjacent motif (PAM) following the about 20 nucleotides of the target sequence.

[0211] a. Cas Protein. A vector can be operably linked to an enzyme-coding sequence encoding a CRISPR enzyme, such as a Cas protein (CRISPR-associated protein). Nonlimiting examples of Cas proteins can include Casl, CaslB, Cas2, Cas3, Cas4, Cas5, Cas6, Cas7, Cas8, Cas9 (also known as Csnl or Csxl2), CaslO, Csyl, Csy2, Csy3, Csel, Cse2, Cscl, Csc2, Csa5, Csn2, Csm2, Csm3, Csm4, Csm5, Csm6, Cmrl, Cmr3, Cmr4, Cmr5, Cmr6, Csbl, Csb2, Csb3, Csxl7, Csxl4, CsxlO, Csxl6, CsaX, Csx3, Csxl, CsxlS, Csfl, Csf2, CsO, Csf4, Cpfl, c2cl, c2c3, Cas9HiFi, homologues thereof, or modified versions thereof. In some embodiments, the Cas protein is Cas9. A Cas9 endonuclease may create a double strand break in at least one gene (e.g., Gp4). In some cases, a double strand break can be repaired using homology directed repair (HDR), non-homologous end joining (NHEJ), microhomology-mediated end joining (MMEJ), or any combination or derivative thereof.

[0212] An unmodified CRISPR enzyme can have DNA cleavage activity, such as Cas9. A CRISPR enzyme can direct cleavage of one or both strands at a target sequence, such as within a target sequence and / or within a complement of a target sequence. For example, a CRISPR enzyme can direct cleavage of one or both strands within or within about 1, 2, 3, 4,5, 6, 7, 8, 9, 10, 15, 20, 25, 50, 100, 200, 500, or more base pairs from the first or last nucleotide of a target sequence. A vector that encodes a CRISPR enzyme that is mutated with respect to a corresponding wild-type enzyme such that the mutated CRISPR enzyme lacks the ability to cleave one or both strands of a target polynucleotide containing a target sequence can be used. A Cas protein can be a high fidelity cas protein such as Cas9HiFi.

[0213] A vector that encodes a CRISPR enzyme comprising one or more nuclear localization sequences (NLSs), such as 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more NLSs can be used. For example, a CRISPR enzyme can comprise 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more NLSs at or near the amino-terminus, or at or near the carboxyl-terminus, or any combination of these (e.g., one or more NLS at the amino-terminus and one or more NLS at the carboxyl terminus). When more than one NLS is present, each can be selected independently of others, such that a single NLS can be present in more than one copy and / or in combination with one or more other NLSs present in one or more copies.

[0214] Cas9 can refer to a polypeptide with at least about 50%, 60%, 70%, 80%, 90%, 100% sequence identity and / or sequence similarity to a wild-type exemplary Cas9 polypeptide (e.g., Cas9 from S. pyogenes). Cas9 can refer to a polypeptide with at most about 50%, 60%, 70%, 80%, 90%, 100% sequence identity and / or sequence similarity to a wild-type exemplary Cas9 polypeptide (e.g., from S. pyogenes). Cas9 can refer to the wildtype or a modified form of the Cas9 protein that can comprise an amino acid change such as a deletion, insertion, substitution, variant, mutation, fusion, chimera, or any combination thereof.

[0215] A polynucleotide encoding an endonuclease (e.g., a Cas protein such as Cas9) can be codon optimized for expression in particular cells, such as eukaryotic cells. This type of optimization can entail the mutation of foreign-derived (e.g., recombinant) DNA to mimic the codon preferences of the intended host organism or cell while encoding the same protein.

[0216] CRISPR enzymes used in the methods can comprise NLSs. The NLS can be located anywhere within the polypeptide chain, e.g., near the N- or C-terminus. For example, the NLS can be within or within about 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 40, 50 amino acids along a polypeptide chain from the N- or C-terminus. Sometimes the NLS can be within or within about 50 amino acids or more, e.g., 100, 200, 300, 400, 500, 600, 700, 800, 900, or 1000 amino acids from the N- or C-terminus.

[0217] An endonuclease can comprise an amino acid sequence having at least about 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100%, amino acid sequence identity to the nuclease domain of a wild-type exemplary site-directed polypeptide (e.g., Cas9 from S. pyogenes). In some cases, a different non-Cas9 endonuclease may be used to target certain genomic targets. In some cases, synthetic SpCas9-derived variants with non-NGG PAM sequences may be used.

[0218] Additionally, other Cas9 orthologues from various species have been identified and these “non-SpCas9s” bind a variety of PAM sequences that could also be useful for the present technology (e.g., Staphylococcus aureus Cas9 (SaCas9)).

[0219] Alternatives to S. pyogenes Cas9 may include RNA-guided endonucleases from the Cpfl family that display cleavage activity in mammalian cells. Unlike Cas9 nucleases, the result of Cpfl -mediated DNA cleavage is a double-strand break with a short 3' overhang. Cpfl's staggered cleavage pattern may open up the possibility of directional gene transfer, analogous to traditional restriction enzyme cloning, which may increase the efficiency of gene editing. Like the Cas9 variants and orthologues described above, Cpfl may also expand the number of sites that can be targeted by CRISPR to AT-rich regions or AT -rich genomes that lack the NGG PAM sites favored by SpCas9.

[0220] Any functional concentration of Cas protein can be introduced to a cell. For example, 15 micrograms of Cas mRNA can be introduced to a cell. In other cases, a Cas mRNA can be introduced from 0.5 micrograms to 100 micrograms. A Cas mRNA can be introduced from 0.5, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100 micrograms.

[0221] b. Guide RNA. A method disclosed herein also can comprise introducing into a cell (e.g., a macrophage or neutrophil) at least one guide RNA or nucleic acid, e.g., DNA encoding at least one guide RNA. A guide RNA can interact with a RNA-guided endonuclease to direct the endonuclease to a specific target site, at which site the 5' end of the guide RNA base pairs with a specific protospacer sequence in a chromosomal sequence.

[0222] A guide RNA may comprise a CRISPR RNA (crRNA) and a transactivating crRNA (tracrRNA). A guide RNA can sometimes comprise a single-guide RNA (sgRNA) formed by fusion of a portion (e.g., a functional portion) of crRNA and tracrRNA. A guide RNA can also be a dual RNA comprising a crRNA and a tracrRNA. A guide RNA can comprise a crRNA and lack a tracrRNA. In some embodiments, a crRNA can hybridizewith a target DNA or protospacer sequence.

[0223] A guide RNA can be an expression product. For example, a DNA that encodes a guide RNA can be a vector comprising a sequence coding for the guide RNA. A guide RNA can be transferred into a cell or organism by transfecting the cell or organism with an isolated guide RNA or plasmid DNA comprising a sequence coding for the guide RNA and a promoter. A guide RNA can also be transferred into a cell or organism in other way, such as using virus-mediated gene delivery. In other embodiments, a guide RNA can be isolated. For example, a guide RNA can be transfected in the form of an isolated RNA into a cell or organism. A guide RNA can be prepared by in vitro transcription using any in vitro transcription system. A guide RNA can be transferred to a cell in the form of isolated RNA rather than in the form of plasmid comprising encoding sequence for a guide RNA.

[0224] A guide RNA can comprise a DNA-targeting segment and a protein binding segment. A DNA-targeting segment (or DNA-targeting sequence, or spacer sequence) comprises a nucleotide sequence that can be complementary to a specific sequence within a target DNA (e.g., a protospacer). A protein-binding segment (or protein-binding sequence) can interact with a site-directed modifying polypeptide, e.g. an RNA-guided endonuclease such as a Cas protein. By “segment” it is meant a segment / section / region of a molecule, e.g., a contiguous stretch of nucleotides in an RNA. A segment can also mean a region / section of a complex such that a segment may comprise regions of more than one molecule. For example, in some cases a protein-binding segment of a DNA-targeting RNA is one RNA molecule and the protein-binding segment therefore comprises a region of that RNA molecule. In other cases, the protein-binding segment of a DNA-targeting RNA comprises two separate molecules that are hybridized along a region of complementarity.

[0225] A guide RNA can comprise two separate RNA molecules or a single RNA molecule. An exemplary single molecule guide RNA comprises both a DNA-targeting segment and a protein-binding segment. An exemplary two-molecule DNA-targeting RNA can comprise a crRNA-like (“CRISPR RNA” or “targeter-RNA” or “crRNA” or “crRNA repeat”) molecule and a corresponding tracrRNA-like (“trans-acting CRISPR RNA” or “activator-RNA” or “tracrRNA”) molecule. A first RNA molecule can be a crRNA-like molecule (targeter-RNA), that can comprise a DNA-targeting segment (e.g., spacer) and a stretch of nucleotides that can form one half of a double-stranded RNA (dsRNA) duplex comprising the protein-binding segment of a guide RNA.

[0226] A second RNA molecule can be a corresponding tracrRNA-like molecule (activator-RNA) that can comprise a stretch of nucleotides that can form the other half of a dsRNA duplex of a protein-binding segment of a guide RNA. In other words, a stretch of nucleotides of a crRNA-like molecule can be complementary to and can hybridize with a stretch of nucleotides of a tracrRNA-like molecule to form a dsRNA duplex of a proteinbinding domain of a guide RNA. As such, each crRNA-like molecule can be said to have a corresponding tracrRNA-like molecule. A crRNA-like molecule additionally can provide a single stranded DNA-targeting segment, or spacer sequence. Thus, a crRNA-like and a tracrRNA-like molecule (as a corresponding pair) can hybridize to form a guide RNA. A subject two-molecule guide RNA can comprise any corresponding crRNA and tracrRNA pair.

[0227] A DNA-targeting segment or spacer sequence of a guide RNA can be complementary to sequence at a target site in a chromosomal sequence, e.g., protospacer sequence) such that the DNA-targeting segment of the guide RNA can base pair with the target site or protospacer. In some cases, a DNA-targeting segment of a guide RNA can comprise from about 10 nucleotides to from about 25 nucleotides or more. For example, a region of base pairing between a first region of a guide RNA and a target site in a chromosomal sequence can be about 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 22, 23, 24, 25, or more than 25 nucleotides in length. Sometimes, a first region of a guide RNA can be about 19, 20, or 21 nucleotides in length.

[0228] A guide RNA can target a nucleic acid sequence of about 20 nucleotides. A target nucleic acid can be less than about 20 nucleotides. A target nucleic acid can be at least about 5, 10, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30 or more nucleotides. A target nucleic acid can be at most about 5, 10, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30 or more nucleotides. A target nucleic acid sequence can be about 20 bases immediately 5' of the first nucleotide of the PAM.

[0229] A guide nucleic acid, for example, a guide RNA, can refer to a nucleic acid that can hybridize to another nucleic acid, for example, the target nucleic acid or protospacer in a genome of a cell. A guide nucleic acid can be RNA. A guide nucleic acid can be DNA. The guide nucleic acid can be programmed or designed to specifically bind to a sequence at a nucleic acid site. A guide nucleic acid can comprise a polynucleotide chain and can be called a single guide nucleic acid. A guide nucleic acid can comprise two polynucleotide chains and can be called a double guide nucleic acid.

[0230] A guide nucleic acid can comprise one or more chemical or physical modifications. A guide nucleic acid can comprise a nucleic acid affinity tag. A guide nucleic acid may comprise one or more synthetic nucleotides, synthetic nucleotide analogs, nucleotide derivatives, and / or modified nucleotides. A guide nucleic acid can comprise a nucleotide sequence (e.g., a spacer), for example, at or near the 5' end or 3' end, that can hybridize to a sequence in a target nucleic acid (e.g., a protospacer). A spacer of a guide nucleic acid can interact with a target nucleic acid in a sequence-specific manner via hybridization (z.e., base pairing). A spacer sequence can hybridize to a target nucleic acid that is located 5' or 3' to a protospacer adjacent motif (PAM). The length of a spacer sequence can be at least about 5, 10, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30 or more nucleotides. The length of a spacer sequence can be at most about 5, 10, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30 or more nucleotides.

[0231] A guide RNA may also comprise a dsRNA duplex region that forms a secondary structure. For example, a secondary structure formed by a guide RNA can comprise a stem (or hairpin) and a loop. A length of a loop and a stem can vary. For example, a loop can range from about 3 to about 10 nucleotides in length, and a stem can range from about 6 to about 20 base pairs in length. A stem can comprise one or more bulges of 1 to about 10 nucleotides. The overall length of a second region can range from about 16 to about 60 nucleotides in length. For example, a loop can be about 4 nucleotides in length and a stem can be about 12 base pairs. A dsRNA duplex region can comprise a protein-binding segment that can form a complex with an RNA-binding protein, such as a RNA-guided endonuclease, e.g., Cas protein.

[0232] A guide RNA can also comprise a tail region at the 5' or 3' end that can be single-stranded. For example, a tail region is sometimes not complementarity to any chromosomal sequence in a cell of interest and is sometimes not complementarity to the rest of a guide RNA. Further, the length of a tail region can vary. A tail region can be more than about 4 nucleotides in length. For example, the length of a tail region can range from about 5 to about 60 nucleotides in length.

[0233] A guide RNA can be introduced into a cell or embryo as an RNA molecule. For example, a RNA molecule can be transcribed in vitro and / or can be chemically synthesized. A guide RNA can then be introduced into a cell or embryo as an RNA molecule. A guide RNA can also be introduced into a cell or embryo in the form of a non-RNA nucleic acid molecule, e.g., DNA molecule. For example, a DNA encoding a guide RNA can beoperably linked to promoter control sequence for expression of the guide RNA in a cell of interest. A DNA molecule encoding a guide RNA may be linear or circular.

[0234] When both a RNA-guided endonuclease and a guide RNA are introduced into a cell as DNA molecules, each can be part of a separate molecule (e.g., one vector containing the RNA-guided endonuclease coding sequence and a second vector containing the guide RNA coding sequence) or both can be part of a same molecule (e.g., one vector containing coding (and regulatory) sequence for both a RNA-guided endonuclease and a guide RNA).

[0235] A Cas protein, such as a Cas9 protein or any derivative thereof, can be precomplexed with a guide RNA to form a ribonucleoprotein (RNP) complex. The RNP complex can facilitate homology directed repair (HDR). The RNP complex can be introduced into primary macrophages or neutrophils. Introduction of the RNP complex can be timed. The cell can be synchronized with other cells at Gl, S, and / or M phases of the cell cycle. The RNP complex can be delivered at a cell phase such that HDR is enhanced.

[0236] A guide RNA can also be modified. The modifications can comprise chemical alterations, synthetic modifications, nucleotide additions, and / or nucleotide subtractions. The modifications can also enhance CRISPR genome engineering. A modification can alter chirality of a gRNA. In some cases, chirality may be uniform or stereopure after a modification. A guide RNA can be synthesized. The synthesized guide RNA can enhance CRISPR genome engineering. A guide RNA can also be truncated. Truncation can be used to reduce undesired off-target mutagenesis. The truncation can comprise any number of nucleotide deletions. For example, the truncation can comprise 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 40, 50 or more nucleotides. A guide RNA can comprise a region of target complementarity of any length. For example, a region of target complementarity can be less than 20 nucleotides in length. A region of target complementarity can be more than 20 nucleotides in length.

[0237] In some cases, a modification is on a 5' end, a 3' end, from a 5' end to a 3' end, a single base modification, a 2'-ribose modification, or any combination thereof. A modification can be selected from a group consisting of base substitutions, insertions, deletions, chemical modifications, physical modifications, stabilization, purification, and any combination thereof. In some embodiments, a modification is a chemical modification.A modification can be selected from 5' adenylate, 5' guanosine-triphosphate cap, 5'N7- Methylguanosine-triphosphate cap, 5' triphosphate cap, 3' phosphate, 3' thiophosphate, 5' phosphate, 5' thiophosphate, Cis-Syn thymidine dimer, trimers, C12 spacer, C3 spacer, C6 spacer, dSpacer, PC spacer, rSpacer, Spacer 18, Spacer 9,3 '-3' modifications, 5 '-5' modifications, abasic, acridine, azobenzene, biotin, biotin BB, biotin TEG, cholesteryl TEG, desthiobiotin TEG, DNP TEG, DNP-X, DOTA, dT-Biotin, dual biotin, PC biotin, psoralen C2, psoralen C6, TESTA, 3 'DABCYL, black hole quencher 1, black hole quencer 2, DABCYL SE, dT-DABCYL, IRDye QC-1, QSY-21, QSY-35, QSY-7, QSY-9, carboxyl linker, thiol linkers, 2' deoxyribonucleoside analog purine, 2' deoxyribonucleoside analog pyrimidine, ribonucleoside analog, 2'-O-methyl ribonucleoside analog, sugar modified analogs, wobble / universal bases, fluorescent dye label, 2' fluoro RNA, 2' O-methyl RNA, methylphosphonate, phosphodiester DNA, phosphodiester RNA, phosphothioate DNA, phosphorothioate RNA, LINA, pseudouridine-5 '-triphosphate, 5-methylcytidine-5'- triphosphate, 2-O-methyl 3phosphorothioate or any combinations thereof. A modification may be a pseudouride modification. In some cases, a modification is a 2-O-methyl 3 phosphorothioate addition. A 2-O-methyl 3 phosphorothioate addition can be performed from 1 base to 150 bases. A 2-O-methyl 3 phosphorothioate addition can be performed from 1 base to 4 bases. A 2-O-methyl 3 phosphorothioate addition can be performed on 2 bases. A 2-O-methyl 3 phosphorothioate addition can be performed on 4 bases. A modification can also be a truncation. A truncation can be a 5 base truncation. In some cases, a 5 base truncation can prevent a Cas protein from performing a cut.

[0238] In some cases, a dual nickase approach may be used to introduce a double stranded break. Cas proteins can be mutated at known amino acids within either nuclease domains, thereby deleting activity of one nuclease domain and generating a nickase Cas protein capable of generating a single strand break. A nickase along with two distinct guide RNAs targeting opposite strands may be utilized to generate a DSB within a target site (often referred to as a “double nick” or “dual nickase” CRISPR system). This approach may dramatically increase target specificity, since it is unlikely that two off-target nicks will be generated within close enough proximity to cause a DSB.

[0239] A gRNA can be introduced at any functional concentration. For example, a gRNA can be introduced to a cell at 10 micrograms. In other cases, a gRNA can be introduced from 0.5 micrograms to 100 micrograms. A gRNA can be introduced from 0.5, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100 micrograms.

[0240] A DNA sequence encoding a guide RNA or transgene disclosed herein can also be part of a vector. Some examples of vectors include plasmid vectors, phagemids, cosmids, artificial / mini-chromosomes, transposons, and viral vectors. Further, a vector can comprise additional expression control sequences (e.g., enhancer sequences, Kozak sequences, polyadenylation sequences, transcriptional termination sequences, etc.), selectable marker sequences (e.g., antibiotic resistance genes), origins of replication, and the like.

[0241] In one aspect, the present disclosure provides an engineered macrophage or neutrophil, wherein the cell lacks detectable expression or activity of a Gp4 polypeptide (e.g., a Gp4 polypeptide comprising an amino acid sequence of SEQ ID NO: 2).

[0242] In another aspect, the present disclosure provides an engineered macrophage or neutrophil, wherein the cell expresses an inhibitory nucleic acid that specifically targets and inhibits the expression of a Gp4 nucleic acid sequence (e.g., a Gp4 nucleic acid sequence comprising SEQ ID NO: 1). The inhibitory nucleic acid may be an antisense oligonucleotide, a siRNA, a sgRNA or a shRNA. Additionally or alternatively, in some embodiments of the engineered macrophages or neutrophils of the present technology, the cells comprise a transgene that encodes a dominant negative Gp4 polypeptide or the inhibitory nucleic acid. The transgene may be operably linked to an ubiquitous promoter, a constitutive promoter, a macrophage-specific promoter, a neutrophil-specific promoter, or an inducible promoter. In one aspect, the present disclosure provides an engineered macrophage or neutrophil comprising a deletion, insertion, inversion, or frameshift mutation in a Gp4 gene (e.g., a Gp4 gene encoded by the nucleic acid sequence of SEQ ID NO: 1). In certain embodiments, the deletion, insertion, inversion, or frameshift mutation in a GP4 gene is generated using at least one sgRNA and at least one endonuclease (e.g., Cas9 endonuclease). Additionally or alternatively, in some embodiments, the engineered macrophage or neutrophil is derived from an autologous donor or an allogeneic donor.

[0243] In some embodiments, immune cells can be transduced with a vector comprising Gp4-specific inhibitory nucleic acid sequences or GP4 dominant-negative constructs. The Gp4-specific inhibitory nucleic acid may be an antisense oligonucleotide, a siRNA, a sgRNA or a shRNA. Additionally or alternatively, in some embodiments, the engineered immune cells may further comprise an engineered receptor (e.g., a CAR) or other ligand that comprises an extracellular antigen-binding domain, a transmembrane domain and an intracellular domain, where the extracellular antigen-binding domain specifically binds atumor antigen, including a tumor receptor or ligand. Examples of tumor antigens include, but are not limited to, 5T4, alpha 5pi-integrin, 707-AP, A33, AFP, ART -4, B7H4, BAGE, Bcl-2, P-catenin, BCMA, Bcr-abl, CA125, CA19-9, CAMEL, CAP-1, CASP-8, CD4, CD5, CD19, CD20, CD21 , CD22, CD25, CDC27 / m, CD33, CD37, CD45, CD52, CD56, CD80, CD123, CDK4 / m, CEA, c-Met, CS-1, CT, Cyp-B, cyclin Bl, DAGE, DAM, EBNA, EGFR, ErbB3, ELF2M, EMMPRIN, EpCam, ephrinB2, estrogen receptor, ETV6-AML1, FAP, ferritin, folate-binding protein, GAGE, G250, GD-2, GM2, GnT-V, gp75, gplOO (Pmel 17), HAGE, HER-2 / neu, HLA-A*0201-R170I, HPV E6, HPV E7, Ki-67, HSP70-2M, HST-2, hTERT (or hTRT), iCE, IGF-1R, IL-2R, IL-5, KIAA0205, LAGE, LDLR / FUT, LRP, MAGE, MART, MART-l / melan-A, MART-2 / Ski, MC1R, mesothelin, MUC16, MUM-1 - B, myc, MUM-2, MUM-3, NA88-A, NYESO-1, NY-Eso-B, p53, proteinase-3, pl90 minor bcr-abl, Pml / RARa, PRAME, progesterone receptor, PSA, PSCA, PSM, PSMA, ras, RAGE, RU1 or RU2, RORI, SART-1 or SART-3, survivin, TEL / AML1, TGFp, TPI / m, TRP-1, TRP-2, TRP-2 / INT2, tenascin, TSTA tyrosinase, VEGF, or WT1. Other examples of tumor antigens include a2b b3 (Glycoprotein Ilb / IIIa), a4, a4b7, a4b7 +aEb7, a5, Activin receptor type-2B, ALK1, Alpha-synuclein, amyloid beta, APP, AXL, Blood Group A, CAIX, CCL-2, CD105 (endoglin), CD115 (CSF1R), CD116a (CSF2Ra), CD123, CD152 (CTLA4), CD 184 (CXCR4), CD 19, CD 192 (CCR2), CD 194 (CCR4), CD 195 (CCR5), CD20, CD200, CD22, CD221 (IGF1R), CD248, CD25, CD257 (BAFF), CD26, CD262 (DR5), CD276 (B7H3), CD3, CD30 (TNFRSF8), CD319 (SLAMF7), CD33, CD332 (FGFR2), CD350 (FZD10), CD37, CD371 (CLEC12A), CD38, CD4, CD49b (a2), CD51 (a5), CD52, CD56, CD61 (a4b3), CD70, CD73 (NT5E), CD74, CEA, Claudin-18.2, cMET, CRLR, DLL3, DLL4, DNA / histone (Hl) complex, EGFR, EpCAM, EGFR- HER3, EGFRvIII, EphA3, ERGT(GalNAc) Tn Antigen, FLT1, FOLR1, frizzled family receptor (FZD), Lewis Y, Lewis X, GCGR, GD2, GD2 a-acetyl, GD3, GM1, GM1 fucosyl, GM2, GPA33, GPNMB, GUCY2C, HER2, HER3, HGFR (cMET), IgHe, IGLF2, Kallikreins, LINGO1, LOXL2, Ly6 / PLAUR domain-containing protein 3, MADCAM1, MAG, Mesothelin, MT1-MMP (MMP14), MUC1, Mucin 5 AC, NaPi2b, NeuGc-GM3, notch, NOTCH2 / NOTCH3 receptors, oxLDL, P-selectin, PCSK9, PDGFRA, PDGFRa, phosphatidylserine, polysialic acid, PSMA, PVRL4, RGMA, CD240D Blood group D antigen, root plate-specific spondin 3, serum amyloid P component, STEAP-1, TACSTD2, TGFb, TWEAKR, TYRP1, VEGFR2, VSIR, CD171 (LI CAM), CD 19, CD47, pMHC[NY- ESO1], pMHC[MARTl], pMHC[MAGEAl], pMHC[Tyrosinase], pMHC[gpl00],pMHC[MUCl], pMHC[tax], pMHC[WT-l], pMHC[EBNA-l], pMHC[LMP2], pMHCfhTERT], GPC3, CD80, CD23, and fibronectin extra domain-B.

[0244] In another aspect, the present disclosure provides methods for engineered macrophages or neutrophils comprising: isolating macrophages or neutrophils from a donor subject; transducing the macrophages or neutrophils with (a) an inhibitory nucleic acid that specifically targets and inhibits the expression of a Gp4 nucleic acid sequence (e.g., SEQ ID NO: 1), and / or (b) an expression vector that encodes a dominant negative Gp4 polypeptide that includes GNB4 p.Gly53Asp or p.Lys89Glu mutation. The inhibitory nucleic acid is an antisense oligonucleotide, a siRNA, a sgRNA or a shRNA.

[0245] Disclosed herein is a method for making engineered macrophages or neutrophils comprising: introducing at least one single guide RNA (sgRNA) and at least one endonuclease into a macrophage or neutrophil under conditions to produce a deletion, an insertion, an inversion, or a frameshift mutation in a GP4 gene, wherein the macrophage or neutrophil comprises an endogenous genome and wherein the sgRNA comprises at least one sequence that is complementary to a Gp4 nucleic acid sequence in the endogenous genome of the macrophage or neutrophil. The at least one endonuclease may be Casl, CaslB, Cas2, Cas3, Cas4, Cas5, Cas6, Cas7, Cas8, Cas9 (also known as Csnl or Csxl2), CaslO, Csyl, Csy2, Csy3, Csel, Cse2, Cscl, Csc2, Csa5, Csn2, Csm2, Csm3, Csm4, Csm5, Csm6, Cmrl, Cmr3, Cmr4, Cmr5, Cmr6, Csbl, Csb2, Csb3, Csxl7, Csxl4, CsxlO, Csxl6, CsaX, Csx3, Csxl, CsxlS, Csfl, Csf2, CsO, Csf4, Cpfl, c2cl, c2c3, Cas9HiFi, homologues thereof, or modified versions thereof. In some embodiments, the engineered macrophages or neutrophils lack detectable expression or activity of wild-type Gp4.Formulations

[0246] Engineered immune cells that either (a) over-express the Gp4 gene, a Gp4- specific inhibitory nucleic acid or a GP4 dominant-negative construct, or (b) lack detectable expression or activity of GP4 (e.g., due to a deletion, insertion, nonsense mutation, missense mutation, inversion, frameshift etc.) and compositions comprising the same can be conveniently provided as sterile liquid preparations, e.g., isotonic aqueous solutions, suspensions, emulsions, dispersions, or viscous compositions, which may be buffered to a selected pH. Liquid preparations are normally easier to prepare than gels, other viscous compositions, and solid compositions. Additionally, liquid compositions are somewhat more convenient to administer, especially by injection. Viscous compositions, on the otherhand, can be formulated within the appropriate viscosity range to provide longer contact periods with specific tissues. Liquid or viscous compositions can comprise carriers, which can be a solvent or dispersing medium containing, for example, water, saline, phosphate buffered saline, polyol (for example, glycerol, propylene glycol, liquid polyethylene glycol, and the like) and suitable mixtures thereof.

[0247] Sterile injectable solutions can be prepared by incorporating the compositions of the presently disclosed subject matter, e.g., a composition comprising engineered immune cells, in the required amount of the appropriate solvent with various amounts of the other ingredients, as desired. Such compositions may be in admixture with a suitable carrier, diluent, or excipient such as sterile water, physiological saline, glucose, dextrose, or the like. The compositions can also be lyophilized. The compositions can contain auxiliary substances such as wetting, dispersing, or emulsifying agents (e.g., methylcellulose), pH buffering agents, gelling or viscosity enhancing additives, preservatives, flavoring agents, colors, and the like, depending upon the route of administration and the preparation desired. Standard texts, such as “REMINGTON' S PHARMACEUTICAL SCIENCE”, 17th edition, 1985, incorporated herein by reference, may be consulted to prepare suitable preparations, without undue experimentation.

[0248] Various additives which enhance the stability and sterility of the compositions, including antimicrobial preservatives, antioxidants, chelating agents, and buffers, can be added. Prevention of the action of microorganisms can be ensured by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, and the like. Prolonged absorption of the injectable pharmaceutical form can be brought about by the use of agents delaying absorption, for example, aluminum monostearate and gelatin. According to the presently disclosed subject matter, however, any vehicle, diluent, or additive used would have to be compatible with the engineered immune cells of the presently disclosed subject matter.

[0249] The compositions can be isotonic, z.e., they can have the same osmotic pressure as blood and lacrimal fluid. The desired isotonicity of the compositions of the presently disclosed subject matter may be accomplished using sodium chloride, or other pharmaceutically acceptable agents such as dextrose, boric acid, sodium tartrate, propylene glycol or other inorganic or organic solutes. Sodium chloride is suitable particularly for buffers containing sodium ions.

[0250] Viscosity of the compositions, if desired, can be maintained at the selected level using a pharmaceutically acceptable thickening agent. Methylcellulose can be used because it is readily and economically available and is easy to work with. Other suitable thickening agents include, for example, xanthan gum, carboxymethyl cellulose, hydroxypropyl cellulose, carbomer, and the like. The concentration of the thickener can depend upon the agent selected. The important point is to use an amount that will achieve the selected viscosity. Obviously, the choice of suitable carriers and other additives will depend on the exact route of administration and the nature of the particular dosage form, e.g., liquid dosage form (e.g., whether the composition is to be formulated into a solution, a suspension, gel or another liquid form, such as a time release form or liquid-filled form).

[0251] Those skilled in the art will recognize that the components of the compositions should be selected to be chemically inert and will not affect the viability or efficacy of the engineered immune cells as described in the presently disclosed subject matter. This will present no problem to those skilled in chemical and pharmaceutical principles, or problems can be readily avoided by reference to standard texts or by simple experiments (not involving undue experimentation), from this disclosure and the documents cited herein.

[0252] One consideration concerning the therapeutic use of the engineered immune cells of the presently disclosed subject matter is the quantity of cells necessary to achieve an optimal effect. The quantity of cells to be administered will vary for the subject being treated. In certain embodiments, from about 102to about 1012, from about 103to about 1011, from about 104to about 1010, from about 105to about 109, or from about 106to about 108engineered immune cells of the presently disclosed subject matter are administered to a subject. More effective cells may be administered in even smaller numbers. In some embodiments, at least about 1 x 108, about 2 x 108, about 3 x 108, about 4 x 108, about 5 x 108, about 1 x 109, about 5 x 109, about 1 x 1010, about 5 x 1010, about 1 x 1011, about 5 x 1011, about 1 x 1012or more engineered immune cells of the presently disclosed subject matter are administered to a human subject. The precise determination of what would be considered an effective dose may be based on factors individual to each subject, including their size, age, sex, weight, and condition of the particular subject. Dosages can be readily ascertained by those skilled in the art from this disclosure and the knowledge in the art. Generally, engineered immune cells are administered at doses that are nontoxic or tolerable to the patient.

[0253] The skilled artisan can readily determine the amount of cells and optional additives, vehicles, and / or carrier in compositions to be administered in methods of the presently disclosed subject matter. Typically, any additives (in addition to the active cell(s) and / or agent(s)) are present in an amount of from about 0.001% to about 50% by weight) solution in phosphate buffered saline, and the active ingredient is present in the order of micrograms to milligrams, such as from about 0.0001 wt % to about 5 wt %, from about 0.0001 wt% to about 1 wt %, from about 0.0001 wt% to about 0.05 wt%, from about 0.001 wt% to about 20 wt %, from about 0.01 wt% to about 10 wt %, or from about 0.05 wt% to about 5 wt %. For any composition to be administered to an animal or human, and for any particular method of administration, toxicity should be determined, such as by determining the lethal dose (LD) and LD50 in a suitable animal model e.g., rodent such as mouse; and, the dosage of the composition(s), concentration of components therein and timing of administering the composition(s), which elicit a suitable response. Such determinations do not require undue experimentation from the knowledge of the skilled artisan, this disclosure and the documents cited herein. And, the time for sequential administrations can be ascertained without undue experimentation.Administration

[0254] Engineered immune cells overexpressing GP4 gene can be provided systemically or directly to a subject for treating CMTD. Further, the presently disclosed engineered immune cells that either (a) express a Gp4-specific inhibitory nucleic acid or GP4 dominant-negative construct or (b) lack detectable expression or activity of Gp4 (e.g., due to a deletion, insertion, nonsense mutation, missense mutation, inversion, frameshift etc.) can be provided systemically or directly to a subject for treating microbial infection or for enhancing the anti-tumor response of chimeric antigen receptor (CAR) immune cells. In certain embodiments, engineered immune cells are directly injected into an organ of interest. Additionally or alternatively, the engineered immune cells are provided indirectly to the organ of interest, for example, by administration into the circulatory system (e.g., the tumor vasculature) or into the tissue of interest (e.g., solid tumor). Expansion and differentiation agents can be provided prior to, during or after administration of cells and compositions to increase production of the engineered immune cells either in vitro or in vivo.

[0255] Engineered immune cells of the presently disclosed subject matter can be administered in any physiologically acceptable vehicle, systemically or regionally, normallyintravascularly, intraperitoneally, intrathecally, or intrapleurally, although they may also be introduced into bone or other convenient site where the cells may find an appropriate site for regeneration and differentiation (e.g., thymus). In certain embodiments, at least 1 x 105cells can be administered, eventually reaching 1 x IO10or more. In certain embodiments, at least 1 x 106cells can be administered. A cell population comprising engineered immune cells can comprise a purified population of cells. Those skilled in the art can readily determine the percentage of engineered immune cells in a cell population using various well-known methods, such as fluorescence activated cell sorting (FACS). The ranges of purity in cell populations comprising engineered immune cells can be from about 50% to about 55%, from about 55% to about 60%, about 60% to about 65%, from about 65% to about 70%, from about 70% to about 75%, from about 75% to about 80%, from about 80% to about 85%; from about 85% to about 90%, from about 90% to about 95%, or from about 95 to about 100%. Dosages can be readily adjusted by those skilled in the art (e.g., a decrease in purity may require an increase in dosage). The engineered immune cells can be introduced by injection, catheter, or the like. If desired, factors can also be included, including, but not limited to, interleukins, e.g., IL-2, IL-3, IL 6, IL-11, IL-7, IL-12, IL-15, IL-21, as well as the other interleukins, the colony stimulating factors, such as G-, M- and GM-CSF, interferons, e.g., y- interferon.

[0256] In certain embodiments, compositions of the presently disclosed subject matter comprise pharmaceutical compositions comprising engineered immune cells (a) overexpressing the GP4 gene or a Gp4-specific inhibitory nucleic acid or GP4 dominantnegative construct or (b) lacking detectable expression or activity of Gp4 (e.g., due to a deletion, insertion, nonsense mutation, missense mutation, inversion, frameshift etc.) with a pharmaceutically acceptable carrier. Administration can be autologous or non-autologous. For example, engineered immune cells (a) overexpressing the Gp4 gene or a Gp4-specific inhibitory nucleic acid or GP4 dominant-negative construct or (b) lacking detectable expression or activity of GP4 (e.g., due to a deletion, insertion, nonsense mutation, missense mutation, inversion, frameshift etc.), and compositions comprising the same can be obtained from one subject, and administered to the same subject or a different, compatible subject. Peripheral blood derived macrophages or neutrophils of the presently disclosed subject matter or their progeny (e.g., in vivo, ex vivo or in vitro derived) can be administered via localized injection, including catheter administration, systemic injection, localized injection, intravenous injection, or parenteral administration. When administering a pharmaceuticalcomposition of the presently disclosed subject matter e.g., a pharmaceutical composition comprising engineered immune cells (a) overexpressing the GP4 gene or a Gp4-specific inhibitory nucleic acid or GP4 dominant-negative construct or (b) lacking detectable expression or activity of GP4 (e.g., due to a deletion, insertion, nonsense mutation, missense mutation, inversion, frameshift etc.), it can be formulated in a unit dosage injectable form (solution, suspension, emulsion).Therapeutic Uses of the Engineered Immune Cells of the Present Technology

[0257] For treatment, the amount of the engineered immune cells provided herein administered is an amount effective in producing the desired effect, for example, treatment of CMTD, infection, or cancer, or one or more symptoms thereof. An effective amount can be provided in one or a series of administrations of the engineered immune cells provided herein. An effective amount can be provided in a bolus or by continuous perfusion. For adoptive immunotherapy using CAR-expressing neutrophils or macrophages, cell doses in the range of about 106to about IO10are typically infused. Lower doses of the engineered immune cells may be administered, e.g., about 104to about 108.

[0258] The engineered immune cells of the presently disclosed subject matter can be administered by any methods known in the art, including, but not limited to, pleural administration, intravenous administration, subcutaneous administration, intranodal administration, intratumoral administration, intrathecal administration, intrapleural administration, intraperitoneal administration, and direct administration to the thymus. In certain embodiments, the engineered immune cells and the compositions comprising thereof are intravenously administered to the subject in need. Methods for administering cells for adoptive cell therapies, including, for example, donor lymphocyte infusion and engineered immune cell therapies, and regimens for administration are known in the art and can be employed for administration of the engineered immune cells provided herein.

[0259] In one aspect, the present disclosure provides a method for treating Charcot- Marie-Tooth Disease (CMTD) in a subject in need thereof comprising administering to the subject an effective amount of any and all embodiments of the Gp4-overexpressing engineered immune cells of the present technology. The subject may harbor a mutation in GNB4 or suffers from or is at risk for dominant intermediate CMT type F (CMTDIF). The Gp4-overexpressing engineered immune cells may be macrophages or neutrophils.

[0260] In one aspect, the present disclosure provides a method for treating a microbial infection in a subject in need thereof comprising administering to the subject an effective amount of any and all embodiments of the Gp4-deficient engineered immune cells disclosed herein. The microbial infection may be a fungal infection, a bacterial infection, or a viral infection. The Gp4-deficient engineered immune cells may be macrophages or neutrophils.

[0261] In another aspect, the present disclosure provides a method for treating cancer in a subject in need thereof comprising administering to the subject an effective amount of any and all embodiments of the Gp4-deficient engineered immune cells disclosed therein, wherein the Gp4-defi cient engineered immune cells further comprise a chimeric antigen receptor (CAR) that specifically binds to a tumor antigen. In some embodiments, the GP4- deficient engineered immune cells comprise macrophages or neutrophils. In some embodiments, the cancer is selected from the group consisting of adrenal cancers, bladder cancers, blood cancers, bone cancers, brain cancers, breast cancers, carcinoma, cervical cancers, colon cancers, colorectal cancers, corpus uterine cancers, ear, nose and throat (ENT) cancers, endometrial cancers, esophageal cancers, gastrointestinal cancers, head and neck cancers, Hodgkin's disease, intestinal cancers, kidney cancers, larynx cancers, acute and chronic leukemias, liver cancers, lymph node cancers, lymphomas, lung cancers, melanomas, mesothelioma, myelomas, nasopharynx cancers, neuroblastomas, nonHodgkin's lymphoma, oral cancers, ovarian cancers, pancreatic cancers, penile cancers, pharynx cancers, prostate cancers, rectal cancers, sarcoma, seminomas, skin cancers, stomach cancers, teratomas, testicular cancers, thyroid cancers, uterine cancers, vaginal cancers, vascular tumors, and metastases thereof. In some embodiments, the cancer is a relapsed or refractory cancer. In some embodiments, the cancer is resistant to one or more cancer therapies, e.g., one or more chemotherapeutic drugs.Combination Therapy

[0262] In some embodiments, the compositions of the present technology may be employed in conjunction with other therapeutic agents useful in the treatment of CMTD. For example, the GP4 over-expressing engineered immune cells of the present technology may be separately, sequentially or simultaneously administered with at least one additional therapy, such as physical therapy, orthopedic devices and surgery.

[0263] In other embodiments, the compositions of the present technology comprising engineered immune cells that lack detectable expression or activity of Gp4 may be-n-employed in conjunction with other therapeutic agents useful in the treatment of systemic microbial infections or enhancing the anti-tumor efficacy of CAR expressing immune cells. In some embodiments, the additional anti-microbial therapy is selected from among antibiotics, antifungal agents, antiviral agents or antiseptics. Examples of suitable antimicrobial therapies include, but are not limited to P-lactams, glycopeptides, P-lactam with P-lactamase inhibitor, macrolides, chloramphenicol, lincosamides, streptogramins, oxazolidanones, aminoglycosides, tetracyclines, flouroquinolones, rifampicin, sulfonamides, folic acid analogues, polymixins, lipopeptides, penicillins, cephalosporins, vancomycin, amoxicillin / clavulanic acid (co-amoxiclav), clindamycin, quinupristin- dalfopristin, linezolid, gentamycin, ciprofloxacin, rifampicin, sulfamethoxazole, trimethoprim, colistin, daptomycin, echinocandins, caspofungin, micafungin, polyenes, amphotericin B, nystatin, azoles, ketoconazole, itraconazole, fluconazole, voriconazole, posaconazole, and ravuconazole.

[0264] In some embodiments, the additional cancer therapy is selected from among a chemotherapy, a radiation therapy, an immunotherapy, a monoclonal antibody, an anticancer nucleic acid, an anti-cancer protein, an anti-cancer virus or microorganism, a cytokine, or any combination thereof. Radiation therapy includes, but is not limited to, exposure to radiation, e.g., ionizing radiation, UV radiation, as known in the art. Exemplary dosages include, but are not limited to, a dose of ionizing radiation at a range from at least about 2 Gy to not more than about 10 Gy or a dose of ultraviolet radiation at a range from at least about 5 J / m2to not more than about 50 J / m2, usually about 10 J / m2. In some embodiments, the methods further comprise sequentially, separately, or simultaneously administering an immunotherapy to the subject. In some embodiments, the immunotherapy regulates immune checkpoints. In further embodiments, the immunotherapy comprises, or consists essentially of, or yet further consists of an immune checkpoint inhibitor, such as an Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA4) inhibitor, or a Programmed Cell Death 1 (PD-1) inhibitor, or a Programmed Death Ligand 1 (PD-L1) inhibitor. In yet further embodiments, the immune checkpoint inhibitor comprises, or consists essentially of, or yet further consists of an antibody or an equivalent thereof recognizing and binding to an immune checkpoint protein, such as an antibody or an equivalent thereof recognizing and binding to CTLA4 (for example, Yervoy (ipilimumab), CP-675,206 (tremelimumab), AK104 (cadonilimab), or AGEN1884 (zalifrelimab)), or an antibody or an equivalent thereof recognizing and binding to PD-1 (for example, Keytruda (pembrolizumab), Opdivo(nivolumab), Libtayo (cemiplimab), Tyvyt (sintilimab), BGB-A317 (tislelizumab), JSOO1 (toripalimab), SHR1210 (camrelizumab), GB226 (geptanolimab), JSOO1 (toripalimab), AB122 (zimberelimab), AK105 (penpulimab), HLX10 (serplulimab), BCD-100 (prolgolimab), AGEN2034 (balstilimab), MGA012 (retifanlimab), AK104 (cadonilimab), HX008 (pucotenlimab), PF-06801591 (sasanlimab), JNJ-63723283 (cetrelimab), MGD013 (tebotelimab), CT-011 (pidilizumab), or Jemperli (dostarlimab)), or an antibody or an equivalent thereof recognizing and binding to PD-L1 (for example, Tecentriq (atezolizumab), Imfinzi (durvalumab), Bavencio (avelumab), CS1001 (sugemalimab), or KN035 (envafolimab)). In some embodiments, the methods further comprise sequentially, separately, or simultaneously administering a cytokine to the subject. In some embodiments, the cytokine is administered prior to, during, or subsequent to administration of the one or more engineered immune cells. In some embodiments, the cytokine is selected from the group consisting of interferon a, interferon P, interferon y, complement C5a, IL-2, TNFa, CD40L, IL12, IL-23, IL15, IL17, CCL1, CCL11, CCL12, CCL13, CCL14-1, CCL14-2, CCL14-3, CCL15-1, CCL15-2, CCL16, CCL17, CCL18, CCL19, CCL19, CCL2, CCL20, CCL21, CCL22, CCL23-1, CCL23-2, CCL24, CCL25-1, CCL25-2, CCL26, CCL27, CCL28, CCL3, CCL3L1, CCL4, CCL4L1, CCL5, CCL6, CCL7, CCL8, CCL9, CCR10, CCR2, CCR5, CCR6, CCR7, CCR8, CCRL1, CCRL2, CX3CL1, CX3CR, CXCL1, CXCL10, CXCL11, CXCL12, CXCL13, CXCL14, CXCL15, CXCL16, CXCL2, CXCL3, CXCL4, CXCL5, CXCL6, CXCL7, CXCL8, CXCL9, CXCL9, CXCR1, CXCR2, CXCR4, CXCR5, CXCR6, CXCR7 and XCL2. The methods may further comprise sequentially, separately, or simultaneously administering to the subject at least one chemotherapeutic agent, optionally selected from the group consisting of nitrogen mustards, ethylenimine derivatives, alkyl sulfonates, nitrosoureas, gemcitabine, triazenes, folic acid analogs, anthracyclines, taxanes, COX-2 inhibitors, pyrimidine analogs, purine analogs, antibiotics, enzyme inhibitors, epipodophyllotoxins, platinum coordination complexes, vinca alkaloids, substituted ureas, methyl hydrazine derivatives, adrenocortical suppressants, hormone antagonists, endostatin, taxols, camptothecins, SN-38, doxorubicin, doxorubicin analogs, antimetabolites, alkylating agents, antimitotics, anti-angiogenic agents, tyrosine kinase inhibitors, mTOR inhibitors, heat shock protein (HSP90) inhibitors, proteosome inhibitors, HD AC inhibitors, pro-apoptotic agents, methotrexate and CPT-11.Kits of the Present Technology

[0265] The presently disclosed subject matter provides kits for the treatment or prevention of Charcot-Marie-Tooth Disease (CMTD). In certain embodiments, the kit comprises a therapeutic or prophylactic composition containing an effective amount of an engineered immune cell comprising a vector that overexpresses Gp4. Also provided herein are kits for use in the manufacture of an engineered immune cell that overexpresses Gp4. In certain embodiments, the kit comprises a vector comprising a heterologous GP4 nucleic acid and instructions for using the same to transduce immune cells. In any of the preceding embodiments of the kits disclosed herein, the engineered immune cell is a neutrophil or a macrophage.

[0266] The present disclosure provides kits for treating systemic microbial infections and for enhancing the anti-tumor response of chimeric antigen receptor (CAR) immune cells. In certain embodiments, the kit comprises a Gp4-specific inhibitory nucleic acid or GP4 dominant-negative construct or a vector comprising the same, and instructions for using the same to manufacture an engineered immune cell that lacks detectable expression or activity of GP4. In other embodiments, the kits comprise reagents and instructions for manufacturing engineered immune cells that comprise a deletion, insertion, nonsense mutation, missense mutation, inversion, or frameshift in the a GP4 gene. Additionally or alternatively, in some embodiments, the kit further comprises a vector comprising an engineered chimeric antigen receptor (CAR) or other cell-surface ligand that binds to a target antigen, such as a tumor antigen or microbial antigen. In some embodiments, the vector comprising the Gp4-specific inhibitory nucleic acid or GP4 dominant-negative construct and the vector comprising the engineered CAR or cell-surface ligand that binds to a target antigen are the same. In other embodiments, the vector comprising the Gp4- specific inhibitory nucleic acid or GP4 dominant-negative construct and the vector comprising the engineered CAR or cell-surface ligand that binds to a target antigen are distinct.

[0267] In some embodiments, the kit comprises a sterile container; such containers can be boxes, ampules, bottles, vials, tubes, bags, pouches, blister-packs, or other suitable container forms known in the art. Such containers can be made of plastic, glass, laminated paper, metal foil, or other materials suitable for holding medicaments.

[0268] If desired, the kits of the present technology can be provided together with instructions for administering the engineered immune cell to a subject having or at risk of developing CMTD, cancer or microbial infection. The instructions will generally include information about the use of the composition for the treatment or prevention of the disease or condition. In other embodiments, the instructions include at least one of the following: description of the therapeutic agent; dosage schedule and administration for treatment or prevention of the disease or condition, or symptoms thereof; precautions; warnings; indications; counter-indications; overdose information; adverse reactions; animal pharmacology; clinical studies; and / or references. The instructions may be printed directly on the container (when present), or as a label applied to the container, or as a separate sheet, pamphlet, card, or folder supplied in or with the container. In some embodiments, the engineered immune cells of the present technology may be provided in the form of a prefilled syringe or autoinjection pen containing a sterile, liquid formulation or lyophilized preparation (e.g., Kivitz et al., Clin. Ther. 28: 1619-29 (2006)).

[0269] A device capable of delivering the kit components through an administrative route may be included. Examples of such devices include syringes (for parenteral administration) or inhalation devices.

[0270] The kit components may be packaged together or separated into two or more containers. In some embodiments, the containers may be vials that contain sterile, lyophilized formulations of engineered immune cell composition that are suitable for reconstitution. A kit may also contain one or more buffers suitable for reconstitution and / or dilution of other reagents. Other containers that may be used include, but are not limited to, a pouch, tray, box, tube, or the like. Kit components may be packaged and maintained sterilely within the containers.EXAMPLES

[0271] The present technology is further illustrated by the following Examples, which should not be construed as limiting in any way.Example 1: Materials and Methods

[0272] Cell lines, growth, and differentiation conditions

[0273] HL-60 cells were obtained from the laboratory of Henry Bourne and validated by RNA sequencing. Jurkat human T cell lymphoblasts (clone E6-1) were purchased from ATCC (cat TIB-152). RAMOS B cell Burkitt’s Lymphoma cells were purchased fromATTC (cat CRL-1596). HL-60, Jurkat, and RAMOS cells were grown in RPMI media supplemented with L-glutamine, 25 mM Hepes, 10 percent (vol / vol) heat inactivated fetal bovine serum (FBS), at 1 percent Pen / Strep. HL-60 progenitor cells were split to 2 * 105cells / mL every 2 days and grown at 37 °C, 5 percent CO2. HL-60 progenitors were differentiated into neutrophil-like cells by transfer into 1.5 percent (vol / vol) DMSO at 2 * 105cells / mL followed by 5 days of incubation at 37 °C, 5 percent CO2. HEK293T lentiX cells (Takara Bio, cat 632180) were grown in DMEM containing 10 percent (vol / vol) heat- inactivated FBS and 1 percent Pen / Step and maintained at 37 °C, 5 percent CO2. All cell lines were routinely checked for mycoplasma contamination.

[0274] HL-60 manipulation

[0275] Gbl-5 were deleted from HL-60 progenitors using the IDT Alt-R CRISPR-Cas9 system (IDT). Briefly, crRNAs specific for Gbl-5 (see table 1 below for sequence details) were resuspended in sterile Duplex Buffer (IDT) to a final concentration of 200 pM. Each crRNA was then mixed with tracrRNA-ATTO 550 (IDT) at a 1 : 1 ratio and annealed using a thermocycler (BioRad). sgRNA:Cas9 RNP’s were formed by mixing 0.3 pL of 36 pM Cas9 protein (IDT) with annealed sgRNAs at a 1 : 1 ratio followed by room temperature incubation for 10-20 minutes. HL-60 progenitor cells at a density of 2.2 * 106(>95

[0276] Table 1: sgRNA RNP sequences crRNA specific for Gbs sequenceTable 2: Rabbit monoclonal antibodies used for staining

[0277] To overexpress Gb4, a GNB4 gene block (IDT) containing homology arms to the lentiviral vector pLVX-Puro (CloneTech) was inserted into Xhol-digested pLVX-Puro using the In-Fusion HD Kit (Takara Bio). The homology arms were 5’- ctaccggactcagatctcga-3 ’ (SEQ ID NO: 9) at the Nterminus of GNB4 and 5’- tcgagctcatcgggatcccgctcgacta-3 ’ (SEQ ID NO: 10) at the C-terminus. The resulting plasmid was combined with plasmids encoding (1) a minimal HIV pLVX with GNB4-2A-Puro transgene, (2) gag-pol from HIV53 and (3) appropriate viral glycoproteins (VSV-G), and the mixture then transfected into HEK293T lentiX cells (Takara Bio) using the Xtremegene transfection reagent (Roche Applied Science). Lentivirus was collected 24 and 48 hours post transfection and stored at -80 °C until use. For transduction, 0.5 to 1 x 106HL-60 progenitor cells were mixed with lentivirus preparations (1 mL of virus supplemented with polybrene and HEPES) and centrifuged at 1400 x g at 37 °C for 2 hours in either 24-well or 6-well polystyrene plates (Coming). Subsequently, 1 mL of RPMI complete media (10 percent FBS, 1 percent Pen / Strep) was added to the cells, followed by overnight incubation at 37 °C, 5 percent CO2. Cells were then placed in 0.5 pg / mL puromycin for 14 days to select for successfully transduced cells. HL-60 progenitors transduced with lentivirus derived from empty pLVX-Puro were prepared in parallel as controls. To express F-tractin- mCherry in HL-60 cells, DNA encoding the F-tractin-mCherry fusion was amplified from a Cl-F-tractin-mCherry plasmid (Addgene, 155218) and then subcloned into the lentiviral vector pLVX-M-Puro (CloneTech) by Gibson reaction. Lentivirus production and transduction was performed as described above.

[0278] Fungal / bacterial lines

[0279] FLARE Aspergillus fumigatus conidia were prepared as previously described(Jhingran et al. 2012). Briefly, Af293 conidia were transformed with pAN7-l(Punt et al. 1987) and pPgpd-dsRed(Mikkelsen et al. 2003), and 5 x 108of the resulting Af293- dsRed conidia were incubated with 0.5 mg / mL Biotin XX, SSE (B-6352; Invitrogen) in 1 mL of 50 mM carbonate buffer (pH 8.3) for 2 h at 4 °C, washed once with 0.1 M Tris-HCl (pH 8), and then labeled using 0.02 mg / mL AF633 -streptavidin (S-21375; Invitrogen) in 1mL PBS for 30 min at room temperature. Double-labeled FLARE conidia were resuspended in PBS + 0.025 percent Tween 20 for experimental use. Pseudomonas aeruginosa expressing GFP (P. aeruginosa PA14 PrhlAB::gfp, kind gift from Joao Xavier) were labeled with AF633 by first incubating 5 x 107bacterial cells with 0.5 mg / mL Biotin XX, SSE (B- 6352; Invitrogen) in 1 ml 50 mM carbonate buffer (pH 8.3) for 2 h at 4 °C. After washing with 0.1 M Tris-HCl (pH 8), cells were labeled using 0.02 mg / mL AF633 -streptavidin (S- 21375; Invitrogen) in 1 mL PBS for 30 min at RT, followed by resuspension in PBS + 0.025 percent Tween 20.

[0280] Polyacrylamide microparticle (MP) cargo

[0281] 10 pm diameter polyacrylamide MPs were synthesized as previously described(Vorselen et al. 2020), with modifications. Aqueous acrylamide solutions were prepared containing 150 mM MOPS (pH 7.4), 0.3 percent (v / v) tetramethylethylenediamene (TEMED), 150 mM NaOH, and 10 percent (v / v) acrylic acid. The mass fraction of total acrylamide was kept constant at 10 percent and the cross-linker mass fraction was 2.4 percent. This mixture was sparged with nitrogen gas for 15 minutes and then kept under nitrogen pressure. Hydrophobic Shirasu porous glass (SPG) filters (1.9 pm pore size) were sonicated under vacuum in n-dodecane, mounted on an internal pressure micro kit extruder (SPG Technology Co), and submerged into the organic phase, consisting of 99 percent hexanes and 1 percent (v / v) Span-80 (Sigma-Aldrich, S6760), with continuous stirring at 300 rpm. 10 mL of the acrylamide mixture was then loaded into the apparatus and extruded under nitrogen pressure into 250 mL of the hexane mixture. To initiate polymerization, the resulting emulsion was heated to 60 °C and 2,2’-azobisisobutyronitrile (2 mg / mL, 500 mg total) was added. The reaction was kept at 60 °C for 3 hours and then at 40 °C overnight. Polymerized MPs were harvested by washing 3 times in hexanes and 2 times in ethanol (30 minutes, 4000 rpm), followed by resuspension in PBS. For functionalization, MPs were washed twice in activation buffer (100 mM MES, 20 mM NaCl, pH 6.0) and then incubated for 15 minutes with 40 mg / mL 1- ethyl-3 -(3 -dimethylaminopropyl) carbodiimide (EDC), 20 mg / mL N-hydroxysuccinimide (NHS) in activation buffer with 0.1 percent (v / v) Tween 20, vortexing briefly every 5 min. After 3 washes in PBST8 (PBS with 0.1 percent (v / v) Tween 20, adjusted to pH 8), MPs were resuspended in PBST8 and a protein / dye solution was added. For streptavidin labeling, 250 pmol streptavidin per million MPs was added. For acidification assays, MPs were conjugated with either 5-FITC-ethylenediamine (5 pM final, AAT Bioquest 126) and LissamineTM Rhodamine B Ethylene Diamene (5 pM final,Invitrogen L2424). After 2 h, unreacted NHS groups were blocked with ethanolamine (100 mM final, in 100 mM Tris HC1). Finally, MPs were washed 3 times in PBST, pH 7.4, and 3 times in PBS, pH 7.4. In certain phagocytosis experiments, labeled MPs were conjugated with pHrodo Dyes rather than FITC / LRB by first washing 3 times in 0.1M NaHCO3, pH 8.4, followed by a 1 h incubation in pHrodoTM Green STP Ester (Invitrogen P35369) or pHrodoTM iFL Red STP Ester (Invitrogen P36010) at 60 pM final concentration, followed by 3 washes in PBS, pH 7.4. Streptavidin conjugated MPs were loaded with Biotin-SP ChromPure Human IgG (Jackson ImmunoResearch 015-060-003), Biotin-SP ChromPure Human Serum IgA (Jackson ImmunoResearch 009-060-011), iC3B (Quidel A423), and Biotin-Phosphatidylserine (Echelon L-31B16) at 200 pmol per million MPs, 100 pmol per million MPs, 100 pmol per million MPs, and 50 pmol per million MPs, respectively, in 750 pL of PBS. iC3B was biotinylated prior to MP coating using the EZ-Link™ Sulfo-NHS- LC-Biotinylation Kit (ThermoFisher).

[0282] Flow cytometric MP phagocytosis assay

[0283] Neutrophils stained with either Hoechst or CellVue Maroon (both from ThermoFisher) were seeded into fibronectin-coated 24 well plates at a density of 150,000 cells per well. FITC / LRB labeled MPs coated with a phagocytic target ligand (e.g. IgG) were then added at a 1 :2 (MP:cell) ratio, followed by incubation at 37 °C, 5 percent CO2 for 3 hours. Cells were then removed by trypsinization and transferred into FACS tubes for analysis using a Cytoflex LX machine (Beckman). Analysis was performed by first gating out free floating MPs and then identifying LRB+FITClow cells, indicative of successful uptake and acidification of MPs. In each sample, the total number of LRB+FITClow cells was normalized to the total number of live cells to generate a percent phagocytosis metric. In experiments using pHrodoGreen or pHrodoRed dyed MPs, the percent phagocytosis metric was calculated using pHrodoBright cells (in FITC or PE channels) as the numerator and total cells as the denominator. In experiments comparing Gb4 and wild type HL-60 cells in the same sample, each cell type was labeled with a different dye (either Hoechst or CellVue Maroon, both from ThermoFisher) to distinguish them during endpoint flow cytometric analysis. Dyes were switched between experiments to control for potential effects of the dyes on phagocytosis.

[0284] Widefield imaging of MP phagocytosis

[0285] Neutrophils or macrophages were stained using Hoechst and / or CellVue Maroon (both from ThermoFisher) and seeded into fibronectin coated 8-well chamber slides (ibidi) at a density of 100,000 or 50,000 cells per well, respectively. FITC / LRB labeled IgG coated MPs were then added at a 1 :2 (MP:cell) ratio, and the samples imaged on a Zeiss Axiovert microscope using a 20* objective lens for at least 2 h at 1 min intervals. DAPI, FITC, and TRITC images were collected at each time point. Phagocytosed MPs were identified in Fiji by a reduction in FITC signal due to phagolysosome acidification. Percent phagocytosis was determined by dividing the number of phagocytes containing acidified MPs by the total number of phagocytes in each frame. High resolution imaging of phagocytic cup closure DGb4 and WT HL-60 cells expressing F-tractin-mCherry were stained with CellVue Maroon (ThermoFisher) using the manufacturer’s guidelines and then seeded at 100,000 cells per well into fibronectin coated 8-well ibidi chambers. IgG-coated, FITC-labeled MPs were either added at a 1 :2 (MP:cell) ratio after cell seeding or, in some experiments, were attached to the bottom of the slide by first coating with biotin poly-L-lysine (ThermoFisher) and then adding MPs for attachment. Cells were imaged using a SoRa spinning disk confocal microscope (Nikon), a Stellaris spinning disk confocal microscope (Leica), or an LSM880 confocal microscope (Zeiss) fitted with 60* objective lenses. In general, timelapse experiments encompassed 30 minutes total with FITC, TRITC, and Cy5 images collected every 15 seconds. Images were analyzed using Fiji and / or Imaris to assess phagocytic cup progression and completion. Cup initiation was determined by an enrichment of F-tractin adjacent to the MP. Phagocytic cup closure was defined as total MP encirclement by F-tractin / plasma membrane. Time to MP engulfment was determined by subtracting the time of cup closure from the time of initiation. Phagocytic cups that were not completed by the end of the 30 min time-lapse were considered “aborted”.

[0286] Staphylococcus aureus bioparticle phagocytosis assay

[0287] HL-60 cells or primary neutrophils were seeded in fibronectin coated 24-well plates at 250,000 cells per well. 10 pL of S. aureus pHrodoRed bioparticles (ThermoFisher), resuspended in sterile PBS at a final concentration of 2 mg / mL, were then added to each well, followed by incubation at 37 °C, 5 percent CO2, for 1 hour. Cells were then harvested and transferred into FACS tubes for analysis using a Cytoflex LX machine (Beckman). Percent phagocytosis was determined by dividing the total number of pHrodoRed+ cells by the total number of cells in each sample.

[0288] Jurkat efferocytosis assay

[0289] 5 X 106Jurkat cells in 10 mL complete RPMI (10 percent FBS, 1 percentPen / Strep) were transferred into a lidless 10 cm dish and subjected to 1500 microJ UV using a UV stratalinker (Marshall Scientific), followed by a 4 h incubation at 37 °C, 5 percent CO2. The cell corpses were then resuspended in 10 mL of room temperature Hank’s buffered salt solution (HBSS), stained with either CypHer5E NHS Ester (1 :4000 in 4 mL PBS, Cytiva) or pHrodoRed (1 :5000, Invitrogen) for 10 min at 37 °C, and then washed into complete RPMI (10 percent FBS, 1 percent Pen / Strep). Terminally differentiated HL-60 cells were stained with CFSE (1 : 1000, ThermoFisher) and then mixed with Jurkat corpses at a ratio of (1 :2 Jurkat cell corpse / HL-60 cell) in a final volume of 1 mL, followed by incubation for 3 h at 37 °C, 5Percent CO2. The cells were then harvested and transferred into FACS tubes for analysis using a Cytoflex LX machine (Beckman). Percent phagocytosis was determined by dividing the total number of FITC+Cypher+ or FITC+pHrodoRed+ HL- 60 cells by the total number of HL-60 cells (FITC+) in each sample.

[0290] Aspergillus fumigatus FLARE fungal phagocytosis and killing assay

[0291] HL-60 cells were seeded at 150,000 cells per well in a 24 well plate and then mixed with FLARE A. fumigatus (see procedure above for preparation) at a 2: 1 (fungi: cell) ratio, followed by incubation at 37 °C, 5 percent CO2 for 1 hour. Cells were then analyzed using a Cytoflex LX flow cytometer (Beckman). Percent phagocytosis was determined by dividing the total number of AF633+ HL-60 cells by the total number of HL-60 cells in each sample.

[0292] Immunoblot Analysis

[0293] For each sample, 106cells were lysed using cold buffer containing 50 mM Tris- HC1, 0.15 M NaCl, 1 mM EDTA, 1 percent NP-40, and 0.25 percent sodium deoxy cholate. Gb4 expression was assessed using monoclonal antibodies against the human ortholog (Abeam, ab223113), with GAPDH (clone D16H11, Cell Signaling Technology) serving as the loading control. IRDye 800 anti-mouse and IRDye 680 anti-rabbit secondary antibodies were used for visualization on Li -Cor Odyssey LX machine.

[0294] Micropipette migration assay

[0295] Differentiated DGb4 and WT HL-60 cells were stained with Hoescht (MilliporeSigma) for 20 min at 25 °C and allowed to attach to fibronectin-coated 35 mm glass-bottom cover slips for 1 h (250,000 cells per dish). Samples were washed to remove nonadherent cells and left in 3 mL of complete RPMI media prior to imaging. A femptotip(Eppendorf) micropipette loaded with sterile filtered RPMI containing 2 percent fatty acid free BSA, 1 percent Pen / Strep, 200 nM fMLF, and trace AF647 dye was attached to a FemptoJet 4i (Eppendorf), and the micropipette tip positioned and the center of the imaging frame. Pressure (400 psi) was then applied to dispense the chemoattractant mixture and serial images (40 s intervals between frames) collected over the course of an hour at 20* magnification using a Ti Eclipse microscope with a CSU-0W1 Yokogawa camera (Nikon) at 37 °C, 5 percent CO2. To measure migration after MP uptake, DGb4 and WT HL-60 cells were preincubated with pHrodoGreen or pHrodoRed labeled MPs, respectively, for 3 hours. Cells that had taken up MPs during this time were FACS sorted based on green (DGb4) or red (WT) fluorescence. A 1 : 1 mixture of these cells was then applied to fibronectin coated cover slips (250,000 cells per dish) and chemotaxis toward a point source of fMLF measured as described above.

[0296] Scanning electron microscopy (SEM)

[0297] HL-60 cells adhered to fibronectin coated 1.5 coverslips (Fisher Scientific) were prepared for SEM with critical point drying. Briefly, samples were dehydrated with ethanol gradient drying in five increments from 50 percent ethanol to 100 percent ethanol, for 10 minutes at each step. They were then subjected to critical point drying in a Bal -Tec CPD 030 device (Bal-Tec, USA) according to manufacturer instructions. Dried samples were sputter-coated using a Cressington 108 Auto Sputter Coater with a 5-10 nm thick layer of gold-palladium (Cressington Scientific Instruments, UK) and imaged using a Zeiss Sigma VP scanning electron microscope (Carl Zeiss, Germany) at 3 kV accelerating voltage, 5 mm working distance in In-Lens mode.

[0298] FIB-SEM imaging and analysis

[0299] Cells were plated on Aclar coverslips coated with fibronectin and then fixed with 2 percent glutaraldehyde, 2 mM CaCh in 0.08 M sodium cacodylate buffer, pH 7.2. This primary fixation was followed by a ROTO protocol (Reduced Osmium- Thiocarbohydrazide-Osmium) as follows: cells were incubated for one hour in 1 percent OsO4, 1.25 percent potassium ferrocyanide in 0.1 M sodium cacodylate buffer on ice, washed with buffer, and then incubated with 1 percent thiocarbohydrazide in water for 12 minutes. After washing, cells were treated with 1 percent Osmium tetroxide in 0.1 M cacodylate buffer for 30 min on ice. The samples were then dehydrated using a graded series of ethanol solutions and embedded in Eponate 12. Sample blocks were trimmed andthen mounted on an SEM sample holder using double-sided carbon tape (EMS). Colloidal silver paint (EMS) was used to electrically ground the sides of the resin block. The entire surface of the specimen was then sputter coated with a thin layer (5 nm) of gold / palladium. The sample was imaged using immersion, TLD, back-scattered electron (BSE) mode on an FEI Helios Nanolab 650 microscope. Images were recorded after each round of ion beam milling using the SEM beam at 2.0 keV and 0.10 nA current with a working distance of < 5mm. Ion beam was held at 30 keV, with a milling current of 80 pA. Data acquisition occurred through automation using Auto Slice and View G3 software. Raw images were 4,096 x 2,048 pixels, with 20-50 nm slices viewed at a -38° cross-sectional angle. Each raw image had a horizontal field width (HFW) of 10-15 pm with an XY pixel size of 2-4 nm and 40 nm Z-step size. Images were aligned using the image processing programs in IMOD. All segmentation was performed using semi-manual thresholding and manual annotation of a test set (10 percent of data) using the LabKit machine learning plug-in for Imaris. 3-D renderings, reconstructions, surface / volume calculations, and internal vesicle volume calculations were performed using Imaris.

[0300] Myriocin sphingolipid synthesis inhibition assays

[0301] For acute myriocin treatment, HL-60 cells on the 5th day of DMSO differentiation were treated with a final concentration of 50 nM myriocin (Millipore Sigma Aldrich) for 12 h prior to phagocytosis or C-trap experiments. For long term inhibition of sphingolipid synthesis, HL-60 progenitor cells were incubated over the 5 day DMSO differentiation in the presence of 50 nM myriocin. Treated cells were then used in phagocytosis or C-trap experiments. No observable effect on viability was observed in either treatment regime.

[0302] Osmotic shock experiments

[0303] HL-60 cells or terminally differentiated primary human macrophages (derived from hiPSC cells) were suspended in 200 pL complete RPMI (10 percent FBS, 1.5 percent DMSO, 1 percent Pen / Strep) or RPMI 1650 (h-mCSF, 10 percent FBS, 1 percent Pen / Strep), respectively, and then applied to a Vi Cell Blue (Beckman Coulter, MA) cell counter to measure cell diameter. The samples were then osmotically shocked for 2 min or 4 min respectively by adding 180 pL of sterile ddH2O to 20 pL of suspended cells (final concentration of 2 * 105 cells per mL) before loading onto the same device. Eachmeasurement was performed using 9 biological replicates. All recorded samples had >90 percent viability during the assay, as monitored by trypan blue (ThermoFisher) exclusion.

[0304] Total internal reflection fluorescence (TIRF) imaging of frustrated phagocytosis

[0305] The inner 4 chambers of an 8 well chamber slide (Ibidi) were coated with biotinylated poly-L lysine, followed by streptavidin and biotinylated human IgG (Jackson ImmunoResearch 015-060-003) using an established protocol (Quann et al. 2009). Coated chamber slides were mounted on an Elyra 7 microscope (Zeiss) equipped with a 60* TIRF objective lens, followed by addition of DGb4 or wild type HL-60 cells expressing F-tractin- mCherry and stained with CFSE (ThermoFisher Scientific). Samples were imaged in TIRF mode for 10 min using 15 s intervals at 37 °C, 5

[0306] Generation of mutant hiPSC lines

[0307] The 731 ,2B-iPSC line was generated from human fibroblasts (GM00731) purchased from the Coriell Institute(Miller et al. 2013). These cells have been stocked and characterized by the Stem Cell Research Facility at MSKCC. They are mycoplasma free, express the expected levels of OCT4, SOX2, and NANOG, and have a normal karyotype. GNB4- / - iPSCs were generated by CRISPR-Cas9 targeting. An sgRNA (TGCGAACAAGACGTACACTG (SEQ ID NO: 11)) specific for GNB4 was first subcloned into the pSpCas9(BB)-2APuro (PX459) V2.0 vector (Addgene plasmid 62988). 731.2B-iPSC cells were then dissociated using Accutase (Innovative Cell Technologies) and electroporated with the sgRNA-Cas9 plasmid using an Amaxa 4D-Nucleofector (Lonza), following manufacturer’s instructions. Electroporated cells were cultured in 1 mL Essential 8 media (ThermoFisher Scientific) and Stemflex media (Stem cell technologies) at 37 °C, 5 percent CO2, for 4 days and then dissociated and subcloned. Approximately 10 days later, individual colonies derived from single cells were picked, mechanically disaggregated and replated into two individual wells of a 96-well plate. Colonies were screened by PCR for biallelic frameshift mutations at the targeting site. Wild type clonal lines from the same targeting experiments were included as controls.

[0308] hiPSC embryoid body formation and human primary macrophage differentiation

[0309] Macrophages were differentiated from hiPSCs using an established protocol (Lachmann et al. 2015), with modifications. Briefly, hiPSCs were seeded on CF1 mouse embryonic feeders and maintained for 3 days in ESC medium (KO-DMEM (10829- 018), 20 percent KO-Serum (10828-028), 2mM L-glutamine (25030-024), 1 percentNonessential Amino Acids (11140-035), 0.2 percent beta-mercaptoethanol (31350-010), 1 percent Pen / Strep (15140163) (all supplied by ThermoFisher) with 10 ng / mL bFGF (Peprotech 100-18B) and subsequently for 4 days in ESC media without bFGF. 7 days after seeding, at day (D)0 of the differentiation process, hiPSC colonies were detached in clusters using a 13 minute incubation with collagenase type IV (250 lU / mL final concentration) (Thermo Fisher Scientific; 17104019) and transferred to 6 well low adhesion plates in ESC media supplemented with 10 pM ROCK Inhibitor (Sigma; Y0503) to initiate the differentiation process. The plates were kept on an orbital shaker at 100 rpm for 6 days to allow for spontaneous formation of embryoid bodies (EB) with hematopoietic potential. At D6 of the differentiation process, wellformed 200-500 pm EBs were picked under a dissecting microscope and transferred onto adherent tissue culture plates (2.5 EBs / cm2) for cultivation in Hematopoietic Differentiation (HD) medium (APEL2 (Stem Cell Tech 05270), Protein free hybridoma medium (ThermoFisher Scientific; 12040077), 1 percent pen / strep, 25 ng / mL hIL-3 (Peprotech; 200-03), and 50 ng / mL hM-CSF (Peprotech, 300- 25)). Starting from DI 8 of the differentiation and then every week onwards for up to two months, macrophages produced by EBs were carefully collected from suspension, filtered through a 100 pm mesh, plated at a density of 10,000 cells / cm2, and cultivated for 6 days in RPMH640 / GlutaMax (ThermoFisher Scientific; 61870036) medium supplemented with 10 percent FBS (EMD Millipore TMS-013-B), and 100 ng / mL human M-CSF before use in downstream experiments. All cells were cultured at 37 °C, 5

[0310] Membrane tension measurements

[0311] Plasma membrane tension was quantified using a C-Trap optical trapping device (Lumicks BV, Netherlands). An IR laser beam (50 mW, 1064 nm) was tightly focused through a series of mirrors, beam expanders and a high numerical aperture objective lens (63x / 1.2 NA, Nikon Instruments) to form a steerable optical trap. Cells were immobilized inside an Ibidi p-slide (Ibidi GmbH, Germany) treated with 200 pg / mL fibronectin (Therm o / Sigma). To measure plasma membrane tension, polystyrene beads (2.2 pm, Spherotech Inc, IL) were coated with concanavalin A (50 pg / mL, Thermo / Sigma) and added to the cell culture medium inside the slide. Beads were momentarily placed in contact with the cell membrane, and tethers were then extruded by moving the bead away from the cell perpendicularly at a speed of 2 pm / s. Force measurements were made using the Lumicks Bluelake software suite by capturing the exiting trapping light with a high numerical aperture condenser lens (63x / 1.45, oil immersion, Zeiss AB, Germany) andmeasuring bead displacement in the trap with position-sensitive detectors through back focal plane interferometry. Membrane tether breaking was documented as a sharp discontinuity in tether force during tether extrusion, with breaking distance measured from simultaneously collected brightfield images using FIJI. Data analysis was performed using Python 3.8.0.

[0312] RNA-sequencing

[0313] Cell samples were lysed in TRIzol (ThermoFisher) and the RNA extracted using the MagMAX mirVana Total RNA Isolation Kit (ThermoFisher catalog A27828) on a KingFisher Flex Magnetic Particle Processor (Thermo Scientific catalog 5400630) according to the manufacturer’s protocol. After RiboGreen quantification and quality control using an Agilent BioAnalyzer, 2 ng total RNA with RNA integrity numbers ranging from 8.5 to 10 was amplified using the SMART-Seq v4 Ultra Low Input RNA Kit (Clonetech catalog 63488), with 12 cycles of amplification. Subsequently, 5 (13194B) or 10(12227B,13028B) ng of amplified cDNA was used to prepare libraries with the KAPA HyperP rep Kit (Kapa Biosystems KK8504 seq data was conducted in Rv.4.0.5, and count normalization and differential gene expression was performed using the R package DESeq2.Atlea

[0314] Lipidomics

[0315] Frozen cell pellets were thawed and extracted using a modified Fol ch protocol (Folch, Lees, and Sloane Stanley 1957). In brief, samples were resuspended in 300 pL of methanol containing SPLASH LIPIDOMIX (Avanti Polar Lipids) as internal standards, vortexed, and then mixed with 600 pL of chloroform. 180 pL of water was added to each tube to induce phase separation, and after mixing, samples were centrifuged at 16,000 x g for 5 min at 4 °C. Subsequently, the lower, chloroform layer was collected and the aqueous layer re-extracted using 450 pL of chloroform:methanol:water (3:48:47 v / v / v). The lower, chloroform layer was collected and pooled with the previous extract. Samples were then dried under nitrogen at 40 °C and resuspended in 100 pL of 90: 10 methanokchloroform. Lipid profiling was performed using an Agilent 6546 Q-TOF mass spectrometer in positive and negative ionization modes, coupled to a ZORBAX Eclipse Plus C-18 Column (100 mmx2.1, 1.8 pm particle size, Agilent). Mobile Phase A consisted of 10 mM ammonium formate in 50:30:20 water:acetonitrile:isopropanol.

[0316] Mobile Phase B consisted of 10 mM ammonium formate in 1 :9:90 water:acetonitrile:isopropanol. LC gradient conditions were: 0 min at 0 percent B; 2.7 min at 45 percent B; 2.8 min at 53 percent B; 9 min at 65 percent B; 9.10 min at 89 percent B; 11 min at 92 percent B; 11.10 min 100 percent B; 12 min at 10 percent B; 15 min at 10 percent B. Other LC parameters were: flow rate at 0.4 mL / min, column temperature at 60 °C and injection volume was 5 pL. MS source parameters included: gas temp: 200 °C; gas flow: 10 L / min; nebulizer pressure: 50 psig; sheath gas temp: 300 °C; sheath gas flow: 12 L / min; VCap: 3000 V; nozzle voltage: 0 V; fragmentor: 150V. For lipid annotation, 5 injections of iterative MS / MS acquisition were performed on a pooled lipid extract in both positive and negative polarity. To identify lipid species, iterative MS / MS acquisition data in positive and negative polarity was processed using Agilent Lipid Annotator software 1.0(Koelmel et al. 2020). Subsequent targeted feature extraction and peak integration was performed using Skyline(Adams et al. 2020). For statistical analysis, the Welch T-test was used for pairwise comparisons between wild type and Gb4 groups with Benjamini- Hochberg FDR correction.

[0317] Generation of Gnb4- / ~ mice

[0318] The animal protocols used for this study were approved by the Institutional Animal Care and Use Committee of MSKCC. Two sgRNA sequences (5’- cgtcaaaatatcgcaagtgc-3 ’ ; SEQ ID NO: 12) and (5’ -aggtgtcagatcaaacc-3 ’ ; SEQ ID NO: 13) targeting exon 4 of the Gnb4 locus (IDT) were injected together with purified Cas9 protein (IDT) into C57BL / 6 zygotes, which were then transferred into C57BL / 6 pseudopregnant females. Founder animals were screened for deletion of the entire exon 4 and the presence of an early stop codon in exon 5, and then bred to homozygosity. Routine genotyping PCRs were performed using the following forward (5’ -ggagaacagctagtactcttaac-3 ’ SEQ ID NO: 14) and reverse (5’-aaaagtatttattagcagtatc-3’; SEQ ID NO: 15) primers. The resulting amplicons for WT and Gnb4 KO mutant alleles are 1360 bp and 305 bp respectively.

[0319] A. fumigatus FLARE intratracheal mouse fungal infections

[0320] Gnb4- / - and WT mice were infected by intratracheal (i.t.) administration of 60 x106FLARE Af293 A. fumigatus (see procedure above for staining protocol) in 50 pL. WT mice were also infected with unlabeled A. fumigatus to serve as analysis controls (see below). 18 h post infection, mice were euthanized and their lungs harvested into 5 mL of digestion buffer (PBS with 5 percent FBS, 0.1 mg / mL DNAse I, and Type IV collagenase(Worthington) at 2.2 mg / mL). Tissue homogenization was performed using a MACSTm Octo Dissociator for 55 sec at 1302 rpm, followed by slow rotation at 37 °C for 40 min. A final mechanical homogenization was performed for 37 sec at 2079 rpm, after which all samples were diluted with 5 mL of PBS + 5 percent FBS, filtered through a 100 pm pore size cell strainer, and centrifuged at 300 * g for 5 min at 4 °C. The pellet was resuspended in 2 mL of ACK lysis buffer (BD) and incubated for 15 min to achieve red blood cell lysis. After quenching in 4 mL of RPML1640 +10 percent FBS, cells were centrifuged at 300 x g for 5 min at 4 °C, followed by resuspension in cold FACS buffer (PBS + 5 percent FBS). To assess dissemination at 24 h, lungs, dLN, spleen, and 200 pL of blood were harvested from each mouse. Lungs were processed as described above. dLN and spleen were homogenized and filtered through a 100 pm pore size cell strainer. Subsequently, the spleen single cell suspension was centrifuged and resuspended in 2 mL of ACK lysis buffer (BD) and incubated for 15 min to achieve red blood cell lysis. After quenching in 4 mL of RPML 1640 +10 percent FBS, cells were centrifuged at 300 x g for 5 min at 4 °C, followed by resuspension in cold FACS buffer (PBS + 5 percent FBS). Blood samples were diluted into 2 mL of ACK lysis buffer (BD) containing 100 mM EDTA and incubated for 15 min to achieve red blood cell lysis. After quenching in 4 mL of RPMI-1640 +10 percent FBS, cells were centrifuged at 300 x g for 5 min at 4 °C, followed by resuspension in cold FACS buffer (PBS + 5 percent FBS). Aliquots of 2xio6cells from each organ were dispensed into round bottom 96 well plates (Coming) and then stained for 20 min at 4 °C with a viability dye (Tonbo Ghostdye Violet 510 1 :250) along with antibodies against Ly6G (BUV395, 1 : 100), CDl lb (BUV805, 1 : 100), Siglec F (BV650, 1 : 100), CD45 (BV785), and CD11c (PE-Cy7, 1 : 100). Samples were then applied to a CytoFlex LX flow cytometer and analyzed using FlowJo software. Neutrophils were identified as CD1 lb+Ly6G+SiglecF- CD11c- cells. Percent phagocytosis was determined by dividing the total number of AF633+ neutrophils in each sample by the total number of neutrophils. Percent FLARE killing was expressed as the number of AF633+dsRed- neutrophils over the total number of AF633+ neutrophils in each sample. Gating for AF633+ neutrophils was facilitated using unlabeled neutrophils extracted from mice infected with unlabeled A. fumigatus. To quantify fungal infection, lung suspensions were diluted 50-fold and 50 pL of each sample was plated on Sabouraud dextrose agar (ThermoFisher). CFUs were quantified after 2 d of incubation at 37 °C. Fluorochromes Antigen Company Clone number dilution BUV395 Ly6G BD Biosciences 1A8 1 : 100 BUV805 CD1 lb BD Biosciences MI / 70 1 : 100 BV510L / D Aqua Tonbo Ghostdye Violet 510 1 : 100 BV650 SiglecF BD Biosciences E50-2440 1 : 100 B V785 CD45 BioLegend 30-F 11 1 : 100 PE-Cy7 CD 11 c BioLegend N418 1 : 100

[0321] Statistics

[0322] Graphpad was used for statistical analysis (Graphpad software, Inc). Details can be found in the legend of each figure. N represents number of independent biological replicates.Example 2: G$4 deficiency enhances phagocytic responses against a wide range of targets

[0323] Heterotrimeric G-proteins regulate phagocytosis and migration in multiple myeloid cell types8'13. Activating signals induce the dissociation of the G-protein a subunit (Ga) from thesubcomplex (G0y), freeing both components to bind and activate specific downstream effector molecules14. The preponderance of prior research in this area has focused on Ga isoforms, with comparatively less known about specific G0 and Gy subunits15. Accordingly, we began our investigations by using CRISPR / Cas9 to knock out each G0 subunit in human neutrophil-like HL-60 cells (Fig. la and Figs. 6a-6b). Gene targeting was carried out in self-renewing HL-60 precursors, which were then differentiated into neutrophils cells by the addition of DMSO. All terminally differentiated cells were CD15+CD16+(Fig. 6c), indicating that the genetic modifications we introduced did not prevent HL60 progenitors from becoming neutrophils.

[0324] To quantify the phagocytic capacity of these cells, knockouts and controls were mixed with 10 pm diameter IgG-coated polyacrylamide microparticles16,17derivatized with the fluorescent dyes FITC and LRB (Fig. la and Fig. 7). FITC, but not LRB, fluorescence is quenched in acidic phagolysosomes, producing a color change that can be monitored by flow cytometry and fluorescence microscopy. In this manner, we were able to identify G0 subunits that either positively or negatively regulated phagocytosis. Consistent with prior work11,12, HL-60 cells lacking G02 exhibited a -40% reduction in particle uptake. By contrast, depletion of G04 induced a striking 4-fold increase in phagocytosis relative to wild type controls (Fig. lb). This hyperphagic behavior was readily apparent in both monocultures as well as cocultures containing 1 : 1 mixtures of wild type and G04 knockout (AG04) HL-60 cells (Figs. 8a-8b), indicating that the phenotype was cell intrinsic. To ensure that our CRISPR-edited cells did not generate any off-target effects, we verified that re-expression of G04 on the knockout background restored phagocytosis to wild type levels(Fig. 1c, Fig. 8c). Using live imaging, we found that AG04 deficiency markedly enhanced particle consumption on a per-cell basis; while the vast majority of phagocytic wild type cells took up just one microparticle (DP), almost half of phagocytic AG04 cells accommodated two or more (Fig. Id). Super-resolution microscopy enabled us to examine engulfment dynamics in more detail. AG04 HL-60 cells formed stereotypical phagocytic cups featuring a pronounced band of filamentous actin (F-actin) at the leading edge (Fig. le). This morphology was much less obvious in wild type cells, which still engaged microparticle targets but only engulfed them less than 50% of the time. AG04 HL-60 cells were highly efficient by comparison, completing over 90% of their phagocytic attempts and doing so more than twice as fast as their wild-type counterparts (Fig. le, data not shown).

[0325] To further explore the scope of the AG04 phenotype, we challenged wild type and AG04 HL-60 cells with microparticles bearing alternative coatings, namely phosphatidylserine (PS), complement, IgG, and IgA. AG04 cells phagocytosed 2-4 fold more cargo in each case, indicating that their hyperphagy was not limited to a specific uptake receptor (Fig. 8d). Next, we measured the phagocytosis of four distinct biological targets: the gram -negative bacterium Pseudomonas aeruginosa, Staphylococcus aureus bioparticles, conidia from the fungus Aspergillus fumigatus, and apoptotic Jurkat T cell corpses (Fig. If, Figs. 8e-8f). AG04 HL-60 cells significantly outperformed controls for all of these targets, further supporting the idea that G04 deficiency potentiates phagocytosis against a diverse biological cargos. Accordingly, we next investigated whether this perturbation could augment the therapeutic phagocytosis of tumors. Many cancer cells evade immune detection and clearance by expressing CD47, a cell surface protein that functions as a “don’t eat me” signal18,19. In certain cases, inhibiting this “don’t eat me” signal with blocking antibodies against CD47 or its receptor, SIRPa, is sufficient to stimulate an engulfment response (Fig. lg)20. To adapt this approach to our experimental system, we challenged HL60 neutrophils with Ramos B lymphoma target cells in the absence and presence of anti-CD47 blockade. In some experiments, opsonizing antibodies against the B cell marker CD20 were added to further promote phagocytosis via Fc receptor engagement. Wild type HL-60 cells did not take up Ramos cells, and treatment with anti- CD47 and / or anti-CD20 failed to enhance their activity. In contrast, AG04 HL-60 cells exhibited a low, but measurable level of baseline phagocytosis, which increased sharply (3- fold) in the presence of anti-CD47, and even more so (8-fold) when anti-CD47 wascombined with anti-CD20 (Fig. 1g). Collectively, these results demonstrate that G04 deficiency substantially augments phagocytic responses across a wide range of targets.Example 3: G!J>4 de ficiency alters cell migration and crosstalk between phagocytosis and motility

[0326] Proper coordination between phagocytosis and migration is essential for effective neutrophil immunosurveillance. Notably, the act of phagocytosis has been shown to transiently inhibit motility21,22, a behavior that is thought to curtail the dissemination of intracellular microbes23. To investigate the effects of G04 on migratory capacity, we employed a chemotaxis assay in which HL60 neutrophils were attached to fibronectin- coated glass and then presented with a point source of the peptide chemoattractant fMLF, applied via micropipette (Fig. 2a). Under these conditions, neutrophils adopt a fan-like morphology with a broad leading edge directed toward the point source and a thin uropod trailing behind. Both AGP4 and wild type cells were able to migrate up the fMLF gradient, but AGP4 cells did so at a significantly slower rate (Fig. 2b, data not shown). This reduction in motility was associated with the formation of elongated “tails” at the rear of migrating AGP4 cells, suggestive of a defect in uropod retraction (Fig. 2b). To interrogate crosstalk between phagocytosis and migration, we measured the chemotactic motility of HL-60 cells after uptake of one IgG-coated microparticle. Wild type and AGP4 neutrophils were fed microparticles with distinct fluorescent labels (pHrodoRed (WT) versus pHrodoGreen (AGP4)) to facilitate imaging and tracking in mixed samples. Particle consumption slowed the movement of wild type neutrophils considerably relative to unfed, wild type controls (Fig. 2b). The same could not be said for AGP4 neutrophils, which moved faster than their unfed AGP4 counterparts (Fig. 2b). Although the instantaneous speed of fed AGP4 neutrophils remained slightly less than that of fed wild type cells, their migration was more persistent, yielding significantly longer tracks that more closely approached the fMLF point source (Figs. 2c-2d, data not shown). These motility phenotypes were mirrored by changes in cell shape. In wild type neutrophils, phagocytosis appeared to hamper migratory polarization; cells periodically collapsed into a rounded configuration, and these morphological changes tended to coincide with stalls in motility (data not shown). By contrast, AGP4 morphology was normalized by particle uptake; fed cells formed persistent leading edges and lacked the extended uropods characteristic of the unfed state (Fig. 2b).Hence, GP4 depletion alters not only the speed of neutrophil migration but also the ability of phagocytosis to inhibit motility.Example 4: G$4 deficiency alters lipid composition and plasma membrane abundance

[0327] The striking uropod extension phenotype displayed by migrating AGP4 HL-60 cells suggested that their cellular architecture was significantly altered. Scanning electron microscopy (SEM) supported this hypothesis by indicating that AGP4 HL-60 cells had a more ruffled surface appearance than wild type controls (Fig. 3a). To investigate this structural difference more closely, we performed Focused Ion Beam-Scanning Electron Microscopy (FIB-SEM), a method in which successive sections from the same sample are imaged by SEM and then used to generate a nanometer-resolution 3-D reconstruction24. Wild type and AGP4 HL60 neutrophils were osmium-stained to highlight lipid-rich cellular components, embedded in resin, and subjected to FIB-SEM at 40 nm sectioning. Supervised machine learning was used to define the plasma membrane in each image, followed by amalgamation of sections into a 3-D rendering25. The resulting reconstructions revealed striking differences in plasma membrane configuration. Whereas the surface of wild type cells was mostly smooth with small extensions, AGP4 cells exhibited large flaps of plasma membrane projecting up to 10 pm from the cell body (Fig. 3b, data not shown). The presence of these structures increased the surface to volume ratio of AGP4 HL-60 cells by a factor of two relative to wild type controls (Fig. 3c). AGP4 cells also contained larger and more abundant cytoplasmic lipid droplets, which appeared as high contrast compartments in osmium-stained FIB-SEM images (Figs. 3b, 3d-3e). This increase in lipid droplet load was confirmed by BODIPY staining of a larger group of cells (Figs. 9a-9b). Hence, GP4 depletion drives plasma membrane accumulation and lipid droplet formation in in HL-60 cells.

[0328] To better quantify the AGP4 membrane accumulation phenotype, we exposed wild type and AGP4 HL-60 cells to osmotic shock, which swells cells to the limits of their plasma membrane capacity and thereby enables comparisons of total surface area. AGP4 HL-60 cells were only slightly larger than their wild type counterparts under isotonic conditions. Upon transfer to hypotonic medium, however, AGP4 cells expanded to twice the size of controls (Fig. 3f). Assuming that swelled HL-60 cells are spherical, this volume differential implies a -60% increase in plasma membrane surface area. This excess plasma membrane would be expected to facilitate the formation of phagocytic cups and therebypromote engulfment. To quantify membrane mobilization during cup formation, we utilized a “frustrated phagocytosis” assay in which HL-60 cells were applied to IgG-coated glass slides. The cells formed flat, unresolved phagocytic cups with these surfaces that were easily visualized by total internal reflection fluorescence microscopy. AGP4 contacts were substantially larger than their wild type counterparts (Fig. 9c), consistent with the idea that increased membrane abundance facilitates phagocytic cup formation.

[0329] Membrane tension is known to inhibit both phagocytosis and migration, presumably by mechanically constraining the formation of actin-based structures and / or activating inhibitory mechanosensory pathways26. We speculated that, by increasing plasma membrane abundance, GP4 deficiency might reduce membrane tension and thereby attenuate these regulatory effects. To explore this possibility, we utilized an established approach in which a concanavalin-A-coated bead is adsorbed to the cell surface and then pulled away using an optical trap27. The displaced bead remains attached to the cell via a thin membrane tether, which exerts a restoring force that is proportional to the square of membrane tension28,29. In this manner, we found that GP4 deficiency reduced tether forces by a factor of two (Fig. 3g). AGP4 cells also generated longer tethers then wild type controls, indicating that they possessed larger plasma membrane reservoirs (Fig. 9d)30. Rescue experiments confirmed that both phenotypes were specific to Gp4 (Fig. 3h). Taken together with the imaging studies and osmotic shock experiments described above, these results imply a central role for plasma membrane abundance in the regulation of neutrophil effector responses.

[0330] To explore potential mechanisms underlying the plasma membrane expansion of AGP4 cells, we subjected AGP4 and wild type HL-60 cells to comparative lipidomics (Fig. 4a and Figs. lOa-lOd). As expected, AGP4 HL-60 cells contained more total lipids than wild type controls on a per cell basis (Fig. 10c). This increase did not apply to all lipid subtypes, however, as some species were unchanged between samples and some, like hexosylceramides, were more abundant in wild type cells (Fig. lOd). AGP4 neutrophils were distinguished by disproportionate enrichment of sphingolipids, particularly ceramide and sphingomyelin (Fig. 4a and Fig. 10c), which are predominantly found in the plasma membrane. Using RNA-sequencing, we documented selective upregulation of sphingolipid synthesis genes in AGP4 neutrophils after microparticle feeding (Fig. 4b), establishing an additional link between sphingolipids and the AGP4 phenotype. To interrogate the role of sphingolipids in plasma membrane expansion more directly, we asked whether inhibition ofsphingolipid synthesis could reverse the AGP4 membrane phenotype. To this end, we applied the small molecule myriocin, a potent inhibitor of serine palmitoyl transferase, the first enzyme in the sphingolipid synthesis pathway (Fig. 4c and Fig. 10e)31,32. Myriocin treatment during differentiation restored the membrane tension of AGP4 HL-60 cells to wild type levels (Fig. 4d), and it also partially reversed their hyperphagic behavior (Fig. 4e). Notably, acute treatment of fully differentiated AGP4 HL-60 cells with myriocin had no effect on microparticle uptake (Fig. lOf), implying that the functionally relevant effects of GP4 signaling on sphingolipid synthesis occur during the differentiation phase. Collectively, these results indicate that the excess plasma membrane characteristic of AGP4 cells is due, at least in part, to increased sphingolipid synthesis.Example 5: G$4 controls membrane abundance and phagocytosis in primary myeloid cells

[0331] To examine the role of GP4in primary cells, we generated ER-HoxB8 immortalized murine neutrophil progenitors33'35and then applied CRISPR / Cas9 to produce isogenic AGP4 and wild type sublines (Figs. 1 la-1 lb). Neutrophils differentiated from these sublines expressed equivalent levels of CD1 lb and Ly6G (Fig. 11c), indicating that GP4 is dispensable for the acquisition of neutrophil cell fate. Like AGP4 HL-60 cells, AGP4 ER- HoxB8 neutrophils displayed clear signs of plasma membrane dysregulation, including reduced membrane tension and increased membrane tether length in optical trap experiments (Figs, lld-lle). They also expanded to twice the volume of wild type controls upon transfer to hypotonic medium (Fig. Ilf). In phagocytosis assays, both wild type and AGP4 ER-HoxB8 neutrophils failed to consume IgG-coated microparticles, likely because murine neutrophils are substantially smaller than HL-60 cells and therefore unable to accommodate larger (~10 pm diameter) cargos. When challenged with smaller (2 pm diameter) Staphylococcus aureus bioparticles, however, AGP4 ER-HoxB8 neutrophils consumed twice as much as wild type controls (Fig. 11g). We conclude that the GP4 pathway regulates plasma membrane abundance and phagocytosis in primary neutrophils.

[0332] CMTD is one of the most common hereditary neurological disorders, afflicting approximately 2.6 million people globally36. Diseased individuals lose both sensory and motor function in their extremities (arms, hands, legs, and feet)37, with affected nerves undergoing progressive demyelination over the course of years. Recent studies have identified GP4 mutations in a subset of CMTD patients, implying a role for this protein in maintaining healthy myelination. Interestingly, depleting macrophages, which patrolendoneurial spaces in peripheral nerves7,38'40, has been shown to attenuate neurodegeneration in two mouse models of CMTD41'43. Accordingly, we reasoned that loss of GP4 might induce CMTD by driving dysregulated, macrophage-dependent phagocytosis of myelin (Fig. 5a).

[0333] To test this hypothesis, we prepared wild type and AGP4 macrophages from human (h)iPSCs (Fig. 5b and Fig. 12)44'46. CRISPR / Cas9 was used to target the GNB4 locus (encoding GP4) at the hiPSC stage, and wild type control hiPSCs were generated in parallel using a nontargeting guide RNA (Fig. 13). Granulocyte monocyte progenitor (GMP) cells derived from these hiPSC lines were then differentiated into mature CD1 lb+CD14+CD68+macrophages (Fig. 5b and Fig. 14a). Importantly, loss of GP4 did not affect the efficacy of this differentiation protocol (Fig. 14a). In optical trap experiments, AGP4 macrophages generated weaker tether forces and longer membrane tethers than wild type controls, indicative of reduced membrane tension and larger membrane reservoirs, respectively (Figs. 5c-5d). AGP4 macrophages also became substantially larger than their wild type counterparts in hypotonic medium, despite being similarly sized under isotonic conditions (Fig. 5e). These data, which mirrored our results in the HL-60 and ER-HoxB8 systems, strongly suggested that AGP4 macrophages possess excess plasma membrane.

[0334] Next, we evaluated phagocytic capacity and found that GP4 deficiency markedly increased the uptake of IgG-coated microparticles (Fig. 5f). To assess the potential of this enhanced phagocytosis to drive demyelination, we performed uptake assays using purified mouse myelin as cargo (Fig. 5g)47. Myelin was stained with CFSE and pHrodo Red, which fluoresces under acidic conditions, to detect the accumulation of cargo in phagolysosomes. Over the course of the ~8 hour assay, more AGP4 macrophages (-25%) than wild type controls (-10%) consumed myelin (Figs. 5h-5i). AGP4 cultures generated substantially more pHrodo Red fluorescence, as well, implying more myelin uptake into phagolysosomes (Fig. 5h, data not shown). Hence, GP4 deficiency in macrophages does indeed promote myelin phagocytosis.

[0335] Taken together, our results identify GP4 as a critical regulator of plasma membrane abundance in myeloid cells. Our work also reveals a central role for the plasma membrane in controlling phagocytic capacity and enabling functional crosstalk between phagocytosis and movement. Because the plasma membrane must be mobilized to build protrusive cellular structures, limiting its abundance provides a simple mechanism for notonly constraining the magnitude of a given architectural response (e.g. phagocytosis) but also enabling cross-regulation between responses (e.g. phagocytosis inhibiting migration). Accordingly, the mechanisms governing plasma membrane allocation in myeloid cells effectively dictate their functional potential.

[0336] Notably, the plasma membrane dependent control mechanism studied here appears to most strongly affect the phagocytosis of large (~10 um diameter) cargos, such as apoptotic cells and cancer cells, while being less important for the uptake of small entities like bacteria and conidial spores. This distinction likely reflects the fact that engulfing large, unbroken targets with high surface area places a disproportionate burden on plasma membrane mobilization. The importance of GP4 for regulating this type of phagocytosis suggests that this protein may be particularly relevant for target uptake in the context of tissue homeostasis and anti-tumor immunosurveillance.

[0337] Without wishing to be bound by theory, it is believed that the GP4 pathway acts during myeloid cell differentiation to dictate the size and composition of the plasma membrane, which then serves as a master mechanoregulator of morphology and effector responses in the terminally differentiated state (Fig. 14b). This model is consistent with our observations that AGP4 neutrophils and macrophages exhibit architectural abnormalities at rest (Figs. 3a-3e and Figs. 9a-9b) and also that acute myriocin treatment fails to reverse the AGP4 phagocytosis phenotype (Fig. 101). We postulate that differential GP4 expression among myeloid progenitors might promote functional diversification by enabling the formation of differentiated subsets with a spectrum of plasma membrane-defined phagocytic and migratory setpoints. This sort of diversity could enable the innate immune system to accommodate a wide variety of homeostatic and microbial challenges.

[0338] In conjunction with prior work implicating both macrophages and GP4 in CMTD, our finding that AGP4 macrophages consume substantially more myelin than normal suggests that dysregulated phagocytosis may be a critical pathological driver for at least some CMTD subtypes.Example 6: G 4 regulates anti-fungal immunity in vivo

[0339] To evaluate the role of Gb4-dependent membrane allocation during this early phase of immunity, we generated mice with a targeted deletion of exon 4 of the Gnb4 locus (Figs. 16a-16b). This modification prematurely terminated the Gnb4 open reading frame, leading to constitutive Gb4 deficiency. Mice homozygous for this deletion (Gnb4- / -) andWT (Gnb4+ / +) littermate controls were infected intratracheally with Aspergillus fumigatus, a fungal pathogen that elicits the robust recruitment of phagocytically active neutrophils to the lung. To enable flow cytometric detection of fungal uptake by these cells, we employed Fluorescent Aspergillus Reporter (FLARE) conidia that expressed dsRed, a degradable fluorescent protein, and were also labeled with Alexa Fluor (AF)633, a non-degradable small molecule dye. Cells that take up FLARE conidia turn AF633+dsRed+, while cells that have killed the phagocytized fungi become AF633+dsRed- (Fig. 15a). A. fumigatus infection induced similar levels of neutrophil recruitment to the lungs of WT and Gnb4- / - animals, with CD1 lb+Ly6G+SiglecF-cells accounting for 70 percent of CD45+ infiltrates, in both experimental groups (Fig. 15b). Fungal phagocytosis was almost 3 times higher in Gnb4- / - neutrophils (Fig. 15c), however, mirroring the hyperphagic phenotype seen in HL- 60 cells, ER-HoxB8 neutrophils, and hiPSC derived macrophages lacking Gb4. Among these phagocytic cells, the frequency of fungal killing was unaffected by Gb4 deficiency (Fig. 16c), consistent with the interpretation that Gb4 signaling modulates cargo uptake and not subsequent acidification of the phagolysosome. Gnb4- / - animals also exhibited a 10 fold reduction in fungal CFU in the lung relative to WT controls at the 18 hour time point (Fig. 15d), indicating that the increased conidial phagocytosis conferred by loss of Gb4 improved fungal clearance during early stage infection.

[0340] Given that Gb4 deficient HL-60 cells failed to arrest their motility after cargo uptake (Figs. 2b-2e), we speculated that Gnb4- / - phagocytes might exhibit altered trafficking behavior in vivo. Accordingly, we examined the organ distribution of phagocytic WT and Gnb4- / - neutrophils 24 hours after FLARE infection (Fig. 15a). In WT mice, neutrophils bearing AF633-labeled material were found predominantly in the lungs, with trace amounts in the draining lymph nodes (dLNs) and essentially none in the spleen and blood (Figs. 15e-15g, Fig. 16d). These observations were consistent with the expectation that phagocytosis inhibits motility after conidial uptake in the lungs, thereby preventing the dissemination of neutrophils with internalized pathogens to other organs. By contrast, we observed a substantial number of AF633+ neutrophils in the dLNs of Gnb4- / - animals (Fig. 15e-15f), suggesting that Gb4 deficiency at least partially relieves the brake on motility applied by phagocytosis. Importantly, whereas essentially all AF633+ neutrophils in WT dLNs were DsRed-, indicating that they had degraded their internalized conidia, a substantial fraction of DsRed+AF633+ neutrophils were observed in Gnb4- / - dLNs (Fig. 15h). Given that Gb4 deficiency does not affect phagolysosome maturation (Fig. 1), theseresults strongly suggest that Gnb4- / - neutrophils continue to migrate after conidial uptake, enabling them to reach proximal organs like the dLN before their cargo is broken down. We conclude that Gb4 deficiency not only increases the phagocytic capacity of myeloid cells in vivo but also disrupts the cross-regulatory relationship between phagocytosis and migration.

[0341] To investigate whether the altered behavior of Gnb ^ neutrophils affected the overall efficacy of anti-fungal immunity, we infected Gnb ' and WT mice with A. fumigatus CEA10, a clinically derived strain with increased pathogenicity in mice (Fig. 17a). WT mice experienced acute weight loss in the first 72 hours after CEA10 administration and half succumbed to the infection within the first week (Figs. 17b-17c). Both weight loss and mortality were significantly attenuated in Gnb ^ animals, indicating that loss of GP4 protects mice from the adverse effects of A. fumigatus infection.

[0342] These results demonstrate that the engineered immune cells of the present technology are useful for treating microbial infection in a subject in need thereof.EQUIVALENTS

[0343] The present technology is not to be limited in terms of the particular embodiments described in this application, which are intended as single illustrations of individual aspects of the present technology. Many modifications and variations of this present technology can be made without departing from its spirit and scope, as will be apparent to those skilled in the art. Functionally equivalent methods and apparatuses within the scope of the present technology, in addition to those enumerated herein, will be apparent to those skilled in the art from the foregoing descriptions. Such modifications and variations are intended to fall within the scope of the present technology. It is to be understood that this present technology is not limited to particular methods, reagents, compounds compositions or biological systems, which can, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting.

[0344] In addition, where features or aspects of the disclosure are described in terms of Markush groups, those skilled in the art will recognize that the disclosure is also thereby described in terms of any individual member or subgroup of members of the Markush group.

[0345] As will be understood by one skilled in the art, for any and all purposes, particularly in terms of providing a written description, all ranges disclosed herein alsoencompass any and all possible subranges and combinations of subranges thereof. Any listed range can be easily recognized as sufficiently describing and enabling the same range being broken down into at least equal halves, thirds, quarters, fifths, tenths, etc. As a nonlimiting example, each range discussed herein can be readily broken down into a lower third, middle third and upper third, etc. As will also be understood by one skilled in the art all language such as “up to,” “at least,” “greater than,” “less than,” and the like, include the number recited and refer to ranges which can be subsequently broken down into subranges as discussed above. Finally, as will be understood by one skilled in the art, a range includes each individual member. Thus, for example, a group having 1-3 cells refers to groups having 1, 2, or 3 cells. Similarly, a group having 1-5 cells refers to groups having 1, 2, 3, 4, or 5 cells, and so forth.

[0346] All patents, patent applications, provisional applications, and publications referred to or cited herein are incorporated by reference in their entirety, including all figures and tables, to the extent they are not inconsistent with the explicit teachings of this specification.REFERENCES Uribe-Querol, E. & Rosales, C. Phagocytosis: Our Current Understanding of a Universal Biological Process. Front Immunol 11, 1066, doi: 10.3389 / fimmu.2020.01066 (2020). Moreau, H. D., Piel, M., Voituriez, R. & Lennon-Dumenil, A. M. Integrating Physical and Molecular Insights on Immune Cell Migration. Trends Immunol 39, 632-643, doi:10.1016 / j.it.20I8.04.007 (2018). Soong, B. W. et al. Exome sequencing identifies GNB4 mutations as a cause of dominant intermediate Charcot-Marie-Tooth disease. Am J Hum Genet 92, 422-430, doi: 10.1016 / j.ajhg.2013.01.014 (2013). Hsu, Y. H. et al. Mutation spectrum of Charcot-Marie-Tooth disease among the Han Chinese in Taiwan. Ann Clin Transl Neurol 6, 1090-1101, doi : 10.1002 / acn3.50797 (2019). Lassuthova, P. et al. Confirmation of the GNB4 gene as causal for Charcot-Marie-Tooth disease by a novel de novo mutation in a Czech patient. Neuromuscul Disord 27, 57-60, doi:10.1016 / j.nmd.2016.09.010 (2017). Kwon, H. M. et al. Clinical and Neuroimaging Features in Charcot-Marie-Tooth Patients with GNB4 Mutations. Life (Basel) 11, doi: 10.3390 / life 11060494 (2021).Yuan, X. et al. Macrophage Depletion Ameliorates Peripheral Neuropathy in Aging Mice. J Neurosci 38, 4610-4620, doi:10.1523 / JNEUROSCI.3030-17.2018 (2018).Peracino, B. et al. G protein beta subunit-null mutants are impaired in phagocytosis and chemotaxis due to inappropriate regulation of the actin cytoskeleton. J Cell Biol 141, 1529- 1537, doi: 10.1083 / jcb.141.7.1529 (1998).Wen, X. et al. G-protein-coupled formyl peptide receptors play a dual role in neutrophil chemotaxis and bacterial phagocytosis. MolBiol Cell 30, 346-356, doi: 10.1091 / mbc.E18-06- 0358 (2019).Pan, M., Xu, X., Chen, Y. & Jin, T. Identification of a Chemoattractant G-Protein-Coupled Receptor for Folic Acid that Controls Both Chemotaxis and Phagocytosis. Dev Cell 36, 428- 439, doi:10.1016 / j.devcel.2016.01.012 (2016).Cohen, A. et al. Genome-scale CRISPR screening reveals that C3aR signaling is critical for rapid capture of fungi by macrophages. PLoS Pathog 18, el010237, doi : 10.1371 / j ournal .ppat.1010237 (2022).Kamber, R. A. et al. Inter-cellular CRISPR screens reveal regulators of cancer cell phagocytosis. Nature 597, 549-554, doi: 10.1038 / s41586-021-03879-4 (2021).Yamada, K. M. & Sixt, M. Mechanisms of 3D cell migration. Nat Rev Mol Cell Biol 20, 738- 752, doi: 10.1038 / s41580-019-0172-9 (2019).Clapham, D. E. & Neer, E. J. G protein beta gamma subunits. Annu Rev Pharmacol Toxicol 37, 167-203, doi: 10.1146 / annurev.pharmtox.37.1.167 (1997).Kankanamge, D., Tennakoon, M., Karunarathne, A. & Gautam, N. G protein gamma subunit, a hidden master regulator of GPCR signaling. J Biol Chem 298, 102618, doi: 10.1016 / j.jbc.2022.102618 (2022).Vorselen, D. et al. Microparticle traction force microscopy reveals subcellular force exertion patterns in immune cell-target interactions. Nat Commun 11, 20, doi: 10.1038 / s41467-019- 13804-z (2020).Vorselen, D. et al. Phagocytic 'teeth' and myosin-II 'jaw' power target constriction during phagocytosis. Elife 10, doi: 10.7554 / eLife.68627 (2021).Chao, M. P., Weissman, I. L. & Majeti, R. The CD47-SIRP alpha pathway in cancer immune evasion and potential therapeutic implications. Curr Opin Immunol 24, 225-232, doi: 10.1016 / j.coi.2012.01.010 (2012).Logtenberg, M. E. W Scheeren, F. A. & Schumacher, T. N. The CD47-SIRP alpha Immune Checkpoint. Immunity 52, 742-752, doi:10.1016 / j.immuni.2020.04.011 (2020).Willingham, S. B. et al. The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc Natl Acad Sci U S A 109, 6662-6667, doi : 10.1073 / pnas.1121623109 (2012).Hamza, B. et al. Retrotaxis of human neutrophils during mechanical confinement inside microfluidic channels. Integr Biol (Camb) 6, 175-183, doi:10.1039 / c3ib40175h (2014).Crainiciuc, G. et al. Behavioural immune landscapes of inflammation. Nature 601, 415-421, doi : 10.1038 / s41586-021 -04263 -y (2022).Neta, R. & Salvin, S. B. Cellular immunity in vitro: migration inhibition and phagocytosis. Infect Immun 4, 697-702, doi:10.1128 / iai.4.6.697-702.1971 (1971).Ritter, A. T. et al. ESCRT -mediated membrane repair protects tumor-derived cells against T cell attack. Science 3 6, 377-382, doi:10.1126 / science.abl3855 (2022).Wang, G. et al. PyMIC: A deep learning toolkit for annotation-efficient medical image segmentation. Comput Methods Programs Biomed 231, 107398, doi : 10.1016 / j . cmpb .2023.107398 (2023).Masters, T. A., Pontes, B., Viasnoff, V., Li, Y. & Gauthier, N. C. Plasma membrane tension orchestrates membrane trafficking, cytoskeletal remodeling, and biochemical signaling during phagocytosis. Proc Natl Acad Sci U S A 110, 11875-11880, doi: 10.1073 / pnas.1301766110 (2013).Dai, J. & Sheetz, M. P. Mechanical properties of neuronal growth cone membranes studied by tether formation with laser optical tweezers. Biophys J 68, 988-996, doi: 10.1016 / S0006- 3495(95)80274-2 (1995).Bo, L. & Waugh, R. E. Determination of bilayer membrane bending stiffness by tether formation from giant, thin-walled vesicles. Biophys J 55, 509-517, doi: 10.1016 / S0006- 3495(89)82844-9 (1989).Heinrich, V. & Waugh, R. E. A piconewton force transducer and its application to measurement of the bending stiffness of phospholipid membranes. Annals of biomedical engineering 24, 595-605 (1996).Raucher, D. & Sheetz, M. P. Characteristics of a membrane reservoir buffering membrane tension. Biophys J 77 , 1992-2002, doi: 10.1016 / S0006-3495(99)77040-2 (1999).Glares, E. N. et al. Inhibition of atherosclerosis by the serine palmitoyl transferase inhibitor myriocin is associated with reduced plasma glycosphingolipid concentration. Biochem Pharmacol 73, 1340-1346, doi: 10.1016 / j.bcp.2006.12.023 (2007).Wadsworth, J. M. et al. The chemical basis of serine palmitoyltransferase inhibition by myriocin. J Am Chem Soc 135, 14276-14285, doi:10.1021 / ja4059876 (2013).Hopke, A. et al. Neutrophil swarming delays the growth of clusters of pathogenic fungi. Nat Commun 11, 2031, doi: 10.1038 / s41467-020-15834-4 (2020).Greene, C. J. etal. Macrophages disseminate pathogen associated molecular patterns through the direct extracellular release of the soluble content of their phagolysosomes. Nat Commun 13, 3072, doi: 10.1038 / s41467-022-30654-4 (2022).Khoyratty, T. E. et al. Distinct transcription factor networks control neutrophil-driven inflammation. Nat Immunol 22, 1093-1106, doi: 10.1038 / s41590-021-00968-4 (2021).Bucci, C., Bakke, O. & Progida, C. Charcot-Marie-Tooth disease and intracellular traffic. Prog Neurobiol 99, 191-225, doi:10.1016 / j.pneurobio.2012.03.003 (2012).Pareyson, D. & Marchesi, C. Diagnosis, natural history, and management of Charcot-Mari e- Tooth disease. Lancet Neurol 8, 654-667, doi: 10.1016 / S1474-4422(09)70110-3 (2009).Zigmond, R. E. & Echevarria, F. D. Macrophage biology in the peripheral nervous system after injury. Prog Neurobiol 173, 102-121, doi: 10.1016 / j.pneurobio.2018.12.001 (2019).Carenini, S. et al. The role of macrophages in demyelinating peripheral nervous system of mice heterozygously deficient in pO. J Cell Biol 152, 301-308, doi: 10.1083 / jcb,152.2.301 (2001).Kolter, J., Kierdorf, K. & Henneke, P. Origin and Differentiation of Nerve-Associated Macrophages. J Immunol 204, 271-279, doi: 10.4049 / jimmunol.1901077 (2020).Klein, D. et al. Early targeting of endoneurial macrophages alleviates the neuropathy and affects abnormal Schwann cell differentiation in a mouse model of Charcot-Marie-Tooth 1 A. Glia 'll, 1100-1116, doi: 10.1002 / glia.24158 (2022). Klein, D., Groh, J., Weishaupt, A. & Martini, R. Endogenous antibodies contribute to macrophage-mediated demyelination in a mouse model for CMT1B. J Neuroinflammation 12, 49, doi: 10.1186 / sl2974-015-0267-y (2015). Klein, D. et al. Targeting the colony stimulating factor 1 receptor alleviates two forms of Charcot-Marie-Tooth disease in mice. Brain 138, 3193-3205, doi: 10.1093 / brain / awv240 (2015). Zhang, H. & Reilly, M. P. Human Induced Pluripotent Stem Cell-Derived Macrophages for Unraveling Human Macrophage Biology. Arterioscler Thromb Vase Biol 37, 2000-2006, doi: 10.1161 / ATVBAHA.117.309195 (2017). Vaughan- Jackson, A. et al. Differentiation of human induced pluripotent stem cells to authentic macrophages using a defined, serum-free, open-source medium. Stem Cell Reports 16, 3093, doi: 10.1016 / j.stemcr.2021.11.010 (2021). Alsinet, C. et al. Robust temporal map of human in vitro myelopoiesis using single-cell genomics. Nat Commun 13, 2885, doi: 10.1038 / s41467-022-30557-4 (2022). Rolfe, A. J., Bosco, D. B., Broussard, E. N. & Ren, Y. In Vitro Phagocytosis of Myelin Debris by Bone Marrow-Derived Macrophages. J Vis Exp, doi: 10.3791 / 56322 (2017).

Claims

WHAT IS CLAIMED IS1. An engineered immune cell comprising a non-endogenous expression vector that includes a mammalian GNB4 nucleic acid sequence.

2. The engineered immune cell of claim 1, wherein the mammalian GNB4 nucleic acid sequence comprises SEQ ID NO: 1 or wherein the mammalian GNB4 nucleic acid encodes a Gp4 polypeptide comprising the amino acid sequence of SEQ ID NO: 2.

3. The engineered immune cell of claim 1 or 2, wherein the non-endogenous expression vector including the mammalian GNB4 nucleic acid sequence is a plasmid, a cosmid, a bacmid, a bacterial artificial chromosome (BAC), a yeast artificial chromosome (YAC), or a viral vector.

4. The engineered immune cell of claim 3, wherein the viral vector is a retroviral vector.

5. The engineered immune cell of any one of claims 1-4, wherein the mammalian GNB4 nucleic acid sequence is operably linked to an expression control sequence.

6. The engineered immune cell of claim 5, wherein the expression control sequence is an inducible promoter, a native GNB4 promoter, a heterologous promoter or a constitutive promoter.

7. The engineered immune cell of any one of claims 1-6, wherein the non-endogenous vector including the GNB4 nucleic acid sequence further comprises at least one of a bioluminescent protein, a fluorescent protein, a chemiluminescent protein, an epitope tag, or a selectable marker.

8. An engineered immune cell, wherein the cell lacks detectable expression or activity of a mammalian GP4 polypeptide, wherein the mammalian GP4 polypeptide comprises the amino acid sequence of SEQ ID NO: 2.

9. An engineered immune cell, wherein the cell expresses an inhibitory nucleic acid that specifically targets and inhibits Gp4 expression.

10. The engineered immune cell of claim 9, wherein the inhibitory nucleic acid is an antisense oligonucleotide, a siRNA, a sgRNA or a shRNA.

11. The engineered immune cell of any one of claims 8-10, wherein the cell comprises a transgene that encodes a dominant negative GP4 or the inhibitory nucleic acid.

12. The engineered immune cell of claim 11, wherein the transgene is operably linked to an ubiquitous promoter, a constitutive promoter, a macrophage-specific promoter, a neutrophil-specific promoter, or an inducible promoter.

13. An engineered immune cell comprising a deletion, insertion, inversion, or frameshift mutation in a Gp4 gene encoded by the nucleic acid sequence of SEQ ID NO: 1.

14. The engineered immune cell of any one of claims 1-13, further comprising a chimeric antigen receptor (CAR) that specifically binds to a tumor antigen.

15. The engineered immune cell of claim 14, wherein the CAR comprises an extracellular antigen-binding domain, a transmembrane domain and an intracellular domain.

16. The engineered immune cell of claim 15, wherein the extracellular antigen binding domain comprises a single chain variable fragment (scFv) or a human scFv.

17. The engineered immune cell of any one of claims 15-16, wherein the extracellular antigen binding domain comprises a signal peptide that is covalently joined to the N- terminus of the extracellular antigen binding domain.

18. The engineered immune cell of any one of claims 15-17, wherein the transmembrane domain comprises a CD8 transmembrane domain or a CD28 transmembrane domain.

19. The engineered immune cell of any one of claims 15-18, wherein the intracellular domain comprises one or more costimulatory domains.

20. The engineered immune cell of claim 19, wherein the one or more costimulatory domains are selected from among a CD28 costimulatory domain, a 4- IBB costimulatory domain, an 0X40 costimulatory domain, an ICOS costimulatory domain, a DAP- 10 costimulatory domain, a PD-1 costimulatory domain, a CTLA-4 costimulatory domain, a LAG-3 costimulatory domain, a 2B4 costimulatory domain, a BTLA costimulatory domain, a CD3^-chain, or any combination thereof.

21. The engineered immune cell of any one of claims 1-20, wherein the engineered immune cell is a neutrophil or a macrophage.

22. The engineered immune cell of any one of claims 1-21, wherein the engineered immune cells are derived from an autologous donor or an allogenic donor.

23. A composition comprising an effective amount of the engineered immune cell of any one of claims 1-22 and a pharmaceutically acceptable carrier.

24. A method for treating Charcot-Marie-Tooth Disease (CMTD) in a subject in need thereof comprising administering to the subject an effective amount of the engineered immune cell of any one of claims of 1-7 or 21-22.

25. The method of claim 24, wherein the subject harbors a mutation in GNB4 or suffers from or is at risk for dominant intermediate CMT type F (CMTD IF).

26. A method for treating a microbial infection in a subject in need thereof comprising administering to the subject an effective amount of the engineered immune cell of any one of claims of 8-22.

27. The method of claim 27, wherein the microbial infection is a fungal infection, a bacterial infection, or a viral infection.

28. A method for treating cancer in a subject in need thereof comprising administering to the subject an effective amount of the engineered immune cell of any one of claims 14- 22.

29. The method of any one of claims 24-28, wherein the engineered immune cell is administered pleurally, intravenously, subcutaneously, intranodally, intrathecally, intrapleurally or intraperitoneally.

30. The method of any one of claims 24-29, further comprising administering an additional therapeutic agent.

31. A method of preparing immune cells for adoptive cell therapy comprising: (a) isolating immune cells from a donor subject; and (b) transducing the immune cells with a non-endogenous expression vector that includes a GNB4 nucleic acid sequence comprising SEQ ID NO: 1 or a nucleic acid encoding the GP4 polypeptide comprising the amino acid sequence of SEQ ID NO: 2.

32. A method of preparing immune cells for adoptive cell therapy comprising: (a) isolating immune cells from a donor subject; and (b) transducing the immune cells with (i) an inhibitory nucleic acid that specifically targets and inhibits the expression of the GP4 nucleic acid sequence of SEQ ID NO: 1, and / or (ii) an expression vector that encodes a dominant negative Gp4 polypeptide.

33. The method of claim 32, wherein the inhibitory nucleic acid is an antisense oligonucleotide, a siRNA, a sgRNA or a shRNA.

34. The method of any one of claims 31-33, further comprising administering the transduced cells to a recipient subject.

35. A method of preparing immune cells for adoptive cell therapy comprising: (a) isolating immune cells from a donor subject; and (b) contacting the immune cells with at least one single guide RNA (sgRNA) and at least one endonuclease under conditions to produce engineered immune cells including a deletion, an insertion, an inversion, or a frameshift mutation in a GP4 gene, wherein the immune cells comprise an endogenous genome and wherein the sgRNA comprises at least one sequence that is complementary to a Gp4 nucleic acid sequence in the endogenous genome of the immune cells.

36. The method of claim 35, further comprising administering the engineered immune cells to a recipient subject.

37. The method of claim 34 or 36, wherein the donor subject and the recipient subject are the same or different.

38. The method of any one of claims 31-37, wherein the immune cells isolated from the donor subject comprise macrophages or neutrophils.

Citation Information

Patent Citations

  • Digital cell

    US7747390B2

  • Methods for testing binding of a ligand to a g protein-coupled receptor

    WO2010063832A1

  • Systems, methods, and compositions for targeted nucleic acid editing

    WO2018213708A1

  • MIR200c-epcam axis reprogramed immune cells for enhanced Anti-tumor function

    WO2022178211A2